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a truncated aptamer 'l.5M short', suggesting a possible application for this aptamer 
would be as an anticancer or anti-angiogenesis therapy or in a diagnostic assay for the 
detection of heparanase. Also, this aptamer and its full length counterpart have been 
applied to a quartz crystal to test the sensitivity of detection of heparanase using 
microbalance apparatus, with promising results. 
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CHAPTER ONE 
INTRODUCTION 
Page 11 
1.1 What Is cancer? 
Cancer is one of the principal causes of death in developed countries. It is a class of 
diseases which are characterised by uncontrolled proliferation of cells and invasion of the 
surrounding tissue around the body to different organs. This is initially caused by 
damage, or mutations, to DNA that encode for proteins controlling cell division, 
differentiation and survival, by carcinogens such as radiation, chemicals, physical agents 
or viruses [1]. However, cancer has been suggested not to be a one-step process but 
rather a multistep progressive one, with intermediate changes occurring in the genome, 
which when combined, help drive the change from normal healthy cells into malignant 
and metastatic cells. As observed clinically, a mutation causes a genetic lesion within a 
healthy cell, leading to a benign hyperplasia or polyp, which with further genetic mutation 
causes dysplasia (disorderliness of the cells caused by further mutation), and finally, 
cancer. The cancer itself then progresses and more mutations occur; leading to acquired 
ability to metastasise and invade other tissues where space and nutrients are not in 
limited supply. This is reflected in cell culture of both rodent and human cells, where 
more than two induced genetic alterations are required to generate tumorigenic variants 
[2] and is expected due to the many complex anti-cancer mechanisms shared by all cells 
in the body. 
1.1.1 Why and what makes molecules in cancer a good target? 
Due to the many steps required for formation of an invasive tumour there are a number 
of targets and approaches available to investigate possible therapeutics [1], which fall 
into the following main areas [2, 3]: 
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• Mutations can arise in the genes responsible for coordinating checking and repair 
of DNA, thus leaving it unchecked or unrepaired before cell division [1]. An 
example of this is p53; a gene involved in key areas of cell regulation which is 
mutated in approximately 50% of all human tumours, hence losing its function. In 
a healthy cell, p53 activates cell cycle arrest at checkpoint Gl/S, upon detection of 
DNA damage, allowing the cell to repair the damage or induce apoptosis if the 
damage is too severe. Loss of function of p53 leads to damaged DNA remaining 
unrepaired and apoptosis from being triggered. Various cyclin-dependent kinase 
inhibitors are in development to halt the cell cycle, including Flavopiridol, Ispinesib 
and SNS-032 [3]. 
• Mutations can arise in proto-oncogenes, which are responsible for regulating cell 
growth and differentiation, creating oncogenes, which allow the cells to act self-
sufficiently with respect to growth signals [1]. Healthy cells require activation from 
mitogenic growth signals to progress from non-proliferative to proliferative cells. 
These signals can come from growth factors, extracellular matrix (ECM) 
components or cell-cell adhesion/interaction molecules. A key difference 
between healthy and tumour cells is that tumour cells are able to synthesise their 
own growth signals and can 'switch on' and proliferate independently from other 
cells. Examples of this include the synthesis and response to growth factors 
platelet-derived growth factor and tumour growth factor alpha (PDGF and TGFa) 
by glioblastomas and sarcomas [2]. Numbers of Tyrosine Kinase receptors 
themselves are also increased in many cancers, for example, epidermal growth 
factor receptors (EGF-R) are increased in stomach tumours, leading to an 
increased response in the presence of typical levels of growth factors [2}. 
Gefitinib is an EGFR targeted inhibitor, which competes with ATP for binding of the 
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intracellular tyrosine kinase domain; inhibiting autophosphorylation and 
therefore, signal transduction and proliferation of the cell [3]. 
• Mutations occur in tumour suppressor genes, preventing the proteins they code 
for from being synthesised or being active, strongly increasing the probability of a 
tumour forming [1]. These are known as loss-of-function mutations as they form 
due to a loss of tumour suppression and are recessive, as both copies of the 
particular tumour suppressor gene need to be mutated before an effect is seen. 
Retinoblastoma protein (Rb) is responsible for blocking entry into S phase by the 
inactivation of growth factors such as E2F. Transforming growth factor beta 
(TGF~) disrupts the phosphorylation of Rb protein in a normal healthy cell, which 
maintains its activity. However, many human tumours have shown 
downregulation of, or dysfunctional TGF~ receptors, hence allowing Rb to be 
phosphorylated and inactivated, leading to activation of growth factors and 
progression through S phase. 
• Mutations occur in pathways responsible for cell death, therefore allowing the cell 
to escape apoptosis [1]. Intrinsic examples of this are BcI-2 and IGF-1 
overexpression; both of which are cell survival signals. PTEN, which acts by 
blocking the cell survival action of IGF-l and is therefore a tumour suppressor, 
shows an inactivation of both alleles on an almost equal frequency to pS3 
mutations. Extrinsically, decoy receptors for the Fas ligand are upregulated in lung 
and colorectal tumours, which bind Fas but do not transmit its signal for apoptosis 
of the cell. Obatoclax is currently the only small molecule inhibitor target for 
apoptosis regulation and acts via inhibition of the 8c1-2 family of cell-survival 
proteins [3]. 
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• Mutations occur that allow cells to evade terminal differentiation and replicative 
senescence, and hence they do not lose the ability to divide [1]. Normally, cells 
will only divide a finite number of times due to the shortening of telomeres with 
each round of replication, and then they will be subject to cell cycle arrest via the 
p53 pathway. However, if a tumour cell had the mutation and subsequent loss of 
p53; it could proceed with replication but would gain increasing genetic instability 
due to loss of genetic material from each round that would not be repaired. Thus, 
tumour cells have acquired the ability to reactivate telomerase; an enzyme which 
is normally expressed at low levels or even absent from somatic cells and is 
responsible for lengthening telomeres. This scenario has been proven in 
approximately 85% of human tumours, leading to telomerase forming another 
potential target for cancer therapeutics in the form of antisense oligonucleotides, 
reverse transcriptase inhibitors and G-quadruplex DNA-binding drugs. 
• Tumours acquire a blood and lymph supply through mutated cells' ability to carry 
out angiogenesis (production of new blood vessels from pre-existing blood 
vessels) [1]. This is essential because in order for tumour cells to proliferate, they 
must be able to metabolise or they will suffer necrosis. Therefore, growth factors 
promoting growth and differentiation into new capillaries and their components, 
such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) 
and platelet-derived growth factor (PDGF), plus many others have all been shown 
to be expressed and sometimes overexpressed by tumour cells. Inhibitors such as 
anti-VEGF antibodies, decoy VEGF receptors, inhibitors of the tyrosine kinase 
pathway and inhibitors directed against endothelial cell proliferation and 
migration have all been developed as anti-cancer therapeutics [3]. 
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• Cancerous cells can mutate further to allow travel and metastasis throughout the 
body [1]. To achieve this, tumour cells must have the ability to break the cell-cell 
and cell-ECM interactions that are normally present. In some cancers, notably 
breast and stomach, expression of E-cadherin, a cell-cell adhesion molecule 
present in epithelial cells, is lost. Tumour cells may also achieve access to the 
target organ through upregulation and release of extracellular proteases such as 
serine and threonine proteases and matrix metalloproteinases (MMPs). 
Specifically, MMPs 2 and 9 have shown type IV collagen degradation of the 
basement membrane and have shown to be expressed by tumour cells. 
Furthermore, tumour metastasis has shown to be markedly reduced in mice 
deficient in both MMPs 2 and 9, suggesting their importance in tumour metastasis 
[4]. Another such protease, heparanase, forms the topic of these studies. 
1.2 Heparanase as a taraet 
Metastasis accounts for 90% of cancer-related deaths in humans (1). Metastatic tumour 
cells are able to degrade cell surface and extracellular matrix glycoproteins such as 
fibronectin and heparan sulphate proteoglycans, therefore breaching the endothelial cell 
layer and basement membrane to invade the target organ (ectopic site) (5-7). They are 
able to do this by secreting enzymes, one of which has been identified and named 
heparanase (Hpa1) (8,9). 
1.2.1 Heparan sulphate 
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Heparan sulphate (HS) is a highly evolutionarily conserved molecule that is widely 
distributed on cell surfaces, extracellular matrices (ECM) and in basement membranes in 
mammals. It is a linear polysaccharide, expressed as a component of proteoglycan (PG) 
molecules [10] . 
A PG molecule comprises a core protein, to which two or three HS chains are covalently 
attached. There are two major proteoglycans found at the cell surface (figure 1.1): 
transmembrane syndecans with HS near the extracellular tips, and glycosylphosphatidyl 
inositol-linked (GPI) glypicans, with HS located near the plasma membrane. Agrin and 
Perlecan are two types of PG bound and comprising much of the ECM [10]. 
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Figure 1.1 - Cell surface syndecans and GPI-linked glypicans (left) and ECM bound 
HSPGs (right). Core proteins are shown in blue, plasma membranes in red and HS 
chains in yellow. 
HSPGs are synthesised in the Golgi system firstly by formation of a linkage region 
comprised of four sugars attached to a serine residue on the core protein [10]. The HS 
chains are elongated and modified, unit by unit, with alternating hexuronic acid and 
glucosamine residues [11]. Hexuronate can be either D-glucoronate (GlcA) or L-iduronate 
(ldoA), and the amine of the glucosamine is usually acetylated (GIcNAc), sulphated 
(GlcNS03), or unsubstituted [11], as shown in figure 1.2. 
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Figure 1.2 - A snapshot of a heparan sulphate chain showing different residues. The 
blue arrow Indicates the site of deavage of heparanase; between GlcA and GleN. 
(Modified from [12]) 
In addition to their roles of anchoring cells and maintaining the structure of the tissue, 
HSPGs have major roles in development, homeostasis and protein regulation [13-15]. 
They are also able to protect the cell from cationic molecules and macromolecules, to 
bind and assemble ECM proteins such as laminin, fibronectin and collagen, to mediate 
interactions between numbers of different proteins by acting as co-stimulatory receptors, 
and to protect type IV collagen from proteolytic attack [16]. Cell-surface HSPG of 
endothelial cells are able to aid diapedesis and chemotaxis of leukocytes to sites of injury 
by interacting with selectins, together with activation and presentation of chemokines 
and interleukins to slow and attract the moving leukocyte so it 'rolls' along the cells' 
surface (10). HS then activates and presents integrins to adhere and stop the rolling 
leukocyte, enabling it to migrate from the blood vessel into the injured tissue (10). HSPGs 
also have an important storage role as they are able to bind many cytokines and growth 
factors [17) such as basic fibroblast growth factor (bFGF), vascular endothelial growth 
factor (VEGF), hepatocyte growth factor (HGF), keratinocyte growth factor {KG F), 
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transforming growth factor beta (TGF-~), interleukin-8 (ll-8) [18], interieron-v (IFNy) [19] 
and platelet factor 4 (PF4) [20]. 
1.2.2 Formation of Heparanase 
Heparanase is a ~-l,4-endoglycosidase enzyme which cleaves glycosidic bonds of heparan 
sulphate chains by hydrolysis to 10-20 sugar units long [21], between glucoronic acid 
(GIeA) and glucosamine (GleN) [10], as seen in figure 1.2. Chromosome location of the 
human heparanase gene is at 4q21.3 [22]; represented as 14 exons separated by 13 
introns, and encodes 543 amino acids, some of which are cleaved to form the active 
enzyme. Full length pre-proheparanase is shown in figure 1.3. It contains a 35 amino acid 
signal peptide sequence (Met1_Ala35), which is firstly removed upon entering the 
endoplasmic reticulum. It is then heavily N-glycosylated at six asparagine sites before 
being secreted, which is thought to have a role in kinetics of transport from the 
endoplasmic reticulum to the Goigi apparatus, and in secretion and solubility of the 
enzyme [23, 24]. Glycosylation is not thought to contribute to the enzyme's activity. 
After being secreted as a 65KDa protein, proheparanase is transferred to late 
endosomes/lysosomes, sometimes via the cell surface, where it undergoes proteolytic 
processing at site 1: Glul09_SerllO and site 2: Gln157_Lys158, giving an 8KDa polypeptide at 
the N-terminus, a 50KDa polypeptide at the C-terminus, and a 6KDa linker polypeptide. 
The two larger polypeptides then associate non-covalently to form the active enzyme: a 
heterodimer [23, 25]. The fate of the linker peptide after its excision is unknown, 
although the hydrophobic Tyr156 is required for correct processing of the enzyme at site 2 
[26]. 
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Figure 1.3 - A schematic diagram of pre-proheparanase showing N-Glycosylation sites 
(not to scale). 
Investigations have revealed that cathepsin L is the most probable culprit of processing of 
proheparanase as in a cell line to which cell-permeable inhibitors of cathepsin L were 
added, heparanase remained inactive and in a cell free system, recombinant 
proheparanase was processed and activated by addition of cathepsin L [26] . 
Expression of Hpa protein correlates with expression of Hpa mRNA, suggesting that 
overexpression of the protein is regulated at the transcriptional level [27]. Cells with low 
heparanase mRNA expression were treated with an inhibitor of DNA methylation and 
expression of Hpa mRNA increased, although in the presence of cycloheximide (an 
inhibitor of protein synthesis) it had no effect, suggesting that de-methylation of 
transcription factors can regulate heparanase mRNA expression [28, 29]. Early growth 
response transcription factor [30], pS3 [31], inflammatory cytokines [32] and hypoxia [33] 
are all responsible for regulation of heparanase gene expression. Notably, tumour 
variants of pS3 are unable to bind to the promoter region of heparanase, hence were 
unable to suppress transcription [31]. Secretion of active enzyme was stimulated 
extracellularly, by activation of the protein kinase A (PKA) and C (PKC) pathways [34] . 
Formation and secretion of the heparanase protein in its latent form allows for tight 
regulation of its activity post-translation as well as at the transcriptional level. 
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Heparanase activity has been established when full length Hpa cDNA in a vector was 
transfeeted into mammalian cells and when the 65KDa proenzyme was added to 
mammalian cell cultures, which compared with no activity when just the 50KDa enzyme 
and eDNA were expressed, suggesting that just the 50KDa cDNA and enzyme are not 
sufficient for activity without the 8KDa subunit [25, 35]. However, when full length eDNA 
was expressed in insect cells, it resulted in low activity and expression, suggesting that 
proteolytic processing only occurs in mammalian cells [24]. 
Experiments have also shown evidence for heterodimer formation by means of a pull 
down assay, to demonstrate the physical association of both subunits and it has been 
found that the region GIU288_Lys417 on the 50KDa subunit is the region which interacts 
with the 8KDa subunit [23]. It is not known what function the 8KDa peptide has as the 
active site and heparan binding domains are all found in the 50KDa subunit [24]. 
Attempts are being made to establish the minimum sequence from the 8KDa subunit 
needed for the enzyme to be fully functional by using site-directed mutagenesis; 
however, it is thought that complete removal of the linker peptide must be carried out for 
the enzyme to be fully active [24] as leaving only a 1kDa portion of it behind is sufficient 
to inhibit the activity of heparanase [36]. 
1.2.3 Heparanase Structure 
Although a structure has not been determined for heparanase, the enzyme has been 
modelled on the structure of endO-l,4-p-xylanase as there is evidence that heparanase 
may be related to it in the family of clan A glycosyl hydrolases (GH-A), and the predicted 
structure is shown in figure 1.4 [37]. 
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This group uses an acid catalysis mechanism for hydrolysing glycosidic bonds, using a 
proton donor and a nucleophile, and BLAST searches show similar sequences between 
heparanase and the xylanase family of enzymes [37]. The proton donor site in human 
heparanase is predicted to be GIU225 and the nucleophile, Glu343• Site directed 
mutagenesis was carried out on these residues and this rendered the enzyme inactive, 
suggesting that the predictions were correct [37]. There are also 2 heparin binding 
domains present on the SOkDa subunit, located at lys158_Asp162 and Pro271_Met278 [38]. 
These are predicted to reside closely to the proton donor and nucleophile sites to 
comprise the active site of the enzyme [37]. A peptide containing the lys158_Asp162 
sequence showed binding of HS and subsequent inhibition of heparanase uptake and 
activity [38], suggesting that cell surface HS is another important regulatory factor 
responsible for uptake of secreted heparanase. 
The structure prediction suggests that heparanase adopts a TIM barrel fold [37] shown in 
figure 1.4; comprised of six alternating a-helices and ~-sheets from the SOkDa subunit 
and a further two a-helices and ~-sheets from the 8kDa subunit (39). Heparanase is 
currently being subjected to x-ray crystallographic analysis at Imperial College, london, to 
determine its structure. 
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Figure 1.4 - A structural diagram of human heparanase (Hpa1) from (36). Balls and 
sticks represent the predicted proton donor, Glu225 and nucleophile, Glu343. 
1.2.4 Heparanose Activity 
Heparanase activity has been seen in activated leukocytes, mast cells and macrophages 
and is secreted by activated CD4+ T cells [40-42], platelets [43], neutrophils and 
metastatic tumour cells [44]. 
Heparanase secreted by metastatic tumour cells targets heparan sulphate proteoglycans 
in the basement membrane of blood vessels for degradation, leading to an increase in 
permeability of the target cell and allowing the tumour cell to penetrate it (shown in 
figure loS). By degradation of the basement membrane, heparanase is also responsible 
for the release of the once-bound bioactive molecules in stimulating movement and 
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proliferation of endothelial cells to the site of angiogenic stimulus, hence promoting 
neovascularisation. 
Figure 1.5 - Degradation of the basement membrane by an invading tumour cell (taken 
from [45]). 
High levels of heparanase expression in tumour cells correlate with their metastatic 
potential, i.e. their ability to progress through the ECM and basement membrane [8] . 
Heparanase mRNA expression is also increased in tumour sites compared with 
surrounding healthy tissues [46]. Many groups have reported positive correlations 
between high heparanase expression and tumour size, stage, classification, 
vascularisation, postoperative and metastatic recurrence and poor prognosis. In some 
models, fragments of degraded heparan sulphate have been seen to down-regulate T cell 
functions [45] . 
Elevated levels of heparanase mRNA and protein have been found in cancer patients, who 
show significantly shorter postoperative survival times than patients without elevated 
Hpa mRNA levels [27, 47] . In experiments using non-metastatic lymphoma cells 
transfected with either chicken (secreted form), human (not so readily secreted form), or 
chimeric (human enzyme with chicken signal sequence) heparanase, it was found in vitro 
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that the chicken and chimeric heparanases showed a 3-10 fold increase in invasion of a 
reconstituted basement membrane compared to human and control heparanase 
transfected cells, suggesting that cell surface expression and secretion of heparanase 
facilitates lymphoma cell invasion through basement membranes [48]. Mice injected 
with chicken or chimeric heparanase showed accelerated mortality compared to mice 
injected with human heparanase, without the primary tumours exceeding 1% of their 
body weights, suggesting that they died because of the high level of metastasis found in 
the liver. Control mice, with no transfected heparanase showed no infiltration of tumour 
cells into the liver, emphasising the importance of cell surface expression and secretion of 
heparanase in tumour metastasis. High vascularity and vessel density and functionality of 
tumours in mice transfected with chicken and chimeric heparanase was also observed, 
when compared to human transfected and control mice, supporting the theory that 
heparanase also causes angiogenesis [48). 
In addition to these well known effects, heparanase is also known to have other roles in 
tumour progression, including activation of signalling molecules that promote cell 
proliferation and survival, and increasing cell motility and blood vessel density [36). 
Heparanase upregulation correlates with increased phosphorylation and activation of 
signalling molecules Akt [49), p38 [50), Pyk2, integrins and Src [50). Vascular endothelial 
growth factor (VEGF), a vasculogenesis promoter, has shown to be activated by Src and 
latent or active heparanase [50). Interestingly, Src inhibitors prevented VEGF activation 
by heparanase in addition to heparanase-enhanced cell migration, suggesting that Src and 
its inhibitors may be able to mediate heparanase functions too [50). 
Heparanase enzymatic activity is dependent on the pH of the local environment (42). In 
vitro experiments have shown that at pH 3.4 heparanase remains inactive, at pHs greater 
than 6.8 or less than 5.4 there is low activity, but for slightly more acidic than 
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physiological pHs 5.4, 6.4 and 6.8, there is a maximal release of degraded heparan 
sulphate, with an optimum pH of 6.0 [42, 51, 52]. This correlates well with the conditions 
in vivo, where cleavage of HS occurs in the slightly acidic pH areas of inflammation and in 
tumours [42, 53]. Heparanase was found to be inactive at pH 8.5 and above [10]. 
Single nucleotide polymorph isms (SNPs) of heparanase have been investigated [54]. 
Among them, a G to A polymorphism in exon 8, which provides an amino acid 
substitution of arginine for lysine at site 307, has been shown to have no significant effect 
on FIGO (Federation of Gynaecology and Obstetrics) classification of stage of disease [54]. 
However, a polymorphism in intron 2, which shows a substitution of T for C is significantly 
associated with stage of disease, even though it does not directly change the sequence of 
pre-proheparanase [54]. It is thought that through moderation of protein binding to this 
region, the SNP could affect splicing of areas concerned with signal peptide or activation 
cleavage, or that it could be in association with another SNP with a more functional role 
in heparanase protein sequence [54]. 
It has been suggested from the evidence that heparanase plays a crucial role in invasion 
of a target organ by metastatic tumour cells, also that it promotes angiogenesis from the 
release of sequestered growth factors, hence allowing the tumour cell to proliferate. 
Furthermore, heparanase expression has been implicated in a number of different 
cancers, for example, acute myeloid leukaemia [55], bladder [56], brain [57], breast [58], 
colon [59], gastric [60), oesophageal [61), oral [62], and pancreatic [27, 63, 64]. This, 
together with its practical advantages of solubility, being a secreted enzyme (hence 
facilitating its manipulation in the laboratory) and its availability as an active, recombinant 
enzyme expressed in insect cells, suggests that this enzyme may be a very exciting target 
for drug therapy. 
Page \16 
1.2.5 Heparanase Inhibitors 
Heparanase has been the target for a number of drug development efforts. Current 
inhibitors of heparanase include various mono- and polyclonal antibodies [65, 66], 
heparin [67], laminaran sulphate [48], phosphomannopentaose sulphate (PI-88) [68, 69] 
and suramin [70]. 
The inhibitor PI-88 is one of many sulphated oligosaccharides which have been shown to 
inhibit heparanase activity, and is a structural mimic of heparan sulphate [69]. In an in 
vitro angiogenesis assay system, testing a number of different oligosaccharides of which 
the results are represented in figure 1.6, PI-88 has been found to inhibit human 
angiogenesis by 50% at a concentration of 2~g/ml, showing a 25-fold increased inhibitory 
activity than suramin; which has entered clinical trials for its antiangiogenic properties 
[69]. Further investigation of PI-88 showed inhibition of tumour metastasis by >90% in 
high doses of 16-32mg/kg and by 50% in lower doses of 2mg/kg [69]. The drug has 
entered phase II clinical trials in combination therapies with other drugs, under Progen 
Pharmaceuticals Limited, for treatment of prostate cancer, metastatic myeloma, 
advanced lung cancer, primary liver cancer, advanced melanoma and multiple myeloma 
[71, 72]. 
The nature and length of the oligosaccharide backbone have shown to be important, as 
oligosaccharides composed of more than 4 monosaccharides have the highest Inhibitory 
activity, but sulphonated cyclohexa, hepta and octaamyloses and sulphated chondroitin 
tetra, hexa and octasaccharides displayed little or no inhibitory activity respectively (69). 
Experiments testing heparanase inhibition found a similar scenario where the length and 
nature of the oligosaccharide backbone affected the degree of inhibition and that PI-S8 
and maltohexaose sulphate were the most potent inhibitors. Results of an in vitro study 
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to test the antimetastatic activity of the oligosaccharides further confirmed this 
observation [69]. 
Heparin, which has been used in the clinic as a potent anticoagulant for more than half a 
century and is similar in structure to HS, showed no antiangiogenic properties in the same 
assay, although showed the most promising inhibition of heparanase; with an 1(50 of 
l~g/ml [69]. 
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Figure 1.6 - 50% inhibitory concentrations (pg/ml) for angiogenesis, metastasis and 
heparanase inhibition of different sulphated oligosaccharides in comparison with 
heparin and suramin. Data from [69]. 
(R)-3-hexadecanoyl-5-hydroxymethyltetronic acid (RK-682) has been found to inhibit 
heparanase activity by directly binding to the enzyme, among other enzymes, and it has 
been found that by benzylation of the 4-position of RK-682 it is able to selectively inhibit 
heparanase only, with a 50% inhibitory concentration of 17~mol/L, which is comparable 
to other inhibitors found to date [73]. 
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Another class of heparanase inhibitor are derivatives of furanyl-1,3-thiazol-2-yl and 
benzoxazol-S-yl acetic acids, which after optimisation, yielded (2-{4-[(E)-3-{4-
bromophenyl) acryloylamino]-3-fluorophenyl} benzooxazol-5-yl) acetic acid, and showed 
an ICso of heparanase inhibition of 0.4~M, an ICso of angiogenesis of l~M and after 
introduction into mice, displayed improved solubility, modest cell penetration and did not 
inhibit cytochrome P450 enzymes [74]. 
In an experiment linking heparanase with restenosis (re-occurrence of narrowing of blood 
vessel or organ) by release of bFGF from heparan sulphate chains in the ECM, an anti-
heparanase IgG was found to inhibit bFGF release by 60% [66]. And in a cell invasion 
assay, another heparanase polyclonal IgG antibody reduced the invasiveness of an 
ovarian carcinoma cell line by up to 95% in a dose-dependent manner [65]. However, as 
with all antibodies, the prospect of using them as potential therapeutics is difficult as due 
to their large size, they are easily recognised as 'non-self and destroyed by the immune 
system before being able to carry out their function. For this reason, aptamers have been 
chosen as the focus of this study, due to their superior binding properties in terms of 
specificity and selectivity, lower molecular weight and non immunogenic properties. 
1.3 What are aptamers? 
Aptamers are short oligonucleotides, which can be single or double stranded DNA or RNA. 
They have been developed for diagnostic and therapeutic uses and are characterised by 
high binding affinity and specificity to their target molecules [75-77]. Typically, aptamers 
can be from 22 to 100 bases (or base pairs) in length, and carry two distinct regions: a 
region of fixed sequence, used for amplification and identification purposes; and a 
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variable region, for which each base could potentially be an A, C, G or T /U. This creates a 
large number of different sequence combinations, typically in the region of 1015, which is 
responsible for the different folding arrangements, specificities for different molecules, 
and binding affinities of the aptamers. Aptamers can be generated against small 
molecules, purified peptides and proteins, and even against cells and tissues, which 
allows for the target to remain in its native environment and conformation [78, 79], 
although it is more difficult to establish optimal conditions and there is more chance of 
experiencing non-specific binding or selecting aptamers against unwanted targets, due to 
the complexity of such environments. The affinity of aptamers has been compared to 
that of antibodies (i.e. in the nanomolar range), but as aptamers are mostly smaller (8-
15kDa compared to 150kDa), they can penetrate tissues and be cleared from the system 
quicker than antibodies, which can be useful in diagnostic and imaging applications [78]. 
Being cleared from the plasma within minutes of intravenous administration is also a 
disadvantage, when using aptamers in the treatment of disease, as a suitable 
concentration cannot be maintained in the body without constant dosing; hence it is 
often important to modify the aptamers without affecting their activity before they can 
be used effectively in this way [80). 
1.3.1 How are aptamers produced? 
Aptamers are primarily produced based on the SElEX ~ystematic gvolution of !:igands by 
EXponential enrichment) procedure [81] (figure 1.7) where the target Is Immobllised on a 
matrix, aptamer library solution is incubated with It, so that the different sequences 
effectively compete for binding with the target, unbound aptamers are removed by 
introducing wash steps, and finally, bound aptamers are removed by using a solution with 
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a high salt content or by heating them to a high enough temperature to denature the 
target, thus releasing the aptamers. The binding aptamers are then amplified by PCR. 
Typically, this procedure is repeated over many (usually ten) rounds, so that the amplified 
aptamers are incubated with the target molecules again, creating many copies of the 
aptamer sequences with the highest affinity, and removing the ones with lower affinities; 
hence the term: 'exponential enrichment'. Matrices used can be columns packed with 
sepharose containing a coupling reagent such as N-hydroxy-succinamide (NHS), which 
couples the N-terminus of proteins and peptides, nitrocellulose filters, or 'ELISA type' PCR 
tubes, which encourage protein binding. The SElEX procedure has been modified by 
many groups [78, 82-85], and some groups have even developed non-SElEX procedures 
to yield aptamers [86-88], however, the underlying principle remains the same. 
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Figure 1.7 - A diagram of one round of SELEX-type selection. Eluted aptamers can be 
amplified and incubated again to enrich the pool with high affinity species. Rounds can 
be repeated for a number of times (usually 5-10) before adequate enrichment is 
achieved to result in only a few high-affinity and specificity binding species. 
1.3.2 Structures of aptamers 
Aptamers are often GC rich, so are able to form complex three-dimensional structures. 
Their folding allows them to maximise hydrogen bonding with complimentary bases, by 
utilising Watson and Crick binding sites, similar to double stranded DNA. In addition to 
utilising Watson and Crick binding sites, the formation of G-quadruplex structures (see 
figure 1.9) requires Hoogsteen hydrogen bonding sites, which are critical to the stability 
of tetrads. 
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These interactions result in the formation of hairpin loop (see figure 1.8 for an example) 
and G-quadruplex structures, which are both highly stable . Folding of the aptamers in 
this way is another characteristic which contributes to their high affinity and specificity. 
Groups have manipulated these characteristics by creating highly stable DNA aptamers to 
thrombin [89] using natural nucleotides to avoid potential toxic degradation products, 
only by circularisation of the exposed termini of the aptamers so they do not become 
susceptible to degradation by plasma exonucleases [89] . 
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Figure 1.8 - Predicted structure of an aptamer sequence showing its folding to 
maximise hydrogen bonding with complimentary bases. In doing so, this has created 
many hairpin loops within the structure and is therefore highly stable [90]. 
Also, the aptamer AS-1411 to nucleolin is an unmodified 26nt DNA aptamer, which is not 
subject to nuclease resistance through the formation of the G-quadruplex structure [91, 
92]. 
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Figure 1.9 - Formation of G-quadruplex structure showing the basic unit or tetrad (left) 
containing the monovalent metal ion in the centre for further stability. Hydrogen 
bonding acceptors and donors are shown by the red arrows, Watson and Crick binding 
faces are shown in green and Hoogsteen in blue. Tetrads then stack on top of each 
other to form the G-quadruplex (right). Images were modified from [93]. 
1.3.3 Modifications to the aptamer 
It is well known that the bloodstream contains many nucleases, and that an aptamer in its 
native state administered intravenously into the body, would be rapidly broken down in 
the bloodstream and the liver, and excreted within minutes through the kidneys. This is a 
useful property in cancer diagnostics or imaging studies, because any circulating aptamers 
are rapidly eliminated from the system, leaving only the aptamers that are bound to the 
disease site present, thus reducing any background interference. This property, however, 
is not useful in therapeutic applications, because a constant level of drug has to be 
maintained within the body for long periods of time. Most drugs require doses only once 
or twice a day, whereas unmodified aptamers would require doses on a smaller timescale 
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or continuous drip, with more than 90% of the molecules excreted without ever having 
the opportunity to exert their therapeutic effect, making them very inconvenient and 
expensive. 
To overcome this adverse characteristic, aptamers would need to be appropriately 
modified. However, one very useful property of aptamers is that they can be readily 
coupled with other moieties and modified appropriately to suit any application. 
Aptamers can be truncated by carrying out tests to determine the minimum sequence 
required to carry out their function, and removing the unnecessary bases. Groups on 
purine or pyrimidine bases can be replaced with amino, methyl or fluoro groups (2'-NH2' 
2'-OCH3, 2'-F), or inverted bases to confer nuclease resistance [78, 94, 95]. Furthermore, 
aptamers can be coupled to large molecules, for example, polyethylene glycol (PEG) [96], 
a polymer with varying molecular weights (this can also be with or without a radionuclide) 
at their 5' or 3' end [97, 98]. This is designed to improve stability, solubility and reduce 
toxicity and plasma clearance. Another large molecule that has been used is a 
diacylglycerol (DAG) molecule, a dephosphorylated glycerol-3-phosphate molecule with 2 
fatty acid chains attached, which can then also be incorporated into a liposome. This also 
reduces plasma clearance, as the liposome has a large molecular weight, and the 
liposome can also be filled with a cytotoxic drug, for example, Cisplatin [99]. 
Finally, aptamers are currently being developed in nuclear medicine applications for 
diagnosing abnormalities in tissues and organs, offering the possibility of early stage 
detection of cancer and other diseases. USing a chelator, radionuclides such as 
99Technetium and 188Rhenium can be attached to aptamers designed to bind to a 
particular target of interest, thus making them suitable for gamma camera imaging [100]. 
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1.3.4 Administration of aptamers 
Of the three aptamers that have entered clinical trials, only one has been approved for 
therapeutic use. This anti-VEGF aptamer; Pegaptanib, was originally designed to treat 
cancer, but was found to be more promising in treating age-related macular degeneration 
{AMD} and involves administration directly into the eye by intra-vitreal injection [101]. 
The remaining two aptamers, an anti-nucleolin aptamer named AS1411, developed by 
Antisoma has entered phase I clinical trials for treatment of renal and non-small cell lung 
cancers, and acute myelogenous leukaemia [102] and an aptamer developed by 
Archemix; ARC1779, which inhibits platelet aggregation and thrombosis by inhibiting the 
action of von Willebrand Factor {vWF} [103]; are both administered intravenously. 
1.3.5 Aptamers as therapeutics 
Aptamers have been developed for use as cancer therapeutics against many targets 
involved in pathways leading to cell growth, proliferation and angiogenesis and are in 
various stages of development. 
To date, there is only one aptamer developed for the treatment of cancer in clinical trials. 
This aptamer has been developed by Antisoma, and binds to nucleolin, a ubiquitous 
protein expressed in the nucleolus and on the cell surface of proliferating cells, and 
overexpressed in malignant cells in cancers such as prostate, cervical and breast [91,92]. 
The aptamer is unmodified; however it is G-rich and adopts a dimeric G-quadruplex 
formation which confers nuclease resistance. Once bound to nucleolin, the complex is 
internalised and causes arrest of cell division in 5 phase, leading to apoptosis of the 
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tumour cells [91]. This is thought to occur by inhibition of helicase activity in the 
replication fork and subsequent inhibition of DNA replication [92]. 
Vascular endothelial growth factor (VEGF) is a protein involved in the production of de 
novo blood vessels (vasculogenesis), as well as angiogenesis and in increasing the 
permeability of microvessels [95]. VEGF has a number of different splice variants, 
VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206, correlating with the number of amino 
acids in the protein. VEGF is the substrate for tyrosine kinase receptors, which are 
thought to lead to angiogenesis, and, although the exact mechanism it has in the 
promotion of tumours is unclear, overexpression of VEGF in people with tumours is 
associated with poor prognosis (95). A PEGylated anti-VEGF aptamer was the first 
aptamer to reach clinical trials and be used as an approved therapeutic, but although it 
was developed originally to treat cancer, it has not been approved for this use, but 
instead for the treatment of age-related macular degeneration (AMD) (104) in order to 
avoid issues related to systemic administration. The aptamer is injected intravitreally and 
binds to the VEGF165 variant, preventing vascularisation of blood vessels and progression 
ofAMD. 
VEGF was also the target used by Ruckman et 01.(95). RNA aptamers were generated 
against the VEGF165 form and modified to make them as small as possible. Their Ko's 
ranged from 49-130pM. They specifically bound to this form and did not bind to VEGF121 
or the closely related placental growth factor (PIGF129), and showed promise in inhibiting 
the binding of VEGF165 to its receptors VEGFR-l and VEGFR-2. One aptamer in the study 
had the ability to reduce VEGF induced vascular permeability in vivo using the Miles assay 
[105). 
Basic fibroblast growth factor (bFGF) is also a potent angiogenic factor [94, 106] and 
belongs to a family with at least eight other members [106-108]. Jellinek et 01. (94) 
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produced a 2'aminopyrimidine modified RNA aptamer to bFGF with a Ko of 3SnM. The 
modification ensured that the aptamer was 1000-fold more stable in 90% human serum 
than an unmodified version [94]. Binding studies carried out on the aptamer to 
denatured bFGF and other members of the FGF family; acidic FGF, FGF-4, FGF-S, FGF-6 
and FGF-7 plus four other heparin binding proteins, showed considerably lower affinity, 
ranging from 4.1xl0-2 to >10-6M [94]. In a cell culture system, the aptamer inhibited bFGF 
binding to the FGF receptor 1. 
Platelet derived growth factor (PDGF) is another protein responsible for regulating cell 
growth and division. There are five known ligands: PDGF-A, B, C, D and an AB 
heterodimer; and two receptors PDGFRA and PDGFRB, which are tyrosine kinase 
receptors (RTK's). This is part of the phosphatidylinositol 3-kinase (PI3-K) pathway [1, 
109], and activates protein kinase B (PKB) which is involved in mediating cell survival 
signals, and protein kinase C (PKC) [1, 109]. PDGF-B has been implicated in many renal 
diseases and it is thought to induce glomerular mesangial cell proliferation and matrix 
accumulation [110]. A DNA aptamer was produced to target PDGF-B, and coupled with 
40kDa PEG for stability in vivo [96). Treatment in vivo of a rat with initiated 
mesangioproliferative glomerulonephritis on day three of the disease with the PEG 
coupled aptamer, reduced overexpression of PDGF-B in mesangial cells, and arrested 
mesangial cell proliferation (96). 
Raf-l is a serine threonine kinase - the first in the mitogen activated protein (MAP) kinase 
cascade, which is activated by a chain of events from the receptor tyrosine kinase (RTK), 
leading to cell growth and proliferation [1, 109]. Raf-1 is activated upon binding of Ras to 
the Ras binding domain (RBD); amino acids 51-131 of Raf-1. Ras binds to Raf-1 with an 
affinity of 18nM [111-113). Using only the RBD of Raf-1 for selection, RNA aptamers were 
produced, which were all similar to one of two different sequences; RNA 9A and 9B. The 
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two sequences showed binding affinities of 152 and 361nM respectively [114] for the RBD 
of Raf-1 [114]. In a competition experiment, the addition of the two aptamers 
significantly reduced Ras binding to the RBD of Raf-l. RNA aptamer 9A also bound to a 
GST fusion form of Raf-l RBD; B-Raf RBD, with an affinity of 285nM, but in the 
competition experiment it showed specificity for RBD of Raf-l and did not inhibit the 
interaction between Ras and B-Raf RBD [114]. It was found that RNA 9A and B inhibited 
the Raf-l activation reaction in an experiment using full length Raf-l, but that addition of 
the aptamers after the activation reaction had occurred provoked no inhibition by the 
aptamers [114], suggesting that the aptamers function as inhibitors of the activation 
reaction and not to Raf-l itself. These experiments showed that the most potent 
aptamer, RNA 9A, could be a useful regulatory drug for mediating Ras and Raf-1 
interactions in cells, therefore influencing cell growth and proliferation. 
Angiogenin is another molecule involved in angiogenesis and cell proliferation [115]. It is 
a ribonuclease which is thought to become active when it translocates to the nucleolus of 
the cell [116, 117]. DNA aptamers were produced, which showed inhibition of 
angiogenin's ribonucleolytic activity by >50% when present in a threefold excess [118]. 
The aptamer was then truncated and tested for specificity by observing its effect on 
RNase A (another ribonuclease which is 33% homologous to angiogenln) for its substrate 
poly(C), to which there was no significant inhibition, showing that the aptamer was 
specific for angiogenin [118]. In an assay with human endothelial cells, it was found that 
the aptamer inhibited angiogenin induced cell proliferation by 65% at a concentration of 
l~M and by 100% at 5~M, although not Inhibiting, rather cotranslocating with angiogenin 
to the nucleus [118]. 
The production of aptamers has been of use in isolating a protein thought to be a marker 
for angiogenesis, by selecting against microvessels of rat glioma [119]. SELEX was carried 
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out on transformed endothelial cells to produce the single stranded DNA aptamers. One 
aptamer selectively bound to microvessels of rat brain glioblastoma, but not to normal 
vessels in the rat brain [119]. This aptamer was used to identify its specific target, which 
was found to be a rat homologue of mouse pigpen protein, and thought to contribute to 
angiogenesis, although little else is known about this protein. This aptamer served as a 
useful probe, and could be developed further as a therapeutic measure to treat 
glioblastoma in vivo [119]. 
1.3.6 Aptamers as diagnostics 
A number of aptamers have also been developed for diagnostic applications, due to their 
inherent properties. 
RNA aptamers have been produced that bind to protein kinase C with the intention of 
investigating their role in signal transduction pathways other than those involved with 
phospholipid hydrolysis [120]. Aptamers were used because of their substrate specificity 
in the hope that they would inhibit one enzyme but none of the others with high 
sequence homology. An RNA aptamer selected against protein kinase C 1311 showed a Ko 
of 7nM, and exhibited one order of magnitude lower potency for protein kinase C 131, 
which is 96% homologous to the 1311 isozyme [121], and showed no potency for the a 
isozyme [120]. 
Another way in which aptamers have been used as diagnostic agents is exemplified by the 
aptamer produced against neutrophil elastase to provide a useful imaging tool [122-124]. 
Neutrophil elastase is a serine protease which can degrade a variety of proteins, including 
connective tissue, and is found in the granules of neutrophils. When there is infection 
and inflammation in the body, neutrophils are recruited to the site [125-127], whereupon 
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they release their granules, and hence, neutrophil elastase [128]. This is thought to be a 
good marker of inflammation as neutrophil elastase is highly localised in the site of 
inflammation by a protease inhibitor a-1 [127, 129-131]. Aptamers were generated that 
showed a rate constant of 1-3 x 108M-1min-1 for neutrophil elastase [122, 123, 132] and 
were shown by flow cytometry to bind preferentially to activated neutrophils. The 
aptamers were tested for their imaging properties in vivo in a rat model and it was found 
that, compared with an anti-elastase IgG (which is the method clinically used), not only 
was the overall intensity higher, but the background signal was lower, all over a shorter 
time period [122, 123]. This is due to the rapid clearance that the aptamer has from the 
blood because of its smaller size, and minimal perfusion into the surrounding tissues. The 
results showed that aptamers could be a viable alternative in imaging compared to 
antibodies [122, 123]. 
An anti-MUC-1 aptamer is also in developent for diagnostic imaging in breast cancer [100] 
by conjugation to 99mtechnetium via chelator MAG2, and has shown high resistance to 
nuclease degradation and high renal clearance and therefore, less toxic effect. 
The field of biosensors coupled with aptamers has recently developed due to the huge 
potential of biosensor development in point of care (POC) applications and the ability of 
aptamers to fulfil some of the requirements for such applications [133]. The majority of 
the methods developed so far have been based on the 15 nucleotide aptamer to 
Thrombin [134], as this has been well characterised in terms of structure and binding and 
has used as a model system. This aptamer adopts a G-quadruplex structure comprised of 
two tetrads connected by T-T or T-G-T loops and has been used in a number of 
electrochemical sensors, for example, faradic impedance spectroscopy (FIS), measuring 
changes In the electron transfer resistance upon binding of target to aptamer [133, 135]. 
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Other targets used for aptasensors include a biotinylated aptamer for Immunoglobulin E 
to detect atopic diseases such as asthma and dermatitis; used in an electrochemical 
device by an extravidin-alkaline phosphatase label (133), as well as in surface plasmon 
resonance imaging (SPRi), in combination with carbon nanotubes using field-effect 
transistors (FET) and in a piezoelectric quartz crystal microbalance device (135). 
DNA aptamers selected for platelet-derived growth factor (PDGF) were selected for use in 
an electrochemical biosensor using non-faradic impedance spectroscopy, showing a 
detection limit of 40nM; as was an aptamer selected for interferon-v, which was able to 
detect the target down to a level of lpM [133]. 
Both Cocaine and 17-13 estradiol aptamers have also been used in electrochemical 
detection svstems and measured using a redox reaction; the detection limit of 17-13 
estradiol being 10pM [133). 
1.3.7 Modifications to the selection procedure: 
Extracellular signal-related kinase (ERK) is the third protein in the MAP kinase cascade. It 
is activated downstream of Raf-l by MEK, and once activated, it can also lead to cell 
proliferation and differentiation [1, 109]. Bianchini et 01. [82] wanted to shorten the 
length of time taken to run selection, whilst still yielding high affinity binding aptamers, 
and used a process with only two selection steps against the target, ERK2. The first 
selection step utilised a synthetic peptide target corresponding to a fragment of ERK2, 
which contained the two phosphorylation (and therefore, activation) sites, T183 and y18S 
[136]. After peR amplification of the bound product, the target was then 'switched' [83, 
84] to an extract of proteins from a cell line, containing the full-length ERK2 protein. The 
amplified products were Incubated with this, and separated on a nitrocellulose 
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membrane to yield ERK2 specific polyclonal aptamers, which were then amplified by PCR 
and cloned. After screening of clones, an aptamer was found to selectively inhibit ERK2 
with a binding affinity of 63nM (82). 
A problem that White et al. (85) attempted to overcome with selecting RNA aptamers for 
Thrombin was cross-reactivity between different species. When an aptamer is selected 
using a protein target derived from an animal model and tested in the same model, it may 
show high affinity and specificity. However, it may not exhibit the same properties when 
tested in humans, unless the protein is very highly evolutionarily conserved, risking failure 
in clinical trials (85). Using a modified SElEX procedure, they hoped to overcome this by 
alternating porcine and human thrombin as the target in each SElEX round. Thrombin is 
a serine protease which acts as a coagulation protein by converting fibrinogen into fibrin 
and by activating other reactions in the coagulation cascade. It has been suggested that it 
also has a role in cellular proliferation after damage occurring to the vascular system (85). 
This method of SElEX removed non-binding aptamers and aptamers that only bound to 
one of the two targets, leaving high affinity aptamers, which bound to both targets, and 
were then truncated to 25 nucleotides in length. One truncated RNA aptamer bound to 
human thrombin with a Ko of O.54±O.lnM and porcine thrombin with a Ko of 1.4±O.3nM, 
showing that this method not only angled the selection process towards the more 
evolutionarily conserved region of the target, but that, in doing so, no compromise was 
made on the affinity for either target, as the aptamer bound to both with a very high 
affinity (85). 
Tenascin-C (TN-C), an extracellular matrix glycoprotein which is overexpressed during 
tissue remodelling, including tumour growth, was a target for Hicke et 01.[78]. Recent 
evidence has shown that the fibrinogen-like domain of TN-C may bind to a critical integrin 
involved in angiogenesis, av'h [137], and that expression of TN-C in tumours correlates 
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with poor prognosis. Hicke et 01. used a method of 'target switching' between purified 
protein and cell SELEX on TN-C expressing U251 glioblastoma cells, to generate aptamers 
to TN-C [78]. The reasons behind this were to exploit the advantages of easy and rapid 
selection on purified proteins, and expression of the protein in its native state in cell 
SELEX. This would ensure that the enriched aptamers recognise and bind to both the 
purified and native protein, and would make testing in vitro and hopefully in vivo more 
successful. A 13kDa aptamer was produced and then modified by substituting 15 of the 
19 purines with 2'-OCH3 groups to ensure it was more stable against nudeases. It then 
showed a binding affinity of 5x10-9M with the fibrinogen-like domain of TN-C, potentially 
interfering with the binding to aV~3 and hence, angiogenesis. 
Aptamers have also been produced using non-SELEX methods. Berezovski et 01. [86-88] 
developed equilibrium and nonequilibrium capillary electrophoresis of equilibrium 
mixtures (ECEEM and NECEEM). NECEEM attempts to overcome the problems of the 
heterogeneous methods of selection described above, where the target is immobilised to 
a solid phase, as this is quite often expensive, time-consuming and unreliable as not only 
non-specific binding of ligand to the surface may be experienced, but by immobilising the 
target to a solid phase, it may change its conformation [86-88]. These techniques are 
carried out by incubating the aptamers and target to obtain an equilibrium mixture, 
which is then injected into a capillary and run under electrophoresis to remove unbound 
aptamers and secondly, to measure the fraction of aptamer·target complexes and 
dissociated aptamers from these complexes. These methods not only simplify the 
selection procedure by carrying it out in one round, but allow simultaneous calculation of 
Kd and !<off, and has the potential to be automated to become of even more use [86-88]. 
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1.3.8 Future research and scope 
It is evident that the properties of aptamers make them excellent candidates for 
diagnostic use, with only relatively minor modifications needed. However, it is important 
when considering any drug for therapeutic use, to ensure that it can be administered 
effectively, is not broken down and excreted before it carries out its function, and that it 
does not cause an immune response. Aptamers have a high potential to do this, but 
modifications are often needed as the aptamer has many hurdles to overcome before it 
even reaches its target in the body. In time, research will deliver better and more 
competent aptamers for use in vivo and the modifications to selection procedures found 
to be successful will only aid this progress. A molecule called a spiegel mer has been 
developed as a therapeutic reagent in cancer [138] and is designed to overcome the 
problem of in vivo stability that has been associated with aptamers. Spiegelmers are 
comprised of L-ribose or L-2'-deoxyribose, creating mirror image oligonucleotides with 
enhanced in vivo stability compared with aptamers. One such spiegelmer inhibits the 
cascade for release of Gonadotropin-releasing hormone (GnRH) [138], the hormone 
responsible for releasing gonadotropins, lutein ising hormone (LH) and follicle stimulating 
hormone (FSH) in mammalian reproduction [139]. This is important as prostate and 
breast cancers are caused by these hormones [140, 141], as well as endometriosis. The 
spiegelmer showed a Ko of 20nM for GnRH, and high specificity, as when GnRH was 
substituted with an analogue of GnRH (Buserelin), showing a closely related structure, the 
spiegelmer showed no antagonistic activity towards it [138]. Animal studies were 
conducted, which demonstrated that the coupling of the spiegelmer with PEG, not only 
did it not have any adverse effect on the spiegelmer's specificity and biological activity, 
but it caused the molecule to be retained for a longer period of time, causing its activity 
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to be comparable with the drug Cetrorelix, which is a marketed GnRH antagonist [138]. 
The spiegelmer also exhibited no immune response, which is important in assessing the 
safety of the molecule for long-term use [138]. 
1.4 Alms of This Project 
The main aim of this project was to develop aptamers that bind to and selectively 
recognise human recombinant polymorphic heparanase and parts of the protein, for 
potential use in both diagnostic and therapeutic applications. As targets of the project we 
have identified the active heparanase heterodimer, comprised by the 50 and 8kDa 
subunits of heparanase, as well as the linker peptide of the protein, which is 
proteolytically excised from the proenzyme to result in the active enzyme. The reason for 
selecting these two targets of the enzyme was to verify if we could detect the presence 
and inhibit the action of the active enzyme or, in the case of the linker peptide, to see if 
we could block the proteolytic cleavage of this peptide, thus locking the enzyme in the 
inactive proenzymatic form as well as identify the as yet unknown fate of the cleaved 
peptide. 
Experiments were designed to test generated aptamers using a number of different 
assays, then to select the most promising aptamer(s) for further development. Firstly, 
aptamers' binding and affinity were to be characterised using biochemical and 
physicochemical assays such as electrophoretic mobility shift assays (EMSA), fluorescence 
titrations, competition and sandwich enzyme-linked immunosorbent assays (ElISAs), 
using a heparanase polyclonal antibody as a positive control for comparison purposes. 
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Upon distinguishing aptamers with the highest binding affinities for heparanase, these 
would be tested using human tissue in immunohistochemistry and immunofluorescence 
experiments and compared to the heparanase polyclonal antibody as a positive control, 
plus a negative control, to examine if the aptamers bind heparanase specifically and the 
extent of their binding. 
Subject to the aptamers' performance in these assays, they were then to be tested for 
their therapeutic and diagnostic potential. It was determined that to evaluate their 
therapeutic potential, their enzyme inhibiting function would be evaluated in different 
types of invasion assays, as well as their non-specific interaction with serum proteins and 
their susceptibility to nuclease degradation, crucial for the in vivo administration of the 
aptamers. To investigate the diagnostic potential of the aptamers and their ability to 
detect the presence of low levels of heparanase in biological media as an indication of 
metastasis and disease progression, the stability of the aptamers in serum would be 
crucial, as well as the performance of the aptamers in diagnostic assays. This would be 
evaluated in ELISA and quartz crystal microbalance assays that would be relevant for 
clinical settings. In this thesis I am presenting my findings from such studies and 
discussing my results and the future potential my studies open for the development of 
such heparanase aptamers into diagnostic or therapeutic agents. 
Page I 37 
References: 
1. Cowley, S., D. Male, I. Romero, and J. Saffrey, The Interactive Cell. S377 Molecular 
and Cell Biology, ed. I. Nuttall, et al. Vol. 1. 2004: The Open University. 134-135. 
2. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): p. 57-
70. 
3. Missailidis,S., ed. Anticancer Therapeutics. 2008, John Wiley & Sons, ltd. 404. 
4. Itoh, T., M. Tanioka, H. Matsuda, H. Nishimoto, T. Yoshioka, R. Suzuki, and M. 
Uehira, Experimental metastasis is suppressed in MMP-9-deficient mice. elin Exp 
Metastasis, 1999. 17(2): p. 177-81. 
5. Nicolson, G.l., Cancer metastasis. Organ colonization and the cell-surface 
properties of malignant cells. Biochim Biophys Acta, 1982. 695(2): p. 113-76. 
6. Nicolson, G.l. and G. Poste, Tumor cell diversity and host responses in cancer 
metastasis--part I--properties of metastatic cells. Curr Probl Cancer, 1982. 7(6): p. 
1-83. 
7. Paste, G. and IJ. Fidler, The pathogenesis of cancer metastasis. Nature, 1980. 
283(5743): p. 139-46. 
8. Nakajima, M., T. Irimura, D. Oi Ferrante, N. Oi Ferrante, and G.L. Nicolson, Heparan 
sulfate degradation: relation to tumor invasive and metastatic properties of mouse 
816 melanoma sublines. Science, 1983.220(4597): p. 611-3. 
9. Nakajima, M., T. Irimura, N. Oi Ferrante, and G.L. Nicolson, Metastatic melanoma 
cell heparanase. Characterization of heparan sulfate degradation fragments 
produced by 816 melanoma endoglucuronidase. J Bioi Chern, 1984. 159(4): p. 
2283-90. 
Page 138 
10. Li, J.P. and I. Vlodavsky, Heparin, heparan sulfate and heparanase in inflammatory 
reactions. Thromb Haemost, 2009. 102(5): p. 823-8. 
11. Kjellen, L. and U. Lindahl, Proteoglycans: structures and interactions. Annu Rev 
Biochem, 1991. 60: p. 443-75. 
12. Aldrich, S. Heparan Sulphate. [Webpage] 2006 [cited 05/05/2006]; Available from: 
http://www.sigmaaldrich.com/img/assets/19500/heparinase heparin.gif. 
13. Bernfield, M., M. Gotte, P.W. Park, O. Reizes, M.L. Fitzgerald, J. lincecum, and M. 
Zako, Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem, 
1999. 68: p. 729-77. 
14. lin, X., Functions of heparan sulfate proteoglycans in cell signaling during 
development. Development, 2004. 131(24): p. 6009-21. 
15. Whitelock, J.M. and R.V. lozzo, Heparan sulfate: a complex polymer charged with 
biological activity. Chern Rev, 2005. 105(7): p. 2745-64. 
16. Laurie, G.W., c.P. Leblond, and G.R. Martin, Localization of type IV collagen, 
laminin, heparan sulfate proteoglycan, and fibronectin to the basal lamina of 
basement membranes. J Cell Bioi, 1982. 95(1): p. 340-4. 
17. Lindahl, U., M. Kusche-Gullberg, and L. Kjellen, Regulated diversity of heparan 
sulfate. J Bioi Chern, 1998. 273(39): p. 24979-82. 
18. Spillmann, D., D. Witt, and U. Lindahl, Defining the interleukin-8-binding domain of 
heparan sulfate. J Bioi Chern, 1998. 273(25): p. 15487-93. 
19. Lortat-Jacob, H., J.E. Turnbull, and J.A. Grimaud, Molecular organization of the 
interferon gamma-binding domain in heparan sulphate. Biochem J, 1995. 310 ( Pt 
2): p. 497-505. 
20. Stringer, S.E. and J.T. Gallagher, Specific binding of the chemokine platelet factor 4 
to heparan sulfate. J Bioi Chern, 1997. 272(33): p. 20508-14. 
Page I 39 
21. Pikas, D.S., J.P. Li, I. Vlodavsky, and U. Lindahl, Substrate specificity of heparanases 
from human hepatoma and platelets. J Bioi Chem, 1998. 273(30): p. 18770-7. 
22. Dong, J., A.K. Kukula, M. Toyoshima, and M. Nakajima, Genomic organization and 
chromosome localization of the newly identified human heparanase gene. Gene, 
2000.253(2): p. 171-8. 
23. Levy-Adam, F., H.Q. Miao, R.L. Heinrikson, I. Vlodavsky, and N. lIan, Heterodimer 
formation is essential for heparanase enzymatic activity. Biochem Biophys Res 
Commun, 2003. 308(4): p. 885-91. 
24. McKenzie, E., K. Young, M. Hircock, J. Bennett, M. Bhaman, R. Felix, P. Turner, A. 
Stamps, D. McMillan, G. Saville, S. Ng, S. Mason, D. Snell, D. Schofield, H. Gong, R. 
Townsend, J. Gallagher, M. Page, R. Parekh, and C. Stubberfield, Biochemical 
characterization of the active heterodimer form of human heparanase (Hpal) 
protein expressed in insect cells. Biochem J, 2003. 373(Pt 2): p. 423-35. 
25. Fairbanks, M.B., A.M. Mildner, J.W. Leone, G.S. Cavey, W.R. Mathews, R.F. Drong, 
J.L. Slightom, MJ. Bienkowski, C.W. Smith, C.A. Bannow, and R.L. Heinrikson, 
Processing of the human heparanase precursor and evidence that the active 
enzyme is a heterodimer. J Bioi Chem, 1999. 274(42): p. 29587-90. 
26. Abboud-Jarrous, G., Z. Rangini-Guetta, H. Aingorn, R. Atzmon, S. Elgavish, T. 
Peretz, and I. Vlodavsky, Site-directed mutagenesis, proteolytic cleavage, and 
activation of human proheparanase. J Bioi Chem, 2005. 280(14): p. 13568-75. 
27. Koliopanos, A., H. Friess, J. Kleeff, X. Shi, Q. Liao, I. Peeker, I. Vlodavsky, A. 
Zimmermann, and M.W. Buchler, Heparanase expression in primary and 
metastatic pancreatic cancer. Cancer Res, 2001. 61(12): p. 4655-9. 
Page 140 
28. Shteper, P.J., E. Zcharia, Y. Ashhab, T. Peretz, I. Vlodavsky, and D. Ben-Yehuda, 
Role of promoter methylation in regulation of the mammalian heparanase gene. 
Oncogene, 2003. 22(49): p. 7737-49. 
29. Simizu, S., K. Ishida, M.K. Wierzba, T.A. Sato, and H. Osada, Expression of 
heparanase in human tumor cell lines and human head and neck tumors. Cancer 
Lett, 2003. 193(1): p. 83-9. 
30. de Mestre, A.M., S. Rao, lR. Hornby, T. Soe-Htwe, L.M. Khachigian, and M.D. 
Hulett, Early growth response gene 1 (EGR1) regulates heparanase gene 
transcription in tumor cells. J Bioi Chern, 2005. 280(42): p. 35136-47. 
31. Baraz, L., Y. Haupt, M. Elkin, T. Peretz, and I. Vlodavsky, Tumor suppressor p53 
regulates heparanase gene expression. Oncogene, 2006. 25(28): p. 3939-47. 
32. Chen, G., D. Wang, R. Vikramadithyan, H. Yagyu, U. Saxena, S. Pillarisetti, and I.J. 
Goldberg, Inflammatory cytokines and fatty acids regulate endothelial cell 
heparanase expression. Biochemistry, 2004. 43(17): p. 4971-7. 
33. Sandwall, E., S. Bodevin, N.J. Nasser, E. Nevo, A. Avivi, I. Vlodavsky, and J.P. Li, 
Molecular structure of heparan sulfate from Spa lax. Implications of heparanase 
and hypoxia. J Bioi Chern, 2009. 284(6): p. 3814-22. 
34. Shafat, \., I. Vlodavsky, and N. lIan, Characterization 0/ mechanisms involved in 
secretion 0/ active heparanase. J Bioi Chern, 2006. 281(33): p. 23804-11. 
35. Nadav, L., A. Eldor, O. Yacoby-Zeevi, E. Zamir, I. Peeker, N. lIan, B. Geiger, I. 
Vlodavsky, and B.Z. Katz, Activation, processing and trafficking of extracellular 
heparanase by primary human/ibroblasts. J Cell Sci, 2002. 11S(Pt 10): p. 2179-87. 
36. Vlodavsky, I., N. lIan, A. Naggi, and B. Casu, Heparanase: structure, biological 
functions, and inhibition by heparin-derived mimetics 0/ heparan sui/ate. Curr 
Pharm Des, 2007.13(20): p. 2057-73. 
Page 141 
37. Hulett, M.D., J.R. Hornby, S.J. Ohms, J. Zuegg, C. Freeman, J.E. Gready, and C.R. 
Parish, Identification of active-site residues of the pro-metastatic endoglycosidase 
heparanase. Biochemistry, 2000.39(51): p. 15659-67. 
38. Levy-Adam, F., G. Abboud-Jarrous, M. Guerrini, D. Beccati, I. Vlodavsky, and N. 
lIan, Identification and characterization of heparin/heparan sulfate binding 
domains of the endoglycosidase heparanase. J Bioi Chem, 2005. 280(21): p. 20457-
66. 
39. Nardella, c., A. Lahm, M. Pallaoro, M. Brunetti, A. Vannini, and C. Steinkuhler, 
Mechanism of activation of human heparanase investigated by protein 
engineering. Biochemistry, 2004. 43(7): p. 1862-73. 
40. Adams, D.H. and S. Shaw, Leucocyte-endothelial interactions and regulation of 
leucocyte migration. Lancet, 1994.343(8901): p. 831-6. 
41. Blotnick, 5., G.E. Peoples, M.R. Freeman, TJ. Eberlein, and M. Klagsbrun, T 
lymphocytes synthesize and export heparin-binding epidermal growth factor-like 
growth factor and basic fibroblast growth factor, mitogens for vascular cells and 
fibroblasts: differential production and release by CD4+ and CD8+ T cells. Proc Natl 
Acad Sci USA, 1994. 91(8): p. 2890-94. 
42. GHat, D., R. Hershkoviz, I. Goldkorn, L. Cahalon, G. Korner, I. Vlodavsky, and O. 
Lider, Molecular behavior adapts to context: heparanase functions as an 
extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending 
on the local pH. J Exp Med, 1995.181(5): p. 1929-34. 
43. Hulett, M.D., C. Freeman, BJ. Hamdori, R.T. Baker, M.l Harris, and C.R. Parish, 
Cloning of mammalian heparanase, an important enzyme in tumor invasion and 
metastasis. Nat Med, 1999. 5(7): p. 803-9. 
Page 142 
44. Vlodavsky, I., A. Eldor, A. Haimovitz-Friedman, Y. Matzner, R. Ishai-Michaeli, O. 
lider, Y. Naparstek, I.R. Cohen, and Z. Fuks, Expression of heparanase by platelets 
and circulating cells of the immune system: possible involvement in diapedesis and 
extravasation. Invasion Metastasis, 1992. 12(2): p. 112-27. 
45. Nakajima, M. Tumor Heparanase. Glycoword - Proteoglycan [Webpage] 2001 
30/06/2001 [cited 2010 05/08/2010]; Available from: 
www.gak.co.jp/FCCA/glycoword/PGA10/PGA10E.html. 
46. Chen, X.P., Y.B. liu, J. Rui, S.Y. Peng, C.H. Peng, Z.Y. Zhou, l.H. Shi, H.W. Shen, and 
B. Xu, Heparanase mRNA expression and point mutation in hepatocellular 
carcinoma. World J Gastroenterol, 2004. 10(19): p. 2795-9. 
47. Gohji, K., H. Hirano, M. Okamoto, s. Kitazawa, M. Toyoshima, J. Dong, Y. Katsuoka, 
and M. Nakajima, Expression of three extracellular matrix degradative enzymes in 
bladder cancer. Int J Cancer, 2001.95(5): p. 295-301. 
48. Goldshmidt, 0., E. Zcharia, R. Abramovitch, S. Metzger, H. Aingorn, Y. Friedmann, 
V. Schirrmacher, E. Mitrani, and I. Vlodavsky, Cell sUrface expression and secretion 
of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl 
Acad Sci USA, 2002.99(15): p. 10031-6. 
49. Gingis-Velitski, 5., A. Zetser, M.Y. Flugelman, I. Vlodavsky, and N. lIan, Heparanase 
induces endothelial cell migration via protein kinase B/ Akt activation. J Bioi Chem, 
2004. 279(22): p. 23536-41. 
50. Zetser, A., Y. Bashenko, E. Edovitsky, F. levy-Adam, I. Vlodavsky, and N. lIan, 
Heparanase induces vascular endothelial growth factor expression: correlation 
with p38 phosphorylation levels and Src activation. Cancer Res, 2006. 66(3): p. 
1455-63. 
Page I 43 
51. Hoogewerf, AJ., lW. leone, 10M. Reardon, W,J. Howe, D. Asa, R.l. Heinrikson, and 
S.R. ledbetter, CXC chemokines connective tissue activating peptide-III and 
neutrophil activating peptide-2 are heparin/heparan sulfate-degrading enzymes. J 
Bioi Chem, 1995. 270(7): p. 3268-77. 
52. Oosta, G.M., l.V. Favreau, D.l. Beeler, and R.D. Rosenberg, Purification and 
properties of human platelet heparitinase. J Bioi Chem, 1982. 257(19): p. 11249-
55. 
53. Tannock, I.F. and D. Rotin, Acid pH in tumors and its potential for therapeutic 
exploitation. Cancer Res, 1989. 49(16): p. 4373-84. 
54. Ralph,S., P.E. Brenchley, A. Summers, D.O. Rosa, R. Swindell, and G.C. Jayson, 
Heparanase gene haplotype (CGC) is associated with stage of disease in patients 
with ovarian carcinoma. Cancer Sci, 2007.98(6): p. 844-9. 
55. Vlodavsky, I., O. Goldshmidt, E. Zcharia, R. Atzmon, Z. Rangini-Guatta, M. Elkin, T. 
Peretz, and Y. Friedmann, Mammalian heparanase: involvement in cancer 
metastasis, angiogenesis and normal development. Semin Cancer Bioi, 2002. 
12(2): p. 121-9. 
56. Gohji, K., M. Okamoto, S. Kitazawa, M. Toyoshima, J. Dong, Y. Katsuoka, and M. 
Nakajima, Heparanase protein and gene expression in bladder cancer. J Urol, 2001. 
166(4): p. 1286-90. 
57. Marchetti, D. and G.l. Nicolson, Human heparanase: a molecular determinant 0/ 
brain metastasis. Adv Enzyme Regul, 2001. 41: p. 343-59. 
58. Maxhimer, J.B., R.M. Quiros, R. Stewart, K. Dowlatshahi, P. Gattuso, M. Fan, R.A. 
Prinz, and X. Xu, Heparanase-l expression is associated with the metastatic 
potential 0/ breast cancer. Surgery, 2002. 132(2): p. 326-33. 
Page I 44 
59. Friedmann, V., I. Vlodavsky, H. Aingorn, A. Aviv, T. Peretz, I. Peeker, and O. Pappo, 
Expression of heparanase in normal, dysplastic, and neoplastic human colonic 
mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol, 
2000.157(4): p. 1167-75. 
60. Tang, W., V. Nakamura, M. Tsujimoto, M. Sato, X. Wang, K. Kurozumi, M. 
Nakahara, K. Nakao, M. Nakamura, I. Mori, and K. Kakudo, Heparanase: a key 
enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol, 2002. 15(6): 
p.593-8. 
61. Mikami, 5., K. Ohashi, V. Usui, T. Nemoto, K. Katsube, M. Vanagishita, M. Nakajima, 
K. Nakamura, and M. Koike, Loss of syndecan-l and increased expression of 
heparanase in invasive esophageal carcinomas. Jpn J Cancer Res, 2001. 92(10): p. 
1062-73. 
62. Ikuta, M., K.A. Podyma, K. Maruyama, S. Enomoto, and M. Vanagishita, Expression 
of heparanase in oral cancer cell lines and oral cancer tissues. Oral Oncol, 2001. 
37(2): p. 177-84. 
63. Kim, A.W., X. Xu, E.F. Hollinger, P. Gattuso, C.V. Godellas, and R.A. Prinz, Human 
heparanase-l gene expression in pancreatic adenocarcinoma. J Gastrointest Surg, 
2002. &(2): p. 167-72. 
64. Rohloff, J., J. Zinke, K. Schoppmeyer, A. Tannapfel, H. Witzigmann, J. Mossner, C. 
Wittekind, and K. Caca, Heparanase expression is a prognostic Indicator for 
postoperative survival in pancreatic adenocarcinoma. Sr J Cancer, 2002. 86(8): p. 
1270-5. 
65. He, X., P.E. Srenchley, G.C. Jayson, L. Hampson, J. Davies, and I.N. Hampson, 
Hypoxia increases heparanase-dependent tumor cell invasion, which can be 
inhibited by antiheparanase antibodies. Cancer Res, 2004. 64(11): p. 3928-33. 
Page 145 
66. Myler, H.A., E.A. Lipke, E.E. Rice, and lL. West, Novel heparanase-inhibiting 
antibody reduces neointima formation. J Biochem (Tokyo), 2006. 139(3): p. 339-
45. 
67. Bar-Ner, M., A. Eldor, L. Wasserman, Y. Matzner, loR. Cohen, Z. Fuks, and 10 
Vlodavsky, Inhibition of heparanase-mediated degradation of extracellular matrix 
heparan sulfate by non-anticoagulant heparin species. Blood, 1987. 70(2): p. 551-
7. 
68. Chuang, W.L., M.D. Christ, 1 Peng, and D.L. Rabenstein, An NMR and molecular 
modeling study of the site-specific binding of histamine by heparin, chemically 
modified heparin, and heparin-derived oligosaccharides. Biochemistry, 2000. 
39(13): p. 3542-55. 
69. Parish, C.R., C. Freeman, K.J. Brown, OJ. Francis, and W.B. Cowden, Identification 
of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using 
novel in vitro assays for angiogenesis and heparanase activity. Cancer Res, 1999. 
59(14): p. 3433-41. 
70. Nader, H.B., M.A. Porcionatto, LL. Tersariol, M.A. Pinhal, F.W. Oliveira, C.T. 
Moraes, and C.P. Dietrich, Purification and substrate specificity of heparitinase I 
and heparitinase 1/ from Flavobacterium heparinum. Analyses of the heparin and 
heparan sulfate degradation products by 13C NMR spectroscopy. J Bioi Chem, 
1990. 265(28): p. 16807-13. 
71. Khasraw, M., N. Pavlakis, S. McCowatt, C. Underhill, S. Begbie, P. de Souza, A. 
Boyce, F. Parnis, V. Lim, R. Harvie, and G. Marx, Multicentre phase 1/1/ study of PI-
88, a heparanase inhibitor in combination with docetaxel in patients with 
metastatic castrate-resistant prostate cancer. Ann Oneol, 2009. 
Page 146 
72. Lewis, K.D., W.A. Robinson, MJ. Millward, A. Powell, TJ. Price, D.B. Thomson, E.T. 
Walpole, A.M. Haydon, B.R. Creese, K.L. Roberts, lR. Zalcberg, and R. Gonzalez, A 
phase II study of the heparanase inhibitor PI-88 in patients with advanced 
melanoma. Invest New Drugs, 2008. 26(1): p. 89-94. 
73. Ishida, K., G. Hirai, K. Murakami, T. Teruya, S. Simizu, M. Sodeoka, and H. Osada, 
Structure-based design of a selective heparanase inhibitor as an antimetastatic 
agent. Mol Cancer Ther, 2004. 3(9): p. 1069-77. 
74. Courtney, S.M., P.A. Hay, R.T. Buck, e.S. Colville, OJ. Phillips, 0.1. Scopes, F.e. 
Pollard, M.J. Page, J.M. Bennett, M.L. Hircock, E.A. McKenzie, M. Bhaman, R. Felix, 
e.R. Stubberfield, and P.R. Turner, Furanyl-l,3-thiazol-2-yl and benzoxazol-5-yl 
acetic acid derivatives: novel classes of heparanase inhibitor. Bioorg Med Chem 
Lett, 2005. 15(9): p. 2295-9. 
75. Famulok, M. and G. Mayer, Aptamers as tools in molecular biology and 
immunology. Curr Top Microbiollmmunol, 1999. 243: p. 123-36. 
76. Gold, L., B. Polisky, O. Uhlenbeck, and M. Varus, Diversity of oligonucleotide 
functions. Annu Rev Biochem, 1995.64: p. 763-97. 
77. Osborne, S.E., I. Matsumura, and A.D. Ellington, Aptamers as therapeutic and 
diagnostic reagents: problems and prospects. Curr Opin Chem Bioi, 1997. 1(1): p. 
5-9. 
78. Hicke, BJ., C. Marion, V.F. Chang, T. Gould, C.K. lynott, D. Parma, P.G. Schmidt, 
and S. Warren, Tenascin-C aptamers are generated using tumor cells and purified 
protein. J Bioi Chem, 2001. 276(52): p. 48644-54. 
79. Morris, K.N., K.B. Jensen, C.M. Julin, M. We ii, and l. Gold, High affinity ligands 
from in vitro selection: complex targets. Proc Natl Acad Sci USA, 1998. 95(6): p. 
2902-7. 
Page 147 
80. Brody, E.N. and L. Gold, Aptamers as therapeutic and diagnostic agents. J 
Biotechnol, 2000. 74(1): p. 5-13. 
81. Ellington, A.D. and J.W. Szostak, In vitro selection of RNA molecules that bind 
specific ligands. Nature, 1990. 346(6287): p. 818-22. 
82. Bianchini, M., M. Radrizzani, M.G. Brocardo, G.B. Reyes, C. Gonzalez Solveyra, and 
l.A. Santa-Coloma, Specific oligobodies against ERK-2 that recognize both the 
native and the denatured state of the protein. J Immunol Methods, 2001. 252{1-2): 
p.191-7. 
83. Radrizzani, M., M.G. Brocardo, C. Gonzalez Solveyra, M. Bianchini, G.B. Reyes, E.G. 
Cafferata, G. Vila Ortiz, and l.A. Santa-Coloma, Development of monoclonal 
o/igobodies and chemically synthesized o/igobodies. Medicina (B Aires), 2000. 60 
Suppl 2: p. 55-60. 
84. Radrizzani, M., M. Broccardo, C. Gonzalez Solveyra, M. Bianchini, G.B. Reyes, E.G. 
Cafferata, and l.A. Santa-Coloma, Oligobodies: bench made synthetic antibodies. 
Medicina (B Aires), 1999. 59(6): p. 753-8. 
85. White, R., C. Rusconi, E. Scardino, A. Wolberg, J. lawson, M. Hoffman, and B. 
Sullenger, Generation of species cross-reactive aptamers using "toggle" SELEX. Mol 
lher, 2001. 4(6): p. 567-73. 
86. Berezovski, M., A. Drabovich, S.M. Krylova, M. Musheev, V. Okhonin, A. Petrov, 
and S.N. Krylov, Nonequilibrium capillary electrophoresis of equilibrium mixtures: a 
universal tool for development of aptamers. Journal of the American Chemical 
Society, 2005. 127(9): p. 3165-3171. 
87. Berezovski, M., M. Musheev, A. Drabovich, and S.N. Krylov, Non-SELEX selection 0/ 
aptamers. Journal of the American Chemical SOciety, 2006.128(5): p. 1410-1411. 
Page 148 
88. Drabovich, A., M. Berezovski, and S.N. Krylov, Selection of smart aptamers by 
equilibrium capillary electrophoresis of equilibrium mixtures (ECEEM). Journal of 
the American Chemical Society, 2005. 127(32): p. 11224-11225. 
89. Di Giusto, D.A. and G.c. King, Construction, stability, and activity of multivalent 
circular anticoagulant aptamers. J Bioi Chern, 2004. 279(45): p. 46483-9. 
90. Zuker, M., Mfold web server for nucleic acid folding and hybridization prediction. 
Nucleic Acids Res, 2003.31(13): p. 3406-15. 
91. Bates, P.J., J.B. Kahlon, S.D. Thomas, J.~. Trent, and D.M. Miller, Antiprolijerative 
activity of G-rich oligonucleotides correlates with protein binding. The Journal of 
biological chemistry, 1999. 274(37): p. 26369-26377. 
92. Xu, X., F. Hamhouyia, S.D. Thomas, T.J. Burke, A.C. Girvan, W.G. McGregor, J.O. 
Trent, D.M. Miller, and PJ. Bates, Inhibition of DNA replication and induction of S 
phase cell cycle arrest by G-rich oligonucleotides. The Journal of biological 
chemistry, 2001. 276(46): p. 43221-43230. 
93. Laughlin, A.J., O.K. Male, S. Missailidis, R. Mileusnic, and M.C. Hirst, From 
Molecules To Cells. S377 Molecular and Cell Biology, ed. G. Bearman, et al. Vol. 1. 
2004, Milton Keynes. 311. 
94. Jellinek, D., loS. Green, C. Bell, C.K. lynott, N. Gill, C. Vargeese, G. Kirschenheuter, 
D.P. McGee, P. Abesinghe, W.A. Pieken, and et aI., Potent 2'-amino-2'-
deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry, 
1995.34(36): p. 11363-72. 
95. Ruckman, J., loS. Green, J. Beeson, S. Waugh, W.L. Gillette, D.O. Henninger, L. 
Claesson-Welsh, and N. Janjic, 2'-Fluoropyrimidine RNA-based aptamers to the 
165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of 
Page 149 
receptor binding and VEGF-induced vascular permeability through interactions 
requiring the exon 7-encoded domain. J Bioi Chem, 1998. 273(32): p. 20556-67. 
96. Floege, J., T. Ostendorf, U. Janssen, M. Burg, H.H. Radeke, C. Vargeese, S.C. Gill, 
L.S. Green, and N. Janjic, Novel approach to specific growth factor inhibition in 
vivo: antagonism of platelet-derived growth factor in glomerulonephritis by 
aptamers. Am J Pathol, 1999. 154(1): p. 169-79. 
97. Oa Pieve, c., P. Williams, O.M. Haddleton, R.M. Palmer, and S. Missailidis, 
Modification of thiol functionalized aptamers by conjugation of synthetic 
polymers. Bioconjug Chem. 21(1): p. 169-74. 
98. Hicke, BJ., A.W. Stephens, T. Gould, Y.-F. Chang, C.K. lynott, J. Heil, S. Borkowski, 
c.-S. Hilger, G. Cook, S. Warren, and P.G. Schmidt, Tumor Targeting by an 
Aptamer. J Nucl Med, 2006. 47(4): p. 668-678. 
99. Cao, Z., R. Tong, A. Mishra, W. Xu, G.C. Wong, J. Cheng, and Y. lu, Reversible eel/-
specific drug delivery with aptamer-functionalized Iiposomes. Angew Chem Int Ed 
Engl, 2009. 48(35): p. 6494-8. 
100. Pi eve, C.O., A.c. Perkins, and S. Missailidis, Anti-MUCl aptamers: radiolabelling 
with (99m)Tc and biodistribution in MCF-7 tumour-bearing mice. Nucl Med Bioi, 
2009. 36(6): p. 703-10. 
101. Gragoudas, E.S., A.P. Adamis, E.T. Cunningham, Jr., M. Feinsod, O.R. Guyer, and 
V.I.SJ.O.N.C.T.G. the, Pegaptanib for Neovascular Age-Related Macular 
Degeneration. N Engl J Med, 2004. 351(27): p. 2805-2816. 
102. Soundararajan, S., W. Chen, E.K. Spicer, N. Courtenay-luck, and O.J. Fernandes, 
The Nucleolin Targeting Aptamer AS1411 Destabilizes 8cl-2 Messenger RNA in 
Human Breast Cancer Cells. Cancer Res, 2008. 68(7): p. 2358-2365. 
Page I 50 
103. Gilbert, J.c., T. DeFeo-Fraulini, R.M. Hutabarat, C.J. Horvath, P.G. Merlino, H.N. 
Marsh, J.M. Healy, S. BouFakhreddine, T.V. Holohan, and R.G. Schaub, First-in-
Human Evaluation of Anti von Willebrand Factor Therapeutic Aptamer ARC1779 in 
Healthy Volunteers. Circulation, 2007. 116(23): p. 2678-2686. 
104. Group, E.S., Preclinical and phase lA clinical evaluation of an anti-VEGF pegylated 
aptamer (EYE001) for the treatment of exudative age-related macular 
degeneration. Retina (Philadelphia, Pa.), 2002. 22(2): p. 143-152. 
105. Miles, A.A. and E.M. Miles, Vascular reactions to histamine, histamine-liberator 
and leukotaxine in the skin of guinea-pigs. J Physiol, 1952. 118(2): p. 228-57. 
106. Basilico, C. and D. Moscatelli, The FGF family of growth factors and oncogenes. 
Adv Cancer Res, 1992. 59: p. 115-65. 
107. Miyamoto, M., K. Naruo, C. Seko, S. Matsumoto, T. Kondo, and T. Kurokawa, 
Molecular cloning of a novel cytokine cDNA encoding the ninth member of the 
fibroblast growth factor family, which has a unique secretion property. Mol Cell 
Bioi, 1993. 13(7): p. 4251-9. 
108. Tanaka, A., K. Miyamoto, N. Minamino, M. Takeda, B. Sato, H. Matsuo, and K. 
Matsumoto, Cloning and characterization of an androgen-induced growth factor 
essential for the androgen-dependent growth of mouse mammary carcinoma cells. 
Proc Natl Acad Sci USA, 1992.89(19): p. 8928-32. 
109. Cowley,S., D. Male, R. Mileusnic, I. Romero, J. Saffrey, and R. Saunders, The 
Dynamic Cell. 5377 Molecular and Cell Biology, ed. G. Bearman, et al. Vol. 2. 2004. 
117-119. 
110. Slomowitz, l.A., Progression of renal disease. N Engl j Med, 1988. 319(23): p. 
1547-8. 
Page I 51 
111. Chuang, E., D. Barnard, L. Hettich, X.F. Zhang, J. Avruch, and M.S. Marshall, Critical 
binding and regulatory interactions between Ras and Raf occur through a small, 
stable N-terminal domain of Raf and specific Ras effector residues. Mol Cell Bioi, 
1994. 14(8): p. 5318-25. 
112. Herrmann, c., G.A. Martin, and A. Wittinghofer, Quantitative analysis of the 
complex between p21ras and the Ras-binding domain of the human Raf-l protein 
kinase. J Bioi Chem, 1995. 270(7): p. 2901-5. 
113. Vojtek, A.B., S.M. Hollenberg, and J.A. Cooper, Mammalian Ras interacts directly 
with the serine/threonine kinase Raf. Cell, 1993. 74(1): p. 205-14. 
114. Kimoto, M., M. Shirouzu, S. Mizutani, H. Koide, Y. Kaziro, I. Hirao, and S. 
Yokoyama, Anti-{Raf-l} RNA aptamers that inhibit Ras-induced Raf-l activation. 
Eur J Biochem, 2002. 269(2): p. 697-704. 
115. Bussolino, F., A. Mantovani, and G. Persico, Molecular mechanisms of blood vessel 
formation. Trends Biochem Sci, 1997. 22(7): p. 251-6. 
116. Moroianu, J. and IF. Riordan, Identification of the nucleolar targeting signal of 
human angiogenin. Biochem Biophys Res Commun, 1994. 203(3): p. 1765-72. 
117. Moroianu, J. and IF. Riordan, Nuclear translocation of angiogenin in proliferating 
endothelial cells is essential to its angiogenic activity. Proc Natl Acad Sci USA, 
1994. 91(5): p. 1677-81. 
118. Nobile, V., N. Russo, G. Hu, and J.F. Riordan, Inhibition of human angiogenin by 
DNA aptamers: nuclear colocalization of an angiogenin-inhibitor complex. 
Biochemistry, 1998. 37(19): p. 6857-63. 
119. Blank, M., T. Weinschenk, M. Priemer, and H. Schluesener, Systematic evolution of 
a DNA aptamer binding to rat brain tumor micro vessels. selective targeting of 
endothelial regulatory protein pigpen. J Bioi Chern, 2001. 276(19): p. 16464-8. 
Page I 52 
120. Conrad, R., L.M. Keranen, A.D. Ellington, and A.c. Newton, Isozyme-specific 
inhibition of protein kinase C by RNA aptamers. J Bioi Chem, 1994. 269(51): p. 
32051-4. 
121. Dna, Y., T. Kurokawa, T. Fujii, K. Kawahara, K. Igarashi, U. Kikkawa, K. Ogita, and Y. 
Nishizuka, Two types of complementary DNAs of rat brain protein kinase C. 
Heterogeneity determined by alternative splicing. FEBS Lett, 1986. 206(2): p. 347-
52. 
122. Charlton, 1, G.P. Kirschenheuter, and D. Smith, Highly potent irreversible inhibitors 
of neutrophil elastase generated by selection from a randomized DNA-valine 
phosphonate library. Biochemistry, 1997. 36(10): p. 3018-26. 
123. Charlton, 1, 1 Sen nella, and D. Smith, In vivo imaging of inflammation using an 
aptamer inhibitor of human neutrophil elastase. Chem Bioi, 1997.4(11): p. 809-16. 
124. Smith, D., G.P. Kirschenheuter, 1 Charlton, D.M. Guidot, and lE. Repine, In vitro 
selection of RNA-based irreversible inhibitors of human neutrophil elastase. Chem 
Bioi, 1995. 2(11): p. 741-50. 
125. Repine, lE., Scientific perspectives on adult respiratory distress syndrome. Lancet, 
1992. 339(8791): p. 466-9. 
126. Varani, J. and P.A. Ward, Mechanisms of neutrophil-dependent and neutrophil-
independent endothelial cell injury. Bioi Signals, 1994.3(1): p. 1-14. 
127. Weiss, SJ. and S. Regiani, Neutrophils degrade subendothelial matrices in the 
presence of alpha-l-proteinase inhibitor. Cooperative use of lysosomal proteinases 
and oxygen metabolites. J elin Invest, 1984. 73(5): p. 1297-303. 
128. Wright, D.G., Human neutrophil degranulation. Methods Enzymol, 1988. 162: p. 
538-51. 
Page I 53 
129. liou, T.G. and E.l Campbell, Nonisotropic enzyme--inhibitor interactions: a novel 
nonoxidative mechanism for quantum proteolysis by human neutrophils. 
Biochemistry, 1995.34(49): p. 16171-7. 
130. Rice, W.G. and S.l Weiss, Regulation of proteolysis at the neutrophil-substrate 
interface by secretory leukoprotease inhibitor. Science, 1990. 249(4965): p. 178-
81. 
131. Travis, J. and G.S. Salvesen, Human plasma proteinase inhibitors. Annu Rev 
Biochem, 1983. 52: p. 655-709. 
132. Oleksyszyn, J. and J.e. Powers, Irreversible inhibition of serine proteases by peptide 
derivatives of (alpha-aminoalkyl)phosphonate diphenyl esters. Biochemistry, 1991. 
30(2): p. 485-93. 
133. Velasco-Garcia, M.N. and S. MissailidiS, New trends in aptamer-based 
electrochemical biosensors. Gene Therapy and Molecular Biology, 2009. 13(1): p. 
1-9. 
134. Bock, L.C., L.e. Griffin, J.A. latham, E.H. Vermaas, and lJ. Toole, Selection of single-
stranded DNA molecules that bind and inhibit human thrombin. Nature, 1992. 
355(6360): p. 564-6. 
135. de-Ios-Santos-Alvarez, N., M.aJ. lobo-Castan6n, AJ. Miranda-Ordieres, and P. 
Tun6n-Blanco, Aptamers as recognition elements for label-free analytical devices. 
TrAC Trends in Analytical Chemistry, 2008. 27(5): p. 437-446. 
136. Seger, R. and E.G. Krebs, The MAPK signaling cascade. Faseb J, 1995.9(9): p. 726-
35. 
137. Yokoyama, K., H.P. Erickson, Y. Ikeda, and Y. Takada, Identification of amino acid 
sequences in fibrinogen gamma -chain and tenascin C C-terminal domains critical 
for binding to integrin alpha vbeta 3. J Bioi Chem, 2000. 275(22): p. 16891-8. 
Page I 54 
138. Wlotzka, B., S. Leva, B. Eschgfaller, J. Burmeister, F. Kleinjung, C. Kaduk, P. Muhn, 
H. Hess-Stumpp, and S. Klussmann, In vivo properties of an anti-GnRH Spiegelmer: 
an example of an oligonucleotide-based therapeutic substance class. Proc Natl 
Acad Sci USA, 2002.99(13): p. 8898-902. 
139. Conn, P.M. and W.F. Crowley, Jr., Gonadotropin-releasing hormone and its 
analogs. Annu Rev Med, 1994. 45: p. 391-405. 
140. Kettel, L.M. and W.P. Hummel, Modern medical management of endometriosis. 
Obstet Gynecol Clin North Am, 1997.24(2): p. 361-73. 
141. Schally, A.V., Luteinizing hormone-releasing hormone analogs: their impact on the 
control of tumorigenesis. Peptides, 1999.20(10): p. 1247-62. 
Page I 55 
CHAPTER TWO 
MATERIALS AND METHODS 
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2.1 Materials 
Acrylamide/Bis-acrylamide 30% was purchased from Sigma-Aldrich Ltd (Gillingham, UK, 
product code A3699 100ml). 
Agarose was purchased from Sigma-Aldrich ltd (Gillingham, UK, product code A9539). 
Agar Select was purchased from Sigma-Aldrich ltd (Gillingham, UK, product number 
A5054). 
Ampicillin sodium salt was purchased from Sigma-Aldrich Ltd (Gillingham, UK, product 
code A9518 5g). 
Antibodies: 
Anti-Rabbit IgG (whole molecule)-Peroxidase antibody produced in goat was 
purchased from Sigma-Aldrich ltd (Gillingham, UK, product code A6154 1ml). 
Rabbit polyclonal anti-Heparanase IgG [1] was supplied by Professor Paul 
Brenchley, University of Manchester at a concentration of 10mg/ml in buffer 
containing sodium azide. 
Secondary swine-anti-rabbit and goat-anti-mouse biotinylated antibodies were 
supplied by Dako (Ely, UK). 
Mouse monoclonal anti-cytokeratin-7 and control mouse antibody were supplied 
by Dako (Ely, UK). 
Aptamers: 
Aptamer library was supplied at a concentration of 40llmoles in sterile deionised 
water from the University of Nottingham. Internal forward and reverse primers 
were also supplied from the University of Nottingham at concentrations of 
1m mole and 40~moles respectively. 
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All aptamer and biotinylated aptamer specific sequences were purchased as 
custom single stranded oligonucleotides from Eurofins MWG Operon (Ebersberg, 
Germany). 
Biopsy punch (8mm) was purchased from Kai Industries (Gifu, Japan). 
Boric Acid was purchased from Sigma-Aldrich ltd (Gillingham, UK, product code B6768 
1Kg). 
Bovine Serum Albumin (BSA) was purchased from Sigma-Aldrich ltd (Gillingham, UK, 
product code A7030 109). 
Citric acid was purchased from Sigma-Aldrich ltd (Gillingham, UK, product code C2404 
SOOg). 
Dimethylsulfoxide (DMSO) was purchased from Sigma-Aldrich ltd (Gillingham, UK, 
product code 08418). 
2Sbp DNA step ladder was purchased from Promega UK ltd (Southampton, UK, product 
number G4S11). 
Ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA) was purchased from 
Sigma-Aldrich ltd (Gillingham, UK, product code E5513 50g). 
Ethidium Bromide was purchased from Sigma-Aldrich ltd (Gillingham, UK, product code 
E76371g). 
Human recombinant polymorphic heparanase enzyme was supplied at a concentration of 
0.5mg/ml and Linker Peptide at 1mg/ml in 2SmM Tris, O.7M NaCI pH 7.5, from the 
University of Manchester. 
Hydrocortisone was purchased from Sigma-Aldrich ltd (Gillingham, UK). 
KCI was purchased from VWR (lutterworth, UK, product code 10198 500g). 
Matrigel was purchased from BD Discovery labware (Bedford, MA, USA). 
Media and supplements for cell culture were purchased from Invitrogen ltd (Paisley, UK). 
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MgClr6H20 was purchased from Sigma-Aldrich Ltd (Gillingham, UK, product code M2393 
500g). 
Microcons Filters and Ultrafree-15 Centrifugal Filter Devices were purchased from 
Millipore, supplied by Fisher Scientific UK Ltd (Loughborough, UK). 
NaCI was purchased from Fisher Scientific UK Ltd (Lough borough, UK, product code 
S/3120/60 1Kg). 
NaSCN was ordered from Sigma-Aldrich Ltd (Gillingham, UK, product code 251410 100g). 
PBS (phosphate buffered saline) was supplied in tablet form from Sigma-Aldrich Ltd 
(Gillingham, UK, product number P4417). 
PCR reagents: 
Taq DNA Polymerase supplied with lOx PCR buffer Sigma-Aldrich Ltd (Gillingham, 
UK, product code 01806); 
25mM Magnesium Chloride solution supplied by Sigma-Aldrich Ltd (Gillingham, 
UK, product code A3513); 
Deoxynucleotide Triphosphates supplied as dATP, dCTP, dGTP and dITP at 100mM 
each were purchased from Promega UK Ltd (Southampton, UK, product code 
U1240). 
Quartz crystals (5MHz) coated with gold and polished for use at 25°C were purchased 
from Testbourne Ltd (Basingstoke, UK). 
REAL antibody diluent was purchased from Dako (Ely, UK). 
Sodium acetate was purchased from VWR (lutterworth, UK, product code 30104 1Kg). 
StreptABComplex/HRP was purchased from Dako (Ely, UK). 
Streptavidin-Biotinylated Horseradish Peroxidase Complex was purchased from GE 
Healthcare Life Sciences (Little Chalfont, UK, product number RPN1051). 
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Streptavidin coated tubes were ordered from Roche Diagnostics Ltd (Burgess Hill, UK, 
product code 11741772001). 
Tris Buffered Saline (TBS) was supplied in tablet form from Sigma-Aldrich Ltd (Gillingham, 
UK, product number T5030). 
Tetra-methyl benzidine (TMB) was purchased from Sigma-Aldrich Ltd (Gillingham, UK, 
product code 860336). 
Tissue culture inserts (8~m pore size, 10mm diameter) were purchased from NUNC, 
supplied by Fisher Scientific UK Ltd (loughborough, UK, product code 137443). 
Tapa TA Cloning® Kit (with pCR®2.1-TOPO® vector) with One Shot® TOP10 Chemically 
Competent E. coli was purchased from Invitrogen Ltd (Paisley, UK, product code K4500-
40). 
Top Yield PCR tubes were purchased from NUNC, supplied by Fisher Scientific UK Ltd 
(Loughborough, UK, product code 248909) 
Trizma base was purchased from Sigma-Aldrich Ltd (Gillingham, UK, product code T1503 
1Kg). 
Tryptone was ordered from Sigma-Aldrich Ltd (Gillingham, UK, product code T9410 1Kg). 
Tubing for peristaltic pump (0.8mm pore size, 1.6mm wall thickness) was purchased from 
Fisher Scientific UK Ltd (Loughborough, UK, product code FB56465). 
Tween 20 was purchased from Sigma-Aldrich ltd (Gillingham, UK, product code P9416). 
Xylene Cyanole FF was purchased from Sigma-Aldrich ltd (Gillingham, UK, product code 
X4126 109). 
Yeast extract was ordered from Sigma-Aldrich ltd (Gillingham, UK, product code Y1625 
lKg). 
2.2 Buffers and Solutions 
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Carbonate buffer was prepared by adding 0.53g Na2C03 and 0.42g NaHC03 and making up 
to 100ml with ultra pure water, pH 9.6. 
Chromogen was prepared by adding 1.21ml 0.5M sodium acetate solution, 37 .5~1 0.5M 
citric acid solution and 62.5~110% TMB in DMSO to 5ml ultra pure H20, then activated by 
adding 7 .5~1 30% H20 2. 
Citrate buffer is composed of 2.94g sodium citrate and 500~1 Tween 20 in 1 litre of dH20, 
pH 6.0. 
EIA Diluent was prepared by adding 125mg BSA and 500",1 5% tween 20 to 25ml PBS. 
Elution buffer is composed of 1.5M NaCl, 20mM KCI, 5mM MgCh pH 7.2. 
PBS was prepared to working concentration (O.OlM phosphate buffer, 0.0027M KCI, 
0.137M NaCI pH 7.4) by adding one PBS tablet to 200ml ultra pure H20 and sterilising in 
an autoclave. 
Piranha solution comprised of 1 volume 30% H20 2 added to 4 volumes of concentrated 
H2S04 (prepared in fume hood as extremely caustic and exothermic). 
Salt solution is composed of 100mM NaCl, 20mM KCI and SmM MgCI2 at pHs 6.5 and 7.2. 
TBE buffer is composed of 0.045M Trizma base, 0.04SM Boric Acid and O.OOlM EDTA. 
TBS buffer was prepared to working concentration (0.05M Tris and 0.15M NaCI, pH 7.6) 
by adding one TBS tablet to 15ml ultra pure water. 
5% Tween 20 is made by adding 1ml tween 20 to 19m1 ultra pure H20 . 
Wash buffer is composed of PBS containing 2 ml 5% tween 20. 
2.3 Cell lines and culture conditions 
Page 161 
First trimester (8-12 weeks gestation) and term placenta and decidua were obtained 
surgically at termination or completion of pregnancy and both informed consent and local 
ethical committee approval was in place for use of both tissues. 
Uterine leiomyoma tissue was obtained from routine surgical operations after informed 
consent of the donors. The study was approved by the Ethics Committee of the Oulu 
University Hospital. Only non-degenerated myomas were selected for the study. To 
prepare myoma discs for the organotypic culture, the tissue was cut into 3mm slices with 
a disposable scalpel then into discs with an 8mm biopsy punch. Macroscopically 
heterogeneous areas of the myoma tissue were omitted. The myoma discs were stored at 
-70°C in 1:1 DMEM/Fl2 media containing 10% OMSO. 
All cell lines were cultured to 80% confluency and media were supplemented with 10% 
FBS, L-glutamine (2mM), penicillin (100IU/ml) and streptomycin (100~g/ml). Endometrial 
adenocarcinoma, Ishikawa cell line was cultured in OM EM; placental stromal cells (first 
trimester) were cultured in 50% DMEM 50% Ham's Fl2 supplemented with 1% non-
essential amino acids; first trimester immortalised PL4 trophoblasts [2] were cultured in 
Ham's flO medium; trophoblast carcinoma, BeWo cell line was cultured in 50% OMEM 
50% Ham's Fl2, and ovarian carcinoma cell line OC-MZ6 [1, 2] was cultured in OMEM 
containing 10mM HEPES, 116mg/l arginine and 36mg/l asparagine. Human tongue 
squamous carcinoma cells [3]; HSC-3 (JCRB 0623; Osaka National Institute of Health 
Sciences, Osaka, Japan) were cultured in 50% OMEM 50% Ham's F-12 and additionally 
supplemented with 50~g/ml ascorbic acid, 250ng/ml funglzone, 5~g/ml insulin (bovine 
pancreas) and 0.4ng/ml hydrocortisone. Cells were incubated in 95% air/5% C02 at 37°C. 
2.4 Equipment and Instrumentation 
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Pipettes used were Gilson Pipetman Pl000, P200, Pl00 and Pl0 (Gilson S.A.S, Villiers Le 
Bel) and associated tips. 
PCR machine used was an Eppendorf Mastercycler Personal with a heated lid, capable of 
holding 16 500lli or 25 200lli tubes and adjustment of time and temperature increments. 
Fluorimeter used was an Horiba Jobin Yvon Fluoromax-P equipped with a photon counter 
and Peltier system for temperature control and stirring facility, coupled to a PC utilising 
Oatamax software for spectral analysis. 
ELISA plate reader was a Bio-Tek EL808 Ultra Microplate Reader capable of reading one 
96-well ELISA plate at a time with a fixed wavelength, coupled to a PC using Bio-Tek GenS 
microplate data collection and analysis software. 
Gel Imager used was a Kodak Image Station 440CF containing 5 filters for visualising 
chemiluminescent, fluorescent and chromogenic gels and blots, connected to a camera 
using a 6x optical zoom lens and a PC with Kodak 10 Image Analysis Software for 
visualisation and analysis. 
RQCM was produced by Maxtek Inc with three separate channels for simultaneous 
measurement of crystals' frequency and resistance, over a wide frequency range 3.8 to 
6.06MHz or 5.1 to 10MHz using a high performance phase lock oscillator (PLO) circuit. 
This equipment was connected to a PC and used Windows-based RQCM data logging 
software for data collection and analysis. 
UV experiments were conducted on a Bio-Tek Uvikon XL with a Peltier Thermosystem for 
temperature control and stirring facility, connected to a PC utilising Lab Power Junior 
software for data collection and analysis. 
2.S Selection 
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Selection protocols were modified from [4] and our group's previous optimisations [5]. 
2.5.1 Salt selection method 
1. Aptamer Library PCR amplification. Before commencing selection, aptamer library was 
amplified in a 500JlI thin-walled PCR tube by single stranded PCR, prepared on ice, as 
follows: 
Library (40~M) 50 
F primer (lmM) 50 
R primer (40~M) 50 
lOx PCR buffer 20 
25mM dNTP's 20 
25mM MgCI2 5.4 
Taq 2 
dH20 2.6 
200.0~1 total volume 
The conditions in the PCR programme were as follows: 
Step 1: Initial denaturation at 95'C for 10 minutes, 
Step 2: Denaturation at 95'C for 1 minute 30 seconds, 
Step 3: Annealing of primers at 56'C for 30 seconds, 
Step 4: Extension at 72"C for 1 minute 30 seconds, then steps 2-4 repeated 99 times, 
Step 5: Final extension at 72'C for 10 minutes. 
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The amplified library was stored in the refrigerator until it was needed for use. 
This protocol was eventually modified to generate more copies of each aptamer species 
by firstly double stranding the aptamer library before single stranding it, prepared on ice 
in a 500~1 thin-walled PCR tube as follows: 
Library (40~M) 50 
F primer (lmM) 2 
R primer (40~M) 50 
lOx PCR buffer 20 
25mM dNTP's 20 
25mM MgCh 5.4 
Taq 2 
dH20 50.6 
200~1 total volume 
The conditions in the PCR programme were as follows: 
Step 1: Initial denaturation at 95°C for 10 minutes, 
Step 2: Denaturation at 95°C for 1 minute 30 seconds, 
Step 3: Annealing of primers at 56°C for 30 seconds, 
Step 4: Extension at 72·C for 1 minute 30 seconds, then steps 2-4 repeated 30 times, 
Step 5: Final extension at 72·C for 10 minutes. 
This created enough cDNA to amplify to single-stranded DNA in the next step, which was 
again prepared on ice: 
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Product 100 
F primer (lmM) 100 
lOx PCR buffer 30 
2SmM dNTP's 40 
2SmM MgCh 10.8 
Taq 2 
dH20 17.2 
300J.11 total volume 
The conditions in the PCR programme were as follows: 
Step 1: Initial denaturation at 95"C for 10 minutes, 
Step 2: Denaturation at 95"C for 1 minute 30 seconds, 
Step 3: Annealing of primers at 56"C for 30 seconds, 
Step 4: Extension at 72"C for 1 minute 30 seconds, then steps 2-4 repeated 99 times, 
Step 5: Final extension at 72"C for 10 minutes. 
2. Human recombinant polymorphic heparanase was diluted in 100J.11 salt solution (see 
above) to 1S0nM final concentration in a Top Yield PCR tube. This was left to incubate 
overnight in the fume hood at room temperature. 
3. The next day, the tube was washed four times with 200,.11 salt solution and blotted dry on 
blue roll to remove any unbound enzyme. 
4. 150J.11 amplified aptamer library was added to the tube and incubated for 1 hour at room 
temperature, shaking slowly. This was then removed and the tube washed once in salt 
solution to remove any unbound aptamers. 
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5. From a stock solution of elution buffer, dilutions were made as follows: 
Concentration NaCI Volume stock solution added Volume ultra pure H20 added 
(M) hJ.l) (Ill) 
0.2 6.65 43.35 
0.3 10 40 
0.4 13.3 36.7 
0.5 16.65 33.35 
0.6 20 30 
0.7 23.3 26.7 
0.8 26.65 23.35 
0.9 30 20 
1.0 33.3 16.7 
1.1 36.65 13.35 
1.2 40 10 
1.3 43.3 6.7 
1.4 46.65 3.35 
1.5 50 0 
3.0M NaSCN 50 0 
6. Beginning with the 0.2M elution buffer, 50~1 was added to the tube in the same order as 
above for 1 minute and then removed to a clean PCR tube. Adding elution buffer in this 
way removes bound aptamers depending on their binding affinities; for example, the 
0.2M removes aptamers with the lowest binding affinity, whilst the 1.5M and 3.0M 
NaSCN removes aptamers with the highest binding affinities. 
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7. Fractions from the higher salt concentrations were then desalted using Microcons 
centrifugal filters and double strand amplified by PCR, before being visualised on an 
agarose gel. This procedure was either terminated here or repeated a further 9 times to 
yield a ten-round selection method. 
2.5.2 Heat selection method - one round 
1. Aptamer Library PCR amplification. Before commencing selection, aptamer library was 
amplified as indicated above (see salt selection protocol) and the amplified library was 
stored in the refrigerator until it was needed for use. 
2. Human recombinant polymorphic heparanase was diluted in 100JlI salt solution (see 
buffers and solutions section) to lS0nM final concentration in a Top Yield PCR tube. This 
was left to incubate overnight in the fume hood at room temperature. 
3. The next day, the tube was washed four times with 200,.11 salt solution and blotted dry on 
blue roll to remove any unbound protein. 
4. lS0~,d amplified aptamer library were added to the tube and incubated for 1 hour at room 
temperature, shaking slowly. This was then removed and the tube washed once in salt 
solution to remove any unbound aptamers. 
5. SOIlI ultra pure H20 was added to the tube, the tube was sealed and placed in the PCR 
machine. A spare tube containing 1ml ultra pure water was kept in the PCR machine to 
provide water at the correct temperature for all the gradients. 
6. The PCR machine was used to generate S·C intervals from 2S·C to 90·C with a two-minute 
hold on each temperature. After the 90°C temperature gradient, the temperatures 
chosen were 92°C, 94°C, 96°C and 98°C. 
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7. After 1 minute of the two-minute hold at each temperature, SO~I water was removed 
from the tube, placed in a fresh peR tube and retained for double stranded peR. 
8. The SOIlI water was replaced with SOIlI water from the spare tube after each extraction, 
as this was at the same temperature as the water removed. 
9. Collected fractions were subjected to double stranded PCR to prepare the aptamers for 
cloning. 
2.5.3 Heat selection method - ten rounds 
1. Aptamer library PCR amplification. Before commencing selection, aptamer library was 
amplified in a SOOIlI thin-walled PCR tube by single stranded PCR, prepared on ice, as 
indicated above. 
2. Human recombinant polymorphic heparanase was diluted in l00f.11 salt solution to 
lS0nM in a Top Yield PCR tube. This was left to incubate overnight in the fume hood at 
room temperature. 
3. The next day, the tube was washed four times in 200f.1.1 salt solution and blotted dry on 
blue roll to remove any unbound protein. 
4. 150111 amplified aptamer library was added to the tube and incubated for 1 hour at room 
temperature, shaking slowly. This was then removed and the tube washed once in salt 
solution to remove any unbound aptamers. 
5. From here peR reagents were added to the tube as follows: 
lOx PCR buffer 10.0 
2SmM dNTP's 10.0 
2SmM MgCb 2.7 
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Taq 1.0 
10!!M F primer 0.4 
O.4!!M R primer 10 
dH20 25.9 
60.0!!1 
The conditions in the PCR programme were as follows: 
Step 1: Initial denaturation at 95°C for 10 minutes, 
Step 2: Denaturation at 95°C for 1 minute 30 seconds, 
Step 3: Annealing of primers at 56°C for 30 seconds, 
Step 4: Extension at 72"C for 1 minute 30 seconds, then steps 2-4 repeated 99 times·, 
Step 5: Final extension at 72"C for 10 minutes. 
• After 30 cycles of the program, the machine was paused, 1~1 more Taq and 39.6~1 more 
forward primer was added and the program was resumed for the further 69 cycles. This 
was to create some cDNA (as equal concentrations of primers were used in the first part 
of the PCR reaction) that would allow the generation of single stranded DNA copies after 
addition of only the forward primer for the second part of the amplification 
(unidirectional PCR). 
6. Another Top Yield PCR tube was sensitised with the protein target ready for the 
competion of the PCR amplification. PCR products were incubated in the Top Yield tube 
with the target protein instead of amplified library, eliminating at each step molecules 
that did not bind or were competed out by stronger binders in the peR mixture. The 
process above was repeated nine times to create a ten-round selection and amplification 
protocol. The aim of this was to amplify the binding aptamers through each cycle and 
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discard the ones that did not bind or were weaker binders and were thus displaced at 
each further amplification by the stronger binders, thus resulting in only a few high 
affinity aptamers. 
2.6 Desalting using Microcons filters 
These were purchased from Millipore with a 3kDa molecular weight cut off to retain the 
generated aptamers (which are approximately 23kDa). Each spin cycle recommended by 
the manufacturer was 60 minutes at 14,OOOrpm. 
1. 500~1 ultra pure H20 was added to the filter; the filter was capped and centrifuged to 
remove any contaminant glycerin. 
2. The flow through was removed and sample plus ultra pure water was added to make a 
total volume of 500~1, the filter capped and centrifuged again. 
3. Flow through was again removed and 500~1 ultra pure water was added as a wash step, 
then spun again and removed, leaving in the filter a small volume of water containing the 
desalted aptamers. 
4. 20~1 ultra pure water was added to the filters to ensure enough volume was present to 
elute the DNA. This was pipetted up and down, and then the filters were inverted and 
placed into a clean eppendorf tube and spun at 3000rpm for 1 minute to collect the 
desalted DNA, as per manufacturer's recommendations. 
2.7 Buffer exchange using Ultrafree-15 centrifugal filter devices 
These were purchased from Millipore with a 10kOa molecular weight cut-off, to retain the 
58kDa recombinant heparanase. 
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1. 15ml ultra pure water was transferred to the centrifugal filter and the cap closed, then 
placed into a SOml falcon tube (which acted as the filtrate collection tube) and put into 
the centrifuge along with a balance tube. This was spun at 2000g for 30 minutes to wash 
through the membrane and remove any contaminant glycerin. 
2. The filtrate was discarded from the collection tube. 
3. 2ml human recombinant polymorphic heparanase was added to the filter and made up to 
lSml by adding salt solution, the cap was fastened and the tube spun again at 2000g for 
long enough to concentrate the sample but not so that it dried on the membrane 
(approximately 20 minutes). 
4. After 20 minutes the filtrate was removed, the sample topped up to 15ml with salt 
solution and spun again at 2000g, this time for long enough to concentrate the sample 
down to lml using the graduations on the filter. The heparanase was then pipetted into a 
clean stock tube for further use. 
2.8 Double Stranded peR 
Double stranded PCRs were conducted at the end of each selection to amplify retained 
aptamers in preparation for cloning, a sample of which was visualised on an agarose gel 
to confirm their presence. The double stranded aptamers were then cloned into vector in 
E. coli cells. 
Double stranded PCR reaction was prepared on ice, as follows: 
DNA 
lOx Buffer 
50 
7 
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dNTPs (25mM) 0.7 
Taq 0.7 
F primer (1/100) 1.75 
R primer (cone) 0.44 
MgCh (25mM) 1.87 
dH20 7.55 
70.0~1 total volume 
The conditions in the PCR programme were as follows: 
Step 1: Initial denaturation at 95°C for 10 minutes, 
Step 2: Denaturation at 95°C for 1 minute 30 seconds, 
Step 3: Annealing of primers at 56°C for 30 seconds, 
Step 4: Extension at 72°C for 1 minute 30 seconds, then steps 2-4 were repeated 30 
times, 
Step 5: Final extension at 72"C for 10 minutes to create poly A tails for cloning into 
vector. 
2.9 Colony PCR 
Testing of colonies for insertion of the aptamer into the plasmid was carried out using a 
PCR of a single colony from the agar plate and putting it directly into the PCR reagents 
(which were mixed on ice) below: 
lOx PCR buffer 
25mM dNTP's 
2.0 
0.4 
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25mM MgCI2 
Taq 
F primer (internaI10~M/M13 100~M) 
R primer (internal 0.4~M/M13 100~M) 
dH20 
0.53 
0.2 
0.5/0.25 
12.5/0.25 
3.87/16.37 
20.0J.l1 (per colony) 
The conditions in the PCR programme were as follows: 
Step 1: Initial denaturation at 95°C for 10 minutes, 
Step 2: Denaturation at 95°C for 1 minute 30 seconds, 
Step 3: Annealing of primers at 56°C for 30 seconds, 
Step 4: Extension at 72°C for 1 minute 30 seconds, then steps 2-4 were repeated 30 
times, 
Step 5: Final extension at 72°C for 10 minutes. 
Two different primers were used to test each colony, internal and M13. The primers 
referred to as internal are the same ones used in selection, named so because they are 
internal to the M13, which outflank them. The fragment size generated from these 
primers in the PCR should be either 7Sbp if the colonies' DNA contained aptamer or no 
band if it didn't. The M13 primers were supplied with the cloning kit and recognise loci 
within the vector spanning across the insert site, hence show a 200bp If there Is no 
aptamer inserted in the vector, or 27Sbp if there Is aptamer inserted In the vector (200bp 
plus the size of the aptamer). The peR mix was prepared as above for each colony and 
then each colony was picked, swiped first on a clean agar patch plate containing SOmg/ml 
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ampicillin, labelled with colony numbers for identification purposes, and then put into the 
PCR tube. 
2.10 Agarose gel 
Extreme care was taken with the use of ethidium bromide due to its carcinogenic 
properties. 
1. Using a balance, 2g agarose was measured into a conical flask with 100ml TBE buffer. 
2. The conical flask was heated in the microwave to dissolve the agarose in buffer and make 
it molten. This then was cooled to approximately 50·C before adding Sill 10mg/ml 
ethidium bromide. 
3. Masking tape was fixed to the ends of the gel tray to seal them and the gel was poured 
into the tray. The well comb was added, and this was left to set for 30 minutes. 
4. The well comb was removed and the gel tray was put into the gel tank and filled with TBE 
buffer to the level. 
5. 6x gel loading buffer was added to each sample to be loaded. 10~1 25/100bp ladder (see 
figure 2.1) was also prepared with loading dye. 
6. 10~1 of each sample was loaded into each well of the gel, with 5~1 of ladder loaded into 
the wells at either end of the gel. 
7. The power supply was connected and the gel was run at 100 volts for one hour. 
S. The equipment was turned off; the gel was removed and viewed in the imaging 
apparatus. 
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Figure 2.1 - 100bp (left) and 25bp (right) DNA ladders used in agarose gel 
electrophoresis. 
2.11 Cloning 
Cloning was carried out using the Tapa TA cloning kit with chemically competent Topl0 E. 
coli cells. 
1. 0.5111 double stranded PCR product was added to 1111 salt solution (supplied with the kit), 
1111 Tapa vector and 3.5J..l1 sterile deionised water and incubated for 5 minutes at room 
temperature. 
2. 2J..l1 was taken from the mix above, added to a vial of chemically competent Topl0 E. coli 
cells and incubated for 30 minutes on ice. 
3. The cells were heat shocked for 30 seconds without shaking at 42°C, then immediately 
transferred back to ice. 
4. 250111 SOC medium (supplied with the kit) was added to the cells, the caps were sealed 
tightly on the tubes and they were placed in a shaking incubator at 180rpm, 3rC for one 
hour to recuperate. 
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5. 10 and SOIlI volumes of cells were spread on pre-warmed agar plates (containing 
SOmg/ml ampicillin) and left overnight in an incubator at 37·C to allow colonies to grow. 
2.12 ELISA (enzyme linked immuno sorbent assay) 
This was carried out in accordance with [6]. 
1. An ELISA plate or Top Yield 'ELISA type' PCR tubes were sensitised overnight at room 
temperature with 100-200IlI human recombinant polymorphic heparanase at lSOnM 
concentration. 
2. The solution was removed and 10mg/ml BSA in PBS were added and incubated for 20 
minutes at room temperature to block the tubes. 
3. The solution was removed and the tubes were washed three times in wash buffer and 
blotted dry on blue roll. 
4. 100-2001l1 primary antibody in EIA diluent was added to each of the samples. Depending 
on the nature of the ELISA it may have been appropriate to vary the concentration of the 
antibody, and a dilution series was often used. For a competition ELISA, where it was 
needed to measure the activity of the competing agent (I.e. aptamer) with the substrate, 
in comparison to the antibody, either a set concentration of antibody and a dilution series 
of aptamer was used, or a set concentration of aptamer and a dilution series of antibody. 
This was left to incubate at room temperature for one hour. 
5. The solution was removed and the tubes were washed three times in wash buffer and 
blotted dry on blue roll. 
6. 100111 biotinylated antibody at 2.SIlg/ml concentration (in EIA diluent) was added to each 
of the tubes and incubated for one hour at room temperature. 
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7. The solution was removed and the tubes were washed three times in wash buffer and 
blotted dry on blue roll. 
8. 1001.11 streptavidin peroxidase at a 1/500 dilution in EIA diluent was added to each of the 
tubes and incubated for one hour at room temperature. 
9. The solution was removed and the tubes were washed three times in wash buffer and 
blotted dry on blue roll. 
10. 50~1 chromogen was added and incubated for 30 minutes at room temperature. There 
should have been a colour change from colourless to blue. 
11. 2S~1 10% H2S04 was added to stop the reaction and the plate was put in the plate reader 
to analyse at 450nm. 
2.13 ELISA (enzyme linked immuno sorbent assay) using Streptavldln coated peR 
tubes/plates 
Streptavidin-coated peR tubes were purchased pre-coated; however, later ELISA plates 
were coated with streptavidin/neutravidin/extravidin/avidin to save on cost. This 
method was modified from [6]. 
1. For coating of ELISA plates, a 4:1 molar ratio of aptamer:avidin molecule were added in a 
tube and made to the correct concentration with EIA diluent. After 2 hours, 100~1 was 
plated in the relevant wells of the plate and left to incubate overnight at 4°C. Strips of 
streptavidin-coated peR tubes were sensitised overnight at room temperature with 100",1 
S'biotinylated aptamer at varying concentrations, often using a dilution series. 
2. The solution was removed the next day and the tubes were blocked by Incubating them 
with 10mg/ml BSA in PBS for 20 minutes at room temperature. 
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3. The solution was removed and the tubes were washed three times in wash buffer and 
blotted dry on blue roll. 
4. Concentrations of human recombinant polymorphic heparanase were added to the tubes 
and incubated for one hour at room temperature. The concentrations were either fixed if 
the aptamer concentration was varied, or varied using a dilution series, whilst keeping the 
aptamer concentration fixed. 
5. 100~.d rabbit polyclonal anti-heparanase IgG primary antibody in EIA diluent was added to 
each of the samples at a concentration of 165nM. This was left to incubate at room 
temperature for one hour. 
6. The solution was removed and the tubes were washed three times in wash buffer and 
blotted dry on blue roll. 
7. 100111 biotinylated antibody at a 2.51lg/ml concentration (in EIA diluent) was added to 
each of the tubes and incubated for one hour at room temperature. 
8. The solution was removed and the tubes were washed three times in wash buffer and 
blotted dry on blue roll. 
9. 100111 streptavidin peroxidase at a 1/500 dilution in EIA diluent was added to each of the 
tubes and incubated for one hour at room temperature. 
10. The solution was removed and the tubes were washed three times in wash buffer and 
blotted dry on blue roll. 
11. 50111 chromogen was added and incubated for 30 minutes at room temperature. There 
should have been a colour change from colourless to blue. 
12. 25111 10% H2S04 was added to stop the reaction and the plate was put in the plate reader 
to analyse at 450nm. 
2.14 EMSA (electrophoretic mobility shift assay) 
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For 2 gels hll) 1% 8% 10% 15% 18% 
Acrylamide 300 2400 3000 4500 5400 
Water 6742.5 4642.5 4042.5 2542.5 1642.5 
5xTBE 1800 1800 1800 1800 1800 
100mg/ml APS 150 1S0 150 1S0 150 
TEMED 7.5 7.5 7.5 7.5 7.S 
Extreme care was taken whilst using unpolymerised acrylamide due to its carcinogenic 
properties. 
1. Gel plates were carefully washed in water and dried with blue roll. They were then 
clipped into the casting apparatus and into the gel plate. 
2. The gel was made as per the quantities above, leaving the APS and TEMED until last, as 
these caused the gel to polymerise. The gels were poured quickly using a pipette, the 
well combs were subsequently inserted and the gel was left to set for 2 hours. 
3. Meanwhile the reactions were prepared: A 1:1 ratio of aptamer to protein at 41lM 
concentration was used. The volumes required were added to Sill 5x TBE, and the 
volume was made up to 20~,d with ultra pure water. These were then left to Incubate for 
one hour at room temperature. 
4. Before loading the samples, the gel was set to pre-run. The castor was unclipped from 
the gel plate and transferred to the tank. Fresh 1x TBE was added up to the level and the 
well combs were removed. The wells were cleaned out using a syringe and hypodermic 
needle to dislodge any excess gel. The voltage supply was connected and run for 1 hour 
at 120 volts. 
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5. 6x loading dye were added to the samples and ladder and they were loaded on to the gel 
using a pipette. The gel was either run overnight (preferable) at 15-20 volts or for about 
3-4 hours at 70 volts, until the bottom of the loading dye reached the bottom of the gel. 
6. After running the gel, the equipment was switched off, the gel was removed from the 
plates and the equipment was washed. The gel was transferred to a container with 
100ml1x TBE containing O.sllg/ml ethidium bromide (the running buffer was re-used for 
this). A lid was put on the container and shook slowly for one hour. 
7. After the hour, the gel was removed, rinsed in water and viewed under the gel imaging 
equipment. 
2.15 Fluorescence Quenching Titrations 
These were conducted based on the method described by Missailidis et 01. [7]. 
1. The fluorimeter and computer were switched on and left to equilibrate for 30 minutes. 
2. Settings were calibrated for the experiment: emission acquisitions were taken with an 
excitation wavelength of 280nm. Emission spectra were measured from 300nm to 
420nm every 5nm, with 1 second at each measurement and the slits were ±5nm. 
3. In a 100JlI fluorescence cuvette, which was washed with water prior to using, human 
recombinant polymorphic heparanase or linker peptide were diluted to 100JlI at the 
appropriate concentration in salt solution. 
4. The cuvette was immediately placed into the fluorimeter and a scan taken. 
5. Immediately after the scan, appropriate volume additions of 100JlM unmodified aptamer 
to be tested were added to the cuvette so that the total ratios of heparanase:aptamer 
were 10:1, 5:1, 2.5:1, 1.25:1 and 0.625:1. 
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6. After each addition a scan was taken and then after all scans had been taken, the cuvette 
was washed in water, methanol and then nitric acid, ready for the next experiment. 
7. Data were analysed using Microsoft Excel, then Microcal Origin to estimate KA values by 
using the relevant quadratic equation (7) as explained in chapter four. 
2.16 Immunoperoxidase staining of paraffin embedded tissue (sections cut at 5~m) 
These experiments were conducted at The University of Manchester within the Maternal 
and Foetal Research Group under supervision of Drs John Aplin and lynda Harris, as 
follows [2). 
1. Slides were warmed for 10 minutes at 60 degrees to soften wax. 
2. Sections were deparaffinised in three consecutive baths of xylene for 5 minutes each, 
then 100%, 100% and 70% alcohol for one minute each. 
3. Slides were rinsed in running water from tap. 
4. Slides were immersed in a plastic dish containing citrate buffer (see section 2.2 buffers 
and solutions) and microwaved at high temperature for 5 minutes with lid on loosely. 
Buffer level was topped up after 5 minutes and then they were microwaved for a further 
5 minutes. 
5. Slides were left to cool for 20 minutes (in the microwave). 
6. To block endogenous peroxide activity, slides were placed in methanol containing 0.4% 
(v/v) Hel and 0.5% (v/v) H202 for 30 minutes. 
7. Slides were rinsed in running water from tap. 
S. Slides were washed for 5 minutes in three baths containing 18S. 
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9. Excess moisture was wiped from the slides with a soft tissue and the sections were drawn 
around with a Dako pen. 
10. Sections were blocked for 30 minutes with 5% BSA in TBS and then dabbed off without a 
washing step. 
11. Primary antibody/aptamers were diluted using TBS (1:100 dilutions for anti-heparanase 
and anti-cytokeratin 7, neat for control mouse antibody and 1:200 dilution for all 
aptamers; generating similar concentrations), added to the sections and left overnight at 
4°C in a humidity chamber. Concentrations and incubation times were previously 
optimised in this assay using antibodies [2]. 
12. Slides were washed for 5 minutes in three baths containing TBS. 
13. Secondary antibodies were added at 1:200 dilutions for 1 hour at room temperature to 
relevant sections, aptamer-Iabelled sections were incubated with TBS only. 
14. Antibodies were washed off with TBS wash bottle and then slides were washed for 5 
minutes in three baths containing TBS. 
15. Excess moisture was wiped from the slides with a soft tissue, and then avidin peroxidase 
was added to all sections @ 5~g/ml in 0.125M TBS. These were incubated at room 
temperature for 1 hour and then washed off using a TBS wash bottle. 
16. 3,3'-Diaminobenzidine tetrahydrochloride (DAB) was used to develop the avidin 
peroxidase. This was composed of 0.05% (w/v) DAB and 0.015% (v/v) H20 2 in TBS, and 
was firstly added to one section, observed under a microscope, then the reaction was 
stopped upon completion by rinsing in running water. The time for completion of the 
reaction was recorded and used when staining the rest of the sections. 
17. Slides were rinsed in running water from tap. 
18. Slides were counterstained with Mayers' haematoxylin for 5 minutes, and then rinsed 
under tap water. 
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19. Slides were put into acid alcohol solution to remove excess stain for five seconds and then 
rinsed in tap water for 5 minutes. 
20. Slides were dehydrated in 70%, 100% and 100% alcohol, then two consecutive baths of 
xylene for 5 minutes each. 
21. Slides were mounted with large coverslips using XAM. 
2.17 FITe and PI-labelling cell culture coverslips 
These experiments were conducted at The University of Manchester within the Maternal 
and Foetal Research Group under supervision of Drs John Aplin and lynda Harris, as 
follows [2]. 
1. Cells were previously fixed in 4% paraformaldehyde for 15 minutes. 
2. Cells were permeabilised by incubating them in 0.1% triton in PBS for 10 minutes. 
3. Cells were washed in PBS three times. 
4. Primary antibody/biotinylated aptamers were added and incubated for 1 hour at room 
temperature (1:100 dilutions for anti-heparanase and anti-cytokeratln 7, neat for control 
mouse antibody and 1:200 dilutions for all aptamers). Concentrations and incubation 
times were all previously optimised using this assay with antibodies and the aptamers 
used in this study were diluted to these same concentrations. 
5. Cells were washed in PBS three times. 
6. Secondary antibodies were added at 1:200 dilutions to heparanase and control mouse 
antibody-labelled coverslips only and incubated for 1 hour at room temperature 
(aptamer-Iabelled coverslips were left In PBS only). 
7. Cells were washed in PBS three times. 
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8. Streptavidin-FITC conjugate was added to all coverslips at a 1:50 dilution of stock and 
incubated for 1 hour at room temperature underneath a cover to preserve the 
fluorescence. 
9. Cells were washed in PBS three times. 
10. Coverslips were blotted on a soft tissue and mounted onto slides using Vectashield 
mounting medium containing propidium iodide. To secure the coverslips to the slides, 
clear nail varnish was used around the edges. 
2.18 Matrigel invasion assay method 
These experiments were conducted at The University of Manchester within the Maternal 
and Foetal Research Group under the supervision of Drs John Aplin and lynda Harris [2]. 
1. Transwell inserts were placed into each experimental well of a 24-well plate. One 
coverslip per experiment was sterilised in IMS to be used as an indicator of cell 
confluency throughout the experiment. 20~.d Matrigel previously diluted to working 
concentration; (1:8 in serum-free medium) was added to each insert and spread around 
with a pipette tip then left to dry in the incubator for at least 30 minutes. 
2. OC MZ-6 and Pl4 cells for the experiment were passaged. Culture medium was removed 
from the flasks which were then washed twice with PBS, removed and replaced with 3ml 
trypsin EDTA. The flasks were incubated until the cells had detached and then the 
suspension was transferred to a centrifuge tube and spun for 5 minutes @ 1000rpm. The 
supernatant was removed and cells were resuspended in 2ml of their respective 
supplemented medium (specified in section 2.3; Cell lines and culture conditions) and 
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then counted with a haemocytometer. 6x104 cells were required for each well so cell 
concentration was adjusted to 6x10scells/ml. 
3. SOO~I medium was added around the edge of each insert and then 400~,d medium plus 
100~1 cells into the insert. Cells were left in the incubator for one hour to adhere to the 
Matrigel. 
4. The medium from both the insert and the well was removed then replaced with 
aptamer/antibody/control solution (all at 1:100 dilutions in fresh medium) 500~1 each 
into the insert and the well and the plate incubated for 24 hours in the incubator. 
5. After 24 hours the coverslip was viewed to make sure the cells had grown enough. If not, 
they were left for up to another 24 hours. 
6. The cells were then fixed in 4% paraformaldehyde for 15 minutes and permeabilised in 
0.1% triton for 10 minutes, then stored in PBS @4°C until they were ready to be stained. 
7. The transwells were removed with forceps and the inside of the insides of each 
membrane wiped with a cotton bud to remove all cells. Freshly filtered haematoxylin was 
added both sides of the insert to stain the nuclei of the cells. Haematoxylin was replaced 
with PBS then the inserts were plunged into a beaker of hot water to activate the stain. 
The insides of the membranes were once again wiped with a cotton bud and then the 
membranes cut out, placed on the slides and mounted. 
8. The slides were viewed under light microscope at x10 magnification, eight to ten 
representative areas were selected and the cells counted. Data were represented as the 
mean ± its standard deviation, and an unpaired two-tailed t-test was conducted to assess 
the Significance of the results. 
2.19 Myoma organotypic model method 
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These experiments were conducted at The University of Oulu, Finland, within the Institute 
of Dentistry and under supervision of Professor Tuula Salo, Drs Pia Nyberg and Sirpa Salo 
and Sini Nurmenniemi [3]. 
2.19.1 Day 1 
1. Media was warmed prior to use on each day of experiment. 
2. Previously frozen myomas from the same batch were transferred into a petri dish then 
into a SOml tube containing fresh media for 1 hour as they were stored in media 
containing DMSO so need to be washed. Transwell plates were labelled. 
3. Myomas in medium were transferred into a fresh Petri dish and using forceps, pushed 
down vertically into each transwell insert so there were no gaps where cells could fall. 
4. HSC-3 tongue carcinoma cells were prepared by removing the medium, washing x2 in PBS 
then adding 3ml trypsin-EDTA and incubating until cells had detached. 
5. The cell suspension was transferred to a SOml falcon tube and spun down in a centrifuge 
so that the trypsin could be removed and replaced with fresh medium. The cells were 
then counted manually after pipetting 20111 suspension into the haemocytometer. 
700,000 cells per myoma (SOIlI) were required so the cell suspension was diluted to 
14,000,000 cells/ml with fresh medium. 
6. Cells were prepared for the experiment in eppendorf tubes by adding 1S0 III cells plus 
1.SIlI inhibitor. These volumes were correct for a 1/100 dilution of inhibitor, performed in 
triplicate samples. 
7. Medium containing inhibitor was prepared for the whole experiment and stored in lsml 
falcon tubes - 4 or S changes of 1ml per sample. This ensured that each change of media 
contained an equal concentration of inhibitor. 
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8. 1ml medium containing inhibitor was pipetted below the transwell and 50~1 cell 
suspension plus inhibitor pipetted on top of the myoma. The plate was incubated for 24 
hours at 3rC to allow cells to attach to the myoma surface. 
2.19.2 Day2 
1. In fresh 12 well culture plates, a metal grid was transferred to each experimental well 
using sterile forceps. From the transwell plate, the medium (containing its respective 
inhibitor) below the transwell was pipetted to the corresponding well on the 12-well 
plate, then, using sterile forceps, one piece of sterile nylon membrane was added atop of 
each grid. 
2. Using 2 pairs of forceps, the transwell membrane was perforated from the bottom and 
each myoma was carefully lifted out, maintaining its orientation, and placed on top of the 
corresponding grid. 
3. The experiment was cultured for 2 weeks, changing (and retaining) the media on days 5, 8 
and 11 with fresh inhibitor-containing medium. 
2.19.3 Day 14 
1. Media was removed and retained in eppendorf tubes, then frozen for later use. 
2. Myoma tissues were transferred to cassettes and placed in 4% paraformaldehyde to 
dehydrate and fix the tissue. 
2.19.4 Histology, IHe and visualisation 
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1. Myomas were fixed in formalin for 12 hours, then dehydrated, longitudinally bisected and 
embedded in paraffin. 
2. 6~m sections were deparaffinised and endogenous peroxidase activity blocked by 
incubation in 0.3% H202 in methanol for 30 minutes. 
3. Antigen retrieval was performed by microwaving the sections in Tris/EDTA (10mmol/l 
Tris, 1mmol/l EDTA, pH9) for 20 minutes, after which the sections were blocked with 2% 
BSA in PBS for 30 minutes and then incubated with mouse anti-cytokeratin antibody in 
REAL antibody diluent overnight at 4°C in a humidity chamber. 
4. Sections were washed twice in PBS for ten minutes after each step. 
5. Biotinylated anti-mouse secondary antibody was incubated for one hour, then 
StreptABComplex/HRP on O.SM NaCI in PBS for 30 minutes. 
6. 3,3'-diaminobenzidine was incubated on each section for 3 minutes to develop the stain 
on the antigen, then the sections were mounted using xylene. 
7. Slides were viewed under light microscope at x100 magnification and nine representative 
images were taken from each of the three repeats of every treatment. Images were 
analysed using ImageJ software [8] to determine maximal invasion depth (distance from 
surface of tissue to deepest invaded cell), maximum invasion area and invasion index [1-
(non invading area/total area)]. Figures were analysed using Microsoft Office Excel and 
unpaired two-tailed t-tests were used to assess the statistical significance. 
2.19.5 ELISA 
All dilutions were carried out using EIA diluent (20mM Tris, 150mM NaCl, 0.1% BSA, 
0.05% Tween 20, pH 7.5) unless otherwise stated. Experiments were performed In 
triplicate. 
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1. ELISA plates were sensitised with streptavidin and 10~g/ml biotinylated synthetic peptide 
SP102 (QYDSYDVKSGVAVGGGGGK-biotin), then washed three times in wash buffer (see 
section 2.2 buffers and solutions). 
2. In a separate tube, media samples were diluted 1:200 and 13S~1 was added to 1S~1 of a 
1:40 dilution of primary antibody raised in rabbit (against synthetic N terminal 
telopeptide QNYSPQYDSYDVKSGVAVGG from type III collagen). This was incubated for 30 
minutes at room temperature, then 100~1 was added to the corresponding well of the 
ELISA plate and incubated for one hour at room temperature. 
3. Wells were then washed three times with wash buffer and blotted dry. 
4. HRP-conjugated anti-rabbit secondary antibody at a 1:50,000 dilution in Quardian 
peroxidase conjugate stabiliser was added to each well and incubated for one hour at 
room temperature. 
5. Wells were again washed three times with wash buffer. 
6. 100~1 chromogen containing substrate tetramethylbenzidine (TMB) was added to each 
well and after a 30 minute incubation the reaction was stopped by adding 100~1 2M 
H2S04. The absorbance was taken at 4S0nm. 
Controls included TMB substrate solution only and antibody only. 
2.19.6 RIA 
Each sample was processed in duplicate. Media from samples containing cells were 
diluted 1:10 or 1:2 for those without cells. 
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1. 200111 media sample was incubated with 200lli tracer (synthetic peptide 
GGVGAAAIAGIGGEKAGGFAPY - 1251) and 200111 primary antibody (raised in rabbit 
immunised with synthetic peptide GGVGAAAIAGIGGEKAGGFAPY) for two hours at 3rc. 
2. SOOlll PEG containing anti-rabbit secondary antibody was added and incubated for 30 
minutes at 4°C, the samples were spun in a centrifuge at 3000rpm for 30 minutes, 
supernatants were removed and the pellets were measured using a gamma reader. 
Controls used: 
Synthetic peptide (GGVGAAAIAGIGGEKAGGFAPY) diluted between 1:128,000 and 1:4,000 
+ tracer + primary antibody to form standards; 
PBS-tween + tracer + unrelated rabbit antibody to generate no signal; 
Synthetic peptide only to generate no signal; 
PBS-tween + tracer + primary antibody, generating maximum signal; 
Unrelated synthetic peptide + tracer + primary antibody, also generating maximum signal. 
2.20 Serum Stability Assays 
Extreme care was taken whilst using unpolymerised acrylamide due to its carcinogenic 
properties. 
1. In one tube per time point, 1~1100llM aptamer stock was incubated with 17111 human or 
mouse serum and left for the required time (30 minutes, 1, 2, 3, 4 and S hours) at room 
temperature. The reaction was stopped by adding 2~11M EDTA and the samples were 
kept at -20DC until ready to run on a native polyacrylamide gel. 
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2. A 12% native polyacrylamide gel was used: 3.6ml acrylamide, 3.4ml ultra pure water and 
1.8ml 5x TBE were mixed in a 25ml universal bottle, then 1501l1100mg/ml APS and 7.51l1 
TEMED were added, quickly mixed, and the gel poured immediately. The well combs 
were subsequently inserted and the gel was left to set for 2 hours. 
3. The gel was then pre-run and the samples loaded as the protocol for EMSA details. 
2.21 Quartz Crystal Microbalance (QCM) 
2.21.1 Immobilisation of 5'biotinylated aptamers to gold-coated quartz crystals. 
Immobilisations were carried out according to liss et a!. [9). 
1. Gold surfaces of each 5MHz crystal were cleaned with two injections of ice-cold piranha 
solution, with a 500111 wash of ice-cold water after each injection. 
2. Crystals were immersed in ice-cold H20, and then transferred to an oven to dry at lOO·e 
for at least an hour. 
3. Activation of gold surfaces was achieved by adding 4mg/ml 3,3' dithiodipropionic acid 
(DSP) in water-free N,N-dimethylacetamide (DMA), sealing the crystal within a chamber 
and incubating for 15 minutes at room temperature. 
4. The crystals were washed three times with sterile PBS. 
5. Img/ml streptavidin diluted in sterile PBS was injected onto the crystal surface; the 
crystal sealed in a chamber and incubated overnight at 4·e. 
6. The crystals were washed five times with PBS, and then the crystal was blocked by adding 
0.025% BSA in PBS and incubating for one hour at room temperature. 
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7. 5' biotinylated aptamers, diluted to 211M in PBS were added after being heated to 95°C 
and cooled on ice, and incubated for one hour at room temperature. 
8. The crystals were washed well in PBS and used immediately. 
2.21.2 Experiments: 
Experiments were carried out, in accordance with Liss et 01. [9], to measure the binding of 
heparanase to the aptamers immobilised on the crystal using solutions that were kept at 
room temperature, with care taken to avoid fluctuations in temperature, humidity, and 
pressure. 
1. The crystal was placed in the flow cell, taking care to orientate it correctly, and the system 
was set up as shown in figure 2.2. 
2. PBS was run through the system for one minute on fast flow, then the pump was halted, 
the program and monitoring switched on, the capacitance adjusted, and the crystal left to 
equilibrate in the PBS contained within the flow cell for one hour or until the reading was 
stabilised. 
3. After pausing the program and taking care not to introduce any air Into the system, 
human recombinant polymorphic heparanase diluted in PBS was added to the flow cell, 
using the pump to pull the liquid through very slowly, then the pump was halted and the 
program was resumed. 
4. When the readings had stabilised, the program was paused and the crystal was washed 
using the pump to pull 10ml PBS through the system, the pump was ceased and the 
readings resumed. 
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5. After the readings had settled, the program was paused and the crystal was regenerated 
with 10ml 100mM EDTA, then 3.0M NaSCN before the experiment ended. The crystal 
was kept at 4°C in a chamber of PBS containing 0.02% sodium azide until the next 
experiment. 
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Figure 2.2 - Experimental set-up of QCM stop-flow equipment. The peristaltic pump 
pulls sample through the flow cell and all data are sent from the flow cell via the QCM 
detector to the PC for analysis. 
2.22 Interaction of Aptamers with Serum Albumins 
Experiments were conducted based on methods by Silva et aI., [10-12] . Absorbance was 
measured using a UV spectrophotometer to generate a wavelength scan incorporating 
wavelengths of 280 and 290nm. Fluorescence emission was measured between 300 and 
400nm using an excitation wavelength of 290nm, corresponding to the excitation 
wavelength ofthe tryptophan residues. Emission and excitation wavelength slits were set 
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to 3nm for all experiments. Both UV and fluorescence experiment were conducted at 
3rC by use of the Peltier Thermosystems to automatically control the temperature. 
2.22.1 UV titrations 
1. In a 3ml cuvette, 1ml PBS was used to autozero the equipment, which was set up to 
measure samples as per the conditions outlined above. 
2. 1ml HSA diluted to 6J..lM in PBS was transferred to a 3ml cuvette and the absorbance 
measured after allowing 5 minutes for the cuvette and solution to reach 37°(, 
3. Additions of between 1 and 6.4J..l1 of the selected aptamer were made after the previous 
reading had been completed. After making the addition, a pipette was used to mix the 
solution in the cuvette by gradually pipetting up and down. This was then left for one 
minute to mix and interact with the HSA before taking the absorbance measurement. 
Total concentration of aptamer in the cuvette began at O.OlJ..lM and ended with O.33J..lM. 
4. All experiments were repeated at least three times to gain consistency, and data were 
plotted and analysed from Microsoft Office Excel and Microcal Origin. 
5. At the end of the experiment, the cuvettes were washed in detergent and ultra-pure 
water. 
2.22.2 Fluorescence titrations 
1. The equipment was set up to measure samples as per the conditions outlined above. 
2. 1ml HSA diluted to 60J..lM in PBS was transferred to a 3ml cuvette and the absorbance 
measured after allowing 5 minutes for the cuvette and solution to reach 37°(. 
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3. Additions of between 1 and 6.4~1 of the selected aptamer were made after the previous 
reading had been completed and were set up to read every 90 seconds, leaving time to 
make the next addition, pipette up and down gently to mix, and interact before the 
following reading was taken. Total concentration of aptamers began at 0.12~M and 
ended with 7.1J..lM. 
4. A total of three scans were taken per addition, which were then averaged and plotted in 
Microsoft Office Excel and Microcal Origin for analysis. 
5. At the end of the experiment, the cuvettes were washed in detergent and ultra-pure 
water, and then soaked in nitric acid. 
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CHAPTER THREE 
SELECTION OF APTAMERS TO HEPARANASE AND 
LINKER PEPTIDE 
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3.1 Background 
As described in the introduction, selection procedures were based on the SELEX 
methodology and protocol [1] with modifications based on the group's previous 
optimisations and according to the needs of the project. After incubation with target, 
aptamers were eluted using high salt concentrations or temperatures as both have the 
potential to denature or at least reversibly reconfigure the structure of heparanase, so 
that bound aptamers are released. It follows that at lower temperatures or salt 
concentrations, non-binders and weakly bound aptamers are released, whilst retaining 
the strongly bound. Therefore, using either tactic, the most promising aptamers should 
be found in the elutions of highest salt or temperature as will be described in this chapter. 
3.1.1 Aptamer Library 
The aptamer library used contained a 25 base-long variable sequence, of which each 
position could carry an A, C, G or T base, flanked at the 5' end by a 23-base fixed 
sequence (GGG AGA CAA GAA TAA ACG CTC AA) and at the 3' end by a 24-base sequence 
(TIC GAC AGG AGG CTC ACA ACA GGC). These fixed sequences are used for the purpose 
of recognition for primers (GGG AGA CAA GAA TAA ACG CTC AA and GCC TGT TGT GAG 
CCT CCT GTC GAA) whilst amplifying in PCR, and also add stability to the structure of the 
aptamer. The chosen length of variable sequence results In a total of 425 (or 1015) 
different sequence combinations, allowing all known structures to be formed, such as 
hairpins and superloops, and where the sequence is GC-rich, creates stability through the 
formation of quadruplex structures, formed between guanine bases. 
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The Avogadro constant states that one mole of substance contains 6.022x1023 entities or 
molecules, and therefore to ensure that an aptamer library theoretically contains at least 
one copy of each sequence of the 1015 different possibilities, there must be 1.7nmoles of 
aptamer library material. Each aptamer library was ordered to a scale of 40nmoles to 
contain approximately 24 copies of each sequence and then amplified forthwith to 
further enrich the availability of each species and ensure that high binders are not lost 
due to the vast excess of non-specific binders. 
3.1.2 Heparanase and Heparanase Linker Peptide 
Aptamers were generated against human polymorphic recombinant heparanase, 
expressed in insect cells [2], of which amino acids 1-36 (shown in red in diagram below) 
form the signal peptide sequence (not part of the active enzyme); amino acid s 37-108 
form the 8kDa subunit; 109-156 (in purple) form the 6kDa linker peptide, which is exci sed 
and hence not part of the active enzyme, and 157-543 show the 50kDa subunit. Amino 
acid 307 (in orange) shows the polymorphism; a point mutation from arginine to lysine. 
MllRSKPAlP PPlMlllLGP LGPLSPGAlP RPAQAQDVVD LDFFTQEPLH LVSPSFLSVT 
IDANlATDPR FlILlGSPKL RTLARGlSPA YlRFGGTKTD FlIFDPKKES TFEERSYWQS 
QVNQDICKYG SIPPDVEEKL RLEWPYQEQL lLREHYQKKF KNSTYSRSSV DVLYTFANCS 
GLDlIFGlNA LlRTADLQWN SSNAQLlLDY CSSKGYNISW ELGNEPNSFL KKADIFINGS 
QLGEDFIQLH KLLRKSTFKN AKLYGPDVGQ PRRKTAKMLK SFLKAGGEVI DSVTWHHYYL 
NGRTAT~EDF LNPDVlDIFI SSVQKVFQVV ESTRPGKKVW LGETSSAYGG GAPLLSDTFA 
AGFMWLDKlG LSARMGIEVV MRQVFFGAGN YHLVDENFDP lPDYWLSLLF KKlVGTKVLM 
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ASVQGSKRRK LRVYLHCTNT DNPRYKEGDL TLYAINLHNV TKYLRLPYPF SNKQVDKYLL 
RPLGPHGLLS KSVQLNGLTL KMVDDQTLPP LMEKPLRPGS SLGLPAFSYS FFVIRNAKVA ACI 
Recombinant heparanase has been shown to exhibit maximum activity at pH 5, although 
still retains approximately 20% of this level of activity at pH 7 [2]. Furthermore, it has 
been shown to significantly degrade cell-surface heparan sulfate at pH 7.4, after 4 hours, 
with an indistinguishable profile of degradation of heparan sulfate from the native 
enzyme [2]. Analysis of the sequence of recombinant enzyme, based on Henderson-
Hasselbalch parameters, suggests that the isoelectric point (pi) of the enzyme is 
approximately 9.5; therefore at pH 7.2 the enzyme will have a net charge of +17.8, and 
+34.39 at pH 5. This is considered generally advantageous and facilitating aptamer 
binding, as it offers an initial positive electrostatic interaction between the aptamer and 
the target enzyme, although it can also allow an increased non-specific interaction due to 
charge. 
The linker peptide is a GST recombinant fusion peptide of 49 amino acids. It has a 
molecular weight of 6089.7 and a theoretical pi of 4.56. At pH 7.2 the peptide has an 
overall charge of approximately -3.04. The negative charge of the peptide may have 
implications on aptamer selection, as DNA sequences carry an overall negative charge, 
due to the DNA phosphate backbone. However, the presence of arginines in the peptide 
sequence can offer anchors that have been shown to facilitate aptamer binding [3]. Two 
different aptamer selection approaches have been adopted, based on different elution 
protocols, one based on heat denaturation and one on salt elution, as described below. 
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3.2 Heat One-Step Method 
In an attempt to remove desalting steps and optimise the selection procedure from 
previously used protocols involving high salt or chaotropic agents, an alternative method 
of selection was performed. This method was based on using heat, instead of salt, to 
release the bound aptamers from the enzyme. A buffer exchange was carried out on 
recombinant heparanase using Millipore Ultrafree-15 centrifugal devices to replace the 
original 25mM Trizma base, 0.7M NaCI pH 7.5 with O.lM salt solution, pH 6.5 in order to 
reduce the NaCI concentration of the solution and slightly decrease the pH of the 
solution, so as the enzyme to be positively charged. This solution was also used as 
adsorption buffer of the protein to ELISA plates and functionalised 'Top Yield' PCR tubes 
(see below), as carbonate buffer at pH 9.6 would confer a slightly positive charge on the 
enzyme due to it being above the theoretical pi of the protein, which could have an 
adverse effect on aptamer binding and selection. 
Prior to selection, aptamer library was amplified using a single stranded PCR protocol, and 
human recombinant heparanase at a concentration of 10",g/ml, diluted in O.lM salt 
solution pH 6.5, was adsorbed to 'Top Yield' PCR tubes overnight on ice In the fume hood. 
Aptamer library was incubated for one hour with heparanase and, after washing the tube 
with wash buffer, 50",1 volumes of ultra pure H20 were added to the tube, heated to 
increasing temperatures (50, 60, 70, SO, 90, 92, 94, 96, 9Se C), and then removed and 
retained. A PCR was carried out on all of the temperature-eluted samples to double-
strand the DNA for cloning, and a 2% agarose gel was run with 100bp ladder to check for 
presence of aptamers (figure 3.1). The gel showed that the only viable band at 75bp was 
present in the 92°C fraction, which was subsequently taken forward to the cloning stage. 
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Figure 3.1 - A 2% agarose gel was used to check for presence of 75bp aptamers from 
the highest temperature elutions. Only one viable band was observed from the 92·e 
elution, which was selected for cloning. 
The product from the elution at 92·C was cloned into TOPO vector and chemica lly 
competent E. coli cells according to the cloning protocol (see mat erials and methods). 
This generated single colonies on an agar plat e containing ampicillin, which were then 
tested directly using two primer sets: internal forward and reverse primers, and M13 
forward and reverse primers, according to the PCR method . 
2% agarose gels were run to see if the correct size fragments were present following 
cloning (an example of which is shown in figure 3.2). Should cloning have been 
successful, the internal primers would show the full 7Sbp of t he aptamer, whereas the 
M13 primer set would show a band at 200bp if the M 13 gene were uninterrupted (i.e. no 
aptamer inserted) or a 27Sbp band with the aptamer present in t he gene. 
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Figure 3.2 - A 2% agarose gel was used to test for positive colonies using internal and 
M13 primer sets. Clone numbers 35-39 were selected as positive and sent for 
sequencing analysis, whereas clones 40-42 were assumed negative as, even though a 
smear with the internal primer set is seen, the M13 primers suggest no insert is present. 
A smear on the internal negative control is also apparent, suggesting primer front. 
The gels showed that the positive colonies (containing bot h 275 and 75bp fragments) 
were 35, 36, 37, 38, 39, 43, 44, 45, 46, 50, 51, 54 and 57. The agar patch plate containing 
these colonies was sent for sequencing (M acrogen Inc., Korea) . The 5'-3' variab le 
sequences that were generated were displayed usi ng (Iusta l W [4], showing sequence 
homology using different colours as follows: 
36 ----GATTCA- GTA- TACGATG--------- 16 
38 --CTGATCAAAGTA- TAAGTAAAACATT --- 25 
43 --AATAGCAAGTTG - TGAGTTGAAGAAA--- 25 
35 ---GGAACCATATACTAAGTTTTTCTTT --- 25 
44 - - TTCAAGCTATTA- TAG- TCTCATACGG -- 25 
4 6 --TTTAACGTATT - - TAT- TCAAGCTCGTA- 25 
50 --TATATATTCCTA- CACATCTAACTTA--- 25 
39 --CCTAATAAGACTTAACCTTACTAAC---- 25 
54 GATGTGGAATTATAGGACTTTAA -------- 23 
4 5 - -----GAGTTACG----------------- 8 
3 7 AGGCAACAGGAACCTTAGTTG--- - ------ 21 
51 - - - - - - ATGGACTTTTGAATGTGGCAACAAA 25 
The full -length sequences were 38, 39, 43, 44, 46, 50 and 51, which were ordered as 
oligonucleotides from MWG for t esting, wh ereas t he incomplete sequences were 
rejected . It was discovered, following further test ing (see chapter four), that these 
Page I 105 
aptamers were false positives that did not bind heparanase, which led us to attempting 
further selections. 
An additional attempt based on heat denaturation elution protocols was performed, 
where the heat selection protocol was repeated but modified slightly by running ten 
consecutive rounds of incubation followed by elution using high temperature (98°e). The 
aim was to re-amplify the bound aptamers through each cycle and discard the ones that 
did not bind, based on the protocol described by Missailidis [5]. As this method utilises 
ten cycles instead of one cycle, it should re-enforce the highest binding sequences and 
therefore produce a more reliable result. At the end of the ten cycles a double stranded 
peR was carried out as above and the products were run on a 2% agarose gel. There were 
no bands observed on the gel and after repeating the double stranded peR and agarose 
gel there were still no bands thus indicating that no aptamers were selected using this 
protocol. An ELISA (shown in chapter four) confirmed that the 'Top Yield' tubes were 
saturated with heparanase, so this was ruled out as a cause. The ELISA also showed a 
slight increase in signal at 450nm upon heating the enzyme, compared to not heating; 
suggesting that after applying heat to the enzyme, the antibody bound in a stable 
complex with the enzyme nevertheless. For this reason, it was decided to pursue the salt 
selection protocol, as it seemed possible that the aptamer-enzyme complex may also 
have been stable under the condition tested, thus resulting in insufficient elution and 
amplification of the bound aptamer during the heat denaturation processes. 
3.3 Salt One-Step Method 
3.3.1 Selection against the Heparanase active enzyme 
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Following the outcome of the heat selection, a more traditional approach, based on the 
elution of bound aptamers using high salt and chaotropic agent concentrations was 
followed. Aptamer library, theoretically containing at least one copy (1.2x1015 entities) of 
each species, was amplified in a single stranded peR to yield multiple copies of each 
sequence. This was essential as it would give each heparanase molecule a higher chance 
of encountering the tightest binding species and would ensure that higher binders would 
not be displaced by non specific binders due to their excess in the initial solution. Human 
recombinant heparanase was diluted to 10~g/ml in carbonate buffer solution, pH 9.6 in 
'Top Yield' PCR tubes and allowed 24 hours on ice in a fume hood to adsorb to the walls 
of the well, after which, the well was washed three times with O.lM salt solution to 
remove all unbound heparanase molecules. The amplified library was then incubated 
within the tube for one hour, library solution containing unbound species was removed 
and subsequently bound species were eluted by adding increasing concentrations in O.lM 
increments (0.2-1.5M) of salt solution, pH 7.2, followed by an additional wash using 3M 
NaSCN to ensure that all binding aptamers were eluted. All the fractions were removed, 
retained, and desalted using microcon filters with a 3,000 molecular weight cut off (thus 
retaining any aptamers due to their molecular weight of approximately 22,2810a), to 
prevent inhibition of the subsequent peR reaction by the salt present. The product of the 
desalting processes, eluted at approximately 60~1 of pure water, was added to peR 
reagents for double stranded peR, using equal concentrations of both forward and 
reverse primers, to prepare the DNA for cloning into bacterial cells. 
Prior to cloning, products were run on a 2% agarose gel containing ethldium bromide 
(figure 3.3) to check that aptamers had been generated and retained. Only the highest 
four salt concentrations were tested initially, as the aptamers with the highest affinities 
Page 1107 
should have been retained in lower concentrations and eluted only in higher sa lt 
concentrations. The samples were run against a 100bp DNA ladder . 
. 3M 1.4~':[ 105M 3.0M 
600bp 
500bp 
400bp 
300bp 
200bp 
100bp 
Figure 3.3 - A 2% agarose gel to check presence of 7Sbp aptamers from the highest salt 
elutions. No aptamers were visible on this gel. 
There were no bands observed at 7Sbp on the gel, so the microcon filters w ere re-eluted 
to make sure DNA was not retained on the microcon membranes. Th e peR was repeat ed 
and another agarose gel was run (figure 3.4) using the same conditions as above. 
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Figure 3.4 - A 2% agarose gel to check presence of 7Sbp aptamers from the highest salt 
elutions. Multiple bands were observed suggesting annealing of primers or some 
contamination of reagents in the peR mix. 
There were multiple bands observed on all samples in this gel, which suggested either the 
reagents were contaminated or that the primers or aptamers may have annealed to one 
another, so this selection could not progress any further, as single bands at 7Sbp are 
needed to ensure that the correct product is to be cloned . This highlighted the 
importance of using a negative control in peR, as contamination or dimerisation of nucleic 
acids would be easily recognised. 
It was considered that a possible reason why the sa lt se lection method did not work was 
due to the potentially too low amount of individual aptamer species on the original 
library mixture. Therefore, it was decided to amplify the aptamer library in a slightly 
different way, with the aim of achieving more copies of each individual sequence. To do 
this, SO~I of aptamer library (theoretically containing two copies of each aptamer 
sequence) was included in a double-stranded peR for 30 cycles and then 100~tI of this 
product was included in a single stranded peR for 99 cycles. This meant that the library 
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that was included in the single stranded peR was more concentrated and included more 
copies of each sequence due to the exponential nature of the double stranded peR. The 
salt selection protocol was then carried out on a tube sensitised with O.151-l.M Hpal in 
O.lM sa lt solution, pH 6.5. This was chosen so as to increase the positive charge of the 
protein and ensure increased aptamer bil')ding (see heat protocol above) . Furthermore, 
the method was modified slightly so that each salt elution was incubated in the tube for 
five minutes on the rotating mixer before being removed to a clean peR tube . The 
purpose of this was to aid the removal of weakly bound aptamers into each elution from 
agitation together with salt content. The desalting was then carried out in microcon 
filters, using 60 minute spin times instead of 80 minutes, to lower the chance of the filters 
becoming dry. After elution, a peR was carried out to produce double-stranded DNA, 
using new peR reagents to exclude the possibility of contamination, and the products ran 
on a 2% agarose gel stained with ethidium bromide and containing a 25bp ladder (figure 
3.5): 
o.a:; 0.0 0.7 O. O.Q 1.0 L 1.1 1.2 1.3 1.4 1.5 3.0 
Figure 3.S - A 2% agarose gel to determine the presence of aptamers In each salt 
elution from O.SM NaCI to 3M NaSCN. 7Sbp bands were seen In all samples except the 
negative control, suggesting that different species of aptamer had bound with different 
affinities, which were removed with the different salt concentrations. 
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This gel shows single bands at 75bp in each sample, showing th at aptamers were eluted 
from each salt concentration due to their differing affinities, as expected. The negative 
control shows no bands and suggests that multiple bands observed in previous occasions 
were a result of PCR reagent contamination . The l.sM NaCI and 3.0M NaSCN elution 
products were cloned into TOPO and then into E. coli. PCRs were carried out on t he 
appropriate sized colonies using internal and M13 primers, and 2% agarose gels were run 
(see figu re 3.6 for an example), to see which colonies contained aptamers. 
Figure 3.6 - A 2% agarose gel showing products of PCRs on colonies obtained following 
cloning of the 1.5M NaCI elution into E. coli cells. Primers used were M13 and Internal, 
showing 275bp and 75bp fragments upon insertion of aptamers, respectively. From this 
gel, colony numbers 13, 14, 16, 19-21 were selected as positives as they display bands 
at both 275 and 75bp. Numbers 15, 17 and 18 were discarded. 
The colonies from 1.5M NaCI selection products se lected for sequencing were numbers 1-
14, 16, 19-22, 24-36, 62,65-67, 69-73, and the 5'_3' sequences of th e apt amers, displayed 
using Clustal W [4] were as follows: 
25 
72 
34 
--------AAGAAGACTAGCGATGAAGAGCGCT-- 25 
CGGATTATTCGAACTCTTCCAATGA----- _____ 25 
- ---TACTAACTACTCGTACGCAAACGGA--- __ _ 25 
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69 -----AATAGCAAGTTGTAAGTTGAAGAAA----- 25 
22 ---ACTTAATTTGCACTTACCATATGGC----- - - 25 
62 --TAATTGCTTCACCCTTACAAACCAG--- - ---- 25 
2 - TCTCTTTCTTGACGCTCTATAAGCG - ------ - - 25 
7 GCGATCGGGATAATCTGCTATAAGA- --------- 25 
4 -- - ----TATTCATACG--GAACAGAATTCTCCC - 25 
71 - --------CCAATATAA - GAATATTATTGTCTCA 25 
5 - ----CATTGGAAAAATCCGAAAGTGATTA-- --- 25 
20 -----CAGATTAACATACCAAATCTAATTA-- - -- 25 
1 -- - ------ATGGACTTTTGAATGTGGCAACAAA - 25 
13 ---------ATGGACTTTTGAATGTGGCAACAAA - 25 
19 ---------GTCGCCTTTTCACTTCACTAGGGTA- 25 
11 GGACAGTCAGTCACCATGATTATTT - ---- --- - - 25 
32 -------CACTCAACAGCCTTATTTCCCAATG --- 25 
24 - ----GAAAGCAAACGTCCTAATTCCAGAA - - --- 25 
29 -------AACTAAATCTCCAAACAACTTACTG--- 25 
27 - CACCAGGTTCCATGTCCTAAACTTA--- - ----- 25 
21 -------TAATACCTCGCCAGCTACGTCACAG--- 25 
The colony numbers selected for sequencing from the 3.0M NaSCN selection products 
were 1-7, 9-11, 13-26, 28, 31-32 and the sequences of the aptamers, again displayed 
using Clustal W [4] were as follows: 
3 1 TTTAACGTATTTATTCAAGCTCGTA--- 25 
32 TTTAACGTATTTATTCAAGCTCGTA--- 25 
28 TTTAACGTATTTATTCAAGCTCGTA--- 25 
26 TTTAACGTATTTATTCAAGCTCGTA--- 25 
25 TTTAACGTATTTATTCAAGCTCGTA--- 25 
23 TTTAACGTATTTATTCAAGCTCGTA- -- 25 
22 TTTAACGTATTTATTCAAGCTCGTA--- 25 
21 TTTAACGTATTTATTCAAGCTCGTA--- 25 
20 TTTAACGTATTTATTCAAGCTCGTA- - - 25 
1 9 TTTAACGTATTTATTCAAGCTCGTA-- - 25 
1 8 TTTAACGTATTTATTCAAGCTCGTA--- 25 
1 7 TTTAACGTATTTATTCAAGCTCGTA--- 25 
1 6 TTTAACGTATTTATTCAAGCTCGTA--- 25 
1 5 TTTAACGTATTTATTCAAGCTCGTA--- 25 
14 TTTAACGTATTTATTCAAGCTCGTA--- 25 
1 3 TTTAACGTATTTATTCAAGCTCGTA--- 25 
10 TTTAACGTATTTATTCAAGCTCGTA-- - 25 
9 TTTAACGTATTTATTCAAGCTCGTA--- 25 
5 TTTAACGTATTTATTCAAGCTCGTA--- 25 
4 TTTAACGTATTTATTCAAGCTCGTA--- 25 
3 TTTAACGTATTTATTCAAGCTCGTA--- 25 
6 TTTAACATATTTATTCAAGCTCGTA--- 25 
1 ---TATATATTCCTACACATCTAACTTA 25 
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Sequences from the 1.5M NaCI products showed some similarities with 2 sequences 
being entirely homologous. Sequences from the 3.0M selection products showed that all 
except for two sequences were homologous. This is very exciting, as it suggests that this 
is the highest affinity aptamer for Hpal and that all the other sequences were eluted 
earlier during the selection process by salt elution, leaving this as the last aptamer. The 
fact that this aptamer remained bound even when exposed to 1.SM NaCI is significant in 
itself as it suggests that it has a very high affinity for Hpal. These two sequences were 
chosen for structural analysis and functional analysis. 
3.3.2 Selection against the Heparanase Linker Peptide 
The same method, described above for the active enzyme, was used to select aptamers 
against the GST fusion linker peptide sequence. Library was amplified and selection 
carried out exactly as for heparanase, except that the concentration of linker peptide 
introduced to the 'Top Yield' PCR tubes for adsorption was 1.66~M. Desalting was carried 
out on elutions: 1.1, 1.2, 1.3, 1.4, 1.5M NaCI and 3.0M NaSCN, followed by a double 
stranded PCR and 2% agarose gel electrophoresis to analyse PCR products (figure 3.7). 
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Figure 3.7 - A 2% agarose gel showing 2Sbp ladder, plus products of 1.1 to 1.5M NaCI 
and 3M NaSCN elutions. Bands at 7Sbp, confirming presence of aptamers, were seen In 
all elutions. 
The gel shows bands at 75bp, hence aptamers, in all elutions; so the products from 3.0M 
NaSCN elution were cloned into TOPO vector, then into chemically competent E. coli cells. 
45 colonies were analysed by double stranded PCR, using both M13 and internal primer 
sets, and 2% agarose gels were run to confirm insertion of aptamers into the vectors prior 
to sequencing. Figure 3.8 is an example of one such agarose gel. 
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Figure 3.8 - A 2% agarose gel showing 25bp ladder and colony numbers 37-45 tested 
using internal and M13 primer sets. Numbers 40 and 43 were rejected as both the 75 
and 275bp bands were not seen, whereas the rest were assumed positive and 
sequenced. 
Of the 45 colonies, numbers 1, 2,4-7,9, 11-13, 15-18, 20-22, 24, 28, 30-32, 34-35, 37-39, 
41-42 and 44-45 were analysed by sequencing, with the following results as displayed by 
(Iustal W [4]: 
1 
13 
20 
34 
5 
6 
28 
9 
42 
30 
31 
41 
12 
21 
22 
39 
16 
37 
17 
3 2 
2 
4 
35 
44 
- GTGCTGAACCAAGTCGGTTTGTCCA---------
----- -----AAACTCGGTATGCTCACCACCAATG 
- AGTGATCAAAAAACGCACTGCCTGA-------- -
--TCGAGCCACCATCTCACACCCATAA------ - -
------AAAACAATCTCACATATCGGGCTG--- - -
-------GGTACACTTAATAA - TGAACGATAAC- -
-----AAAGCACAACTTACAACTAGACTAT-----
AACTGACTACTATTTTCGTATTTGT-------- - -
------TTTCTATTTAAATGTGTGTCTTCAT----
-------ATGGACTTTTGAATGTGGCAACAAA---
-----TTCTCGAGCTATTTGAATCCGGAC------
-----TTCTCGAGCTATTTGAATCCGGAC------
--CATCTATAGATCTTTTT ----------------
GGCTATGATAAGATCTGATTCTTTA----------
---AATCACAGATTTGTATTCATT-----------
------TATATATTCCTACACATCTAACTTA----
---AATAGCAAGTTGTGAGTTGAAGAAA-------
---AATAGCAAGTTGTGAGTTGAAGAAA -------
---- - TCGCCCGTTCCAAGCAAAC- GCAGCC----
-------TCGCGGTGCAACCAATTTATGAACA---
--------TTGCTCCTTATAGAGCCGTCCGAGC--
--------TTGCTCCTTATAGAGCCGTCCGAGC - -
--------TTGCTCCTTATAGAGCCGTCCGAGC - -
--------TTGCTCCTTATAGAGCCGTCCGAGC --
25 
25 
25 
25 
2 4 
25 
25 
25 
25 
25 
2 4 
2 4 
17 
25 
21 
25 
25 
25 
25 
25 
25 
25 
25 
25 
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38 GTAGAGACCCACCCCTAATCTAGAC---------- 25 
7 CTAAAGTGCCTCACGCTGTTAACTC---------- 25 
1 5 CTAAAGTGCCTCACGCTGTTAACTC--------- - 25 
1 8 CTAAAGTGCCTCACGCTGTTAACTC--------- - 25 
2 4 CTAAAGTGCCTCACGCTGTTAACTC---- - -- - -- 25 
4 5 CTAAAGTGCCTCACGCTGTTAACTC---------- 25 
1 1 --------AGCCACTTGATCCAACCTGCCTTGG-- 25 
Of the results obtained, the sequences highlighted in pink and yellow occurred with the 
highest frequency, suggesting that these were the ones with the highest binding affinity, 
as they were able to out-compete the other sequences. These were chosen for further 
structure-based and functional analysis. 
3.4 Structure Predictions 
To assess the potential structures of these aptamers, sequences were transcribed into 
Mfold [6]; a program used to predict the spontaneous three-dimensional structures of 
DNA/RNA molecules by calculating their minimum Gibbs free energy values [7] as well as 
the free energies of folding of any particular base pair at 37°C. The lower or more 
negative the value, the less energy is required for the predicted structure to be formed 
and, therefore, the more likely it is to be formed spontaneously. The variable and primer 
regions were both assessed as the primer regions help to confer stability upon the 
molecule and therefore are frequently implicated in the folded structure . Figure 3.9 
shows predictions for the 1.5M elution product, whilst figure 3.10 shows predictions for 
the 3.0M NaSCN elution product, both from the heparanase active enzyme selection. 
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Figure 3.9 - Mfold energy dot plot predicted structures of clone numbers 1 and 13 from 
1.5M NaCI elution of heparanase selection. 4G at 37·C for these structures is calculated 
at -3.42 and -3.36kcal/mol respectively [6] . 
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Figure 3.10 - Mfold energy dot plot predicted structures of homologous sequence 
generated from 3.OM NaSCN elution of heparanase selection. L\G at 37·C for this 
structure is -4.45 and -4.54 kcal/mol respectively [6]. 
Using the predicted structures generated by Mfold, it was decided to investigate the 3.0M 
NaSCN sequence as a slightly truncated sequence of 55 nucleotides, including some of 
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both primer regions as in both predicted structures the same sections of primer 
sequences were implicated. This sequence was further known as '3.0M'. For the 1.5M 
NaCI product, the two structure predictions varied significantly, with the one prediction 
implicating most of the primer regions in structure formation, and the other implicating 
neither primers in the structure (see figure 3.10). For this reason, it was decided to order 
this sequence as a full-length and also as a truncated version for further testing. These 
were further known as '1.5M short' and '1.5M long'. 
The two sequences obtained from selection against the linker peptide were also 
transcribed into Mfold, where sequences were suggested having highly negative l1G 
values (see figures 3.11 and 3.12). 
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Figure 3.11 - Mfold energy dot plot predicted structures of homologous sequence 
generated from the pink sequence of 3.0M NaSCN elution of linker peptide selection. 
Four structures were predicted, with 4G values at 37·C of -6.37kcal/mol, -7.19kcal/mol, 
-6.88kcal/mol and -6.67kcal/mol respectively [6] . 
.  
dO . -532,...,.. 
Figure 3.12 - Mfold energy dot plot predicted structure of homologous sequence 
generated from the yellow sequence of 3.0M NaSCN elution of linker peptide selection. 
4G at 37·C for this structure is -S.32kcal/mol [6]. 
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All predicted structures, both for the yellow and pink aptamer, seem to implicate the 
primer regions (see figures 3.11 and 3.12). Thus, these aptamers were also ordered as 
72mer oligonucleotides to commence further testing and referred to as 'pink' and 
'yellow'. 
3.5 Discussion 
Heparanase presented an interesting target for aptamer selection, and aptamers were 
selected for both the active enzyme and the linker peptide that is proteolytically cleaved 
from the pre pro enzyme to allow formation of the active enzyme. The results from the 
different selection processes indicate that selection of bound aptamers using a heat-
based elution method was not suitable for this enzyme. Data obtained from an ELISA 
assay suggested that after heating of heparanase to 98·C, although this process may have 
reversibly or irreversibly damaged the enzyme, did not result in a reduced signal and the 
anti-heparanase polyclonal antibody was still able to recognise and bind to the enzyme, 
more so than in a system conducted at room temperature. This suggests that the 
structure of the enzyme was still mostly intact and that the antibody may even have been 
better able to bind to heparanase after heating. Furthermore, no aptamers were eluted 
from the heating of the heparanase-aptamer complex after heating to 98°C, in agreement 
with the above observation. For this reason, the selection based on a salt elution 
protocol was followed and subsequently optimised by incubation of the target in a 
solution closer to physiological pH to take advantage of the positive charge of the enzyme 
at these conditions, more rigorous amplification of aptamer library, and using agitation to 
aid the Introduction/removal of aptamers to the target. 
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Although aptamer library was amplified in a single stranded PCR before incubation with 
the enzyme, these selection methodologies generated more promising results after 
amplifying the aptamer library exponentially in a double stranded PCR before a single 
stranded PCR. This suggests that initial library enrichment was advantageous due to the 
presence of more copies of each binding species, that better facilitated competitive 
binding to a limited pool of target and resulted in single or few aptamer sequences being 
selected. 
Aptamers were successfully selected against human recombinant heparanase and the 
6kDa linker peptide region using an optimised, modified SELEX protocol based on 
interruption of the interactions formed between protein and aptamer by high salt 
content. Aptamers generated from l.5M NaCI and 3.0M NaSCN elutions each suggested 
one prominent species based on sequence homology, as the greater the number of times 
the species is encountered, the higher affinity for the target it is expected to have, due to 
its out-competing the other sequences. Two sequences from each target were analysed 
using structure predicting software known as Mfold, and ordered as full length and 
truncated single-stranded sequences for further testing both for their affinity for their 
target and for their ability to detect the target in media and/or inhibit its action, as 
described in the following chapters. 
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CHAPTER FOUR 
FUNCTIONAL ASSAYS TO ASSESS BINDING OF 
APTAMERS TO HEPARANASE AND HEPARANASE 
FRAGMENTS 
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4.1 Background 
Following the development and synthesis of aptamers directed against the human 
polymorphic recombinant heparanase and the GST fusion linker peptide, experiments 
were designed to test the affinity and specificity of the aptamers in vitro, in bench-top 
assays. The assays selected were ELISA (~nzyme-!inked immuno~orbent !ssay), EMSA 
(glectrophoretic mobility ~hift !ssay) and fluorescence quenching titrations. 
Unfortunately, due to the unavailability of an antibody for the GST fusion linker peptide, it 
was not possible to test the aptamers for this target using all the above techniques. 
4.2 EUSA 
4.2.1 Optimisation of ELISA 
To optimise the conditions for an ELISA, it was necessary to examine the stoichiometry 
between enzyme and antibody by determining the concentration of antibody needed to 
saturate a plate sensitised with 150nM heparanase. An ELISA was carried out using a 
dilution series from 0 to 660nM polycJonal anti-heparanase antibody. The results, shown 
in figure 4.1, indicated that a 1:1 molar binding ratio was sufficient, as 160nM antibody 
formed the beginning of the plateau due to the free heparanase being mostly exhausted. 
There was a slight increase in signal upon increasing the antibody concentration over 
160nM due to any remainder of heparanase becoming bound. However, this may also 
have been due to some antibody molecules binding to more than one site of heparanase 
as a polyclonal antibody was used. For this reason, 660nM was chosen as the optimum 
concentration and used in further assays. 
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Figure 4.1 - An ELISA using a plate sensitised with 150nM human polymorphic 
recombinant heparanase with addition of increasing concentrations from 0-660nM 
polyclonal anti-heparanase IgG antibody to determine the optimum stoichiometry 
between heparanase and antibody. 660nM was determined to be the optimum 
concentration of antibody as although 160nM (a 1:1 molar binding ratio) gave a strong 
signal, it was important to exhaust all heparanase molecules with antibody. 
In previous experiments carried out, it was determined that the optimum conditions for 
ELISA were to block the wells with 10mgjml BSA in PBS to minimise any of the 
subsequent reagents from binding to the well surface and generating false-positive 
results. 
The traditional competition ELISA was initially used between aptamer and antibody for 
these studies, aiming to demonstrate that the aptamer had the ability to compete out the 
heparanase-bound antibody, based on a protocol previously demonstrated by the MUCl 
aptamer [1]. However, these studies would only show if the aptamer bound and 
competed with the antibody for the same site or bound in close enough proximity to 
disrupt one another's interactions. It is entirely possible, due to their small size compared 
to both antibody and enzyme, due to their negative charge, and due to the fact that a 
polycional antibody was used with no known epitope, that the aptamers may bind at a 
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completely different site from the antibody, which would explain the lack of positive 
results on this assay. 
Hence, the ELISA was modified by immobilising 5' biotinylated aptamers via the use of 
avidin molecules to the surface of the wells, then after a blocking step, incubating 
heparanase, heparanase antibody and following the ELISA to completion. This was 
initially carried out in triplicate using pre-coated streptavidin peR tubes and an example is 
shown of l.5M short aptamer in figure 4.2. 
0.7 
0.6 
-E c: 0.5 
o 
In 
~ 0.4 
Q) 
u 
c: 
1'0 0.3 
..c 
-o ~ 0.2 
« 
0.1 
o 
/ 
II I 
V 
~ T 
~ 
o 
/t"" 
--""-
100 200 
[Aptamer] (nM) 
J 
- Heparanase 
-- No Heparanase 
300 400 
Figure 4.2 - An ELISA using streptavidin pre-coated peR tubes with S' biotinylated 1.SM 
short aptamer. After blocking, then addition of 160nM human recombinant 
polymorphic heparanase and its respective antibody, the ELISA was run to completion. 
The experiments using all three aptamers without heparanase showed a marginal change 
in absorbance at a level between 0.1 and 0.3 absorbance units, compared to those with 
heparanase added. The latter increased in absorbance upon increasing the 
concentrations of aptamers, suggesting that the aptamers did indeed bind heparanase. 
However, this method needed further optimisation to increase consistency and reduce 
costs. Thus, it was decided to allow an interaction between streptavidin and each 
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aptamer for a period of two hours before aliquoting 100lli into the wells of an ELISA plate 
instead of using pre-coated streptavidin PCR tubes. Adding biotinylated aptamers in a 4x 
molar excess of streptavidin (due to the presence of 4 biotin binding sites per streptavidin 
molecule) would ensure that the streptavidin-biotin binding reaction had occurred before 
the exposed areas of streptavidin bound to the wells of the plate, leaving the aptamers 
exposed for recognition by heparanase. Using one preparation of streptavidin-aptamer, 
serially diluted to the appropriate concentrations in this way would make the absorbance 
readings more consistent, as some large error bars were observed in the original trials 
using peR tubes. Carrying out the ELISA in the appropriate plate instead of peR tubes 
would also make the absorbance readings more consistent as in using peR tubes, the final 
solution had to be transferred to an ELISA plate to be analysed, which could have left 
behind some solution; leading to large error bars and non-reproducible results. The peR 
tubes were also very expensive and modifying the ELISA in this way caused the 
experiment to be more cost-effective. 
Unfortunately, due to an unavailability of antibody for the GST linker peptide, the ELISA 
was not a viable test of the linker peptide's interactions with its respective aptamers. 
4.2.2 Troubleshooting selection 
Due to no aptamers being detected at the end of the ten-round heat selection method, it 
was decided to conduct an ELISA in the 'Top Yield' PCR tubes used in selection, to make 
sure that there was heparanase adsorbed to the tubes as this may have been a reason 
why there were no aptamers found at the end of selection. Also, this ELISA was used to 
ascertain if the protein's interactions were being disrupted enough to release the 
aptamers to be amplified at 95°C. Experiments were conducted in triplicate as follows: 
150nM heparanase was incubated in Top Yield PCR tubes overnight at room temperature. 
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Three tubes containing 0.1M salt solution were also incubated to act as the negative 
control. The next day, heparanase-containing tubes were incubated at 95°C for ten 
minutes, 95°C for one hour, 9JOC for one hour or 98°C for one hour. The positive control 
was heparanase-adsorbed tubes that remained unheated . The rest of the ELISA was 
conducted with the removal of unbound heparanase by washing of the tubes, then the 
addition of primary antibody, streptavidin-conjugated secondary antibody and 
chromogen complex plus 10% H2S04• The results are shown in figure 4.3. 
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Figure 4.3 - An ELISA using 'Top Yield' ELISA-type PCR tubes sensitised with 150nM 
human polymorphic recombinant heparanase or O.lM salt solution (negative control). 
After heating all but the negative and positive controls to either 95, 97 or 98°C for the 
times indicated and addition of 660nM anti-heparanase antibody, the ELISA was run to 
completion and it was determined that heparanase had saturated the tubes and 
remained bound during selection, also that the antibody bound to heparanase and not 
to the sides of the tubes, both seen by the difference in absorbance between the 
negative and positive controls. It was also observed that at high temperatures the 
heparanase remained bound to the tubes and furthermore, bound an equal or greater 
number of primary antibody molecules. Error bars represent standard deviation of the 
mean. 
The results of this ELISA show that the 'Top Yield' tubes were saturated with heparanase 
due to the strong signal observed by the positive control, so this can be ruled out as the 
reason why there were no aptamers generated in this method. The difference in 
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absorbance seen between the negative and positive controls also shows that the 
antibody binds to heparanase and not to the sides of the tubes. 
There was an increase in absorbance with a corresponding increase in temperature, 
which suggests that a greater amount of antibody binds to heparanase subjected to 
higher temperatures. This could be due to the heat causing a conformational change in 
the protein such that the antibody binding site is more accessible to the antibody, 
therefore allowing it to bind more tightly and more of it to bind. However, as this 
antibody was raised in rabbit against the recombinant enzyme [2] and not the heat 
denatured protein or an epitope or peptide component of the enzyme, one would expect 
the antibody to recognize the structured enzyme and not recognize it after heat 
denaturation. 
Applying this to the selection method, this could mean that although the protein's 
conformation is changing, it may not be releaSing any bound aptamers. Also, as the tubes 
are heated at the stage where aptamers are incubating with the protein during selection, 
the aptamers may also be adopting a different structure under heat and the heparanase 
and aptamer be stabilising each other and remaining bound. Due to the difficulty in 
establishing a solution for this technique, it was decided to pursue with and address the 
salt selection methods instead. 
4.2.3 Heparanase-selected aptamers using one-round heat method 
To test the binding of seven aptamers (38, 39, 43, 44, 46, 50 and 51) previously selected 
against heparanase using the one-step heat selection method, a competition ELISA was 
carried out by adsorbing 150nM heparanase in O.lM binding solution to an ELISA plate, 
then incubating 660nM polyclonal heparanase antibody for one hour. Aptamer was 
added and incubated for one hour at concentrations from 0 to 700nM and the ELISA was 
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run to completion. The ELISA was measured to see if the addition of any of the aptamers 
had displaced the binding of the antibody to heparanase, and at what concentration . The 
results are shown in figure 4.4 below. 
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Figure 4.4 - An ELISA using a plate sensitised with 150nM heparanase, labelled with 
660nM polyclonal anti-heparanase IgG antibody, and then incubated with 0-700nM of 
each heparanase-selected aptamer to observe if the antibody was displaced. Results 
showed that none of the aptamers displaced the antibody as the signal did not decrease 
significantly from the negative (no aptamer) controls and therefore the aptamers' 
affinities for heparanase were below that of the antibody. 
Unfortunately, none of the aptamers displaced the binding of the antibody to heparanase 
as the absorbance at 450nm should have decreased upon displacement of antibody by 
aptamer but this was not demonstrated in any of the results for the aptamers tested . 
Therefore, a competition ELISA was carried out in reverse, similar to the one described 
above, but by adding the aptamers to the heparanase-sensitised wells first at a 
concentration of 600nM and then adding the antibody at concentrations from 5 to 
330nM to allow the aptamers a chance to bind without the presence of antibody, to 
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investigate whether any would remain bound after addition of even lower concentrations 
of antibody. Figure 4.5 below shows the results. 
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Figure 4.5 - An ELISA using a plate sensitised with 150nM heparanase, incubated with 
600nM of each heparanase-selected aptamer, and then incubated with 0-330nM 
polyclonal heparanase antibody. A negative control containing no aptamer was used to 
demonstrate antibody binding with no aptamer interference. The results all clearly 
follow the pattern shown by the negative control suggesting that the aptamers either 
do not bind at the antibody binding site or do not stay bound to heparanase in the 
presence of heparanase antibody. Error bars represent standard deviation of the mean 
of triplicate samples. 
The results showed that absorbance increased with concentration of antibody added, 
suggesting that if any aptamers were bound, the antibody displaced them. The results 
also did not deviate from the pattern of the negative control where no aptamer was 
added, suggesting that if any aptamers were bound then they were so with only a very 
low affinity. However, an EMSA was carried out to validate this as the ELISA only tests for 
binding to the same site as the antibody, and the aptamers may bind to a completely 
different site. None of these aptamers showed any shift in the EMSA (data not shown), 
thus confirming they did not bind to heparanase. 
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4.2.4 Heparonase aptamers selected using one-round salt method. 
To test aptamers generated from one-round salt selection ('l.5M short', 'l.SM long' and 
'3 .0M') a competition ELISA was conducted by incubating 17SnM heparanase polyclonal 
antibody in wells sensitised with ls0nM heparanase. Aptamers were added in dilution 
series from 0-1.43IlM and the ELISA was run to completion . The experiment was run in 
triplicate and results are shown in figure 4.6. Once again, to give aptamers a greater 
chance of competing with the antibody, an ELISA was conducted with aptamer and 
antibody added in opposite order, shown in figure 4.7, using sOOnM each aptamer, 
followed by 0-17SnM antibody. Error bars represent the standard deviation of the mean 
over the three experiments. 
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Figure 4.6 - A competition ELISA using a plate sensitised with lS0nM human 
recombinant polymorphic heparanase, Incubated with 17SnM heparanase antibody, 
then a dilution series of O-SOOnM each heparanase-selected aptamer. After completing 
the ELISA the results suggested that the aptamers did not displace the antibody as the 
absorbance did not decrease upon increasing aptamer concentration. Error bars 
represent standard deviation of the mean. 
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Figure 4.7 - A competition ELISA using a plate sensitised with lS0nM human 
recombinant polymorphic heparanase incubated with SOOnM each heparanase-selected 
aptamer then with 0-17SnM heparanase polyclonal antibody. Error bars represent 
standard deviation of the mean. 
Addition of either aptamer in these studies at any concentration did not affect the 
absorbance of these assays. In figure 4.6 the absorbance remained stable at 0.6 units 
from 0 to 500nM aptamer and in figure 4.7 the aptamer curves increased in absorbance 
in a fashion similar to the increase shown when no aptamer is present. This 
demonstrated that these aptamers do not interfere with the binding of heparanase to its 
antibody and therefore do not bind at the same site, if at all. 
To determine whether the aptamers bound heparanase, but at a different site from the 
antibody, streptavidin ELiSAs were performed with 187nM 5' biotinylated l.sM short, 
long, 3.0M and an unrelated aptamer as detailed in the methods section; the results of 
which are shown in figure 4.8. The results for the heparanase-selected aptamers show 
that the absorbance increased as the heparanase concentration increased, which 
suggests the aptamers bind heparanase. The negative control (unrelated aptamer) has 
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also shown an increase in absorbance with heparanase concentration, although at a 
lower level than that observed by the heparanase-selected aptamers. This suggests that 
there is some binding due to electrostatic interactions from the positive charge of the 
enzyme and the strong negative charge of the aptamer. The graph of l.5M long and 
3.0M aptamers show a plateau at 100nM heparanase, with a plateau at 70nM for l.5M 
short aptamer when binding sites become exhausted. Also, the absorbance reaches a 
higher maximum for the two longer aptamers which would suggest that more heparanase 
is retained by them, and may be explained by their size in that more 9kDa l.5M short 
aptamers may be obscured and subject to steric hindrance by one 58kDa heparanase 
molecule than a 22kDa l.5M long or 17kDa 3.0M aptamer. Therefore, more l.5M long 
and 3.0M aptamers are available for binding heparanase. 
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Figure 4.8 - A streptavidin ELISA carried out by immobillsation of 187nM of each 5' 
biotinylated aptamer (l.5M short, 1.5M long, 3.0M and an unrelated aptamer) with 
41.5nM streptavidin and the wells of an ELISA plate. After blocking with 10mg/ml BSA 
in PBS, 0-200nM heparanase was incubated for one hour and then the ELISA was run to 
completion. All heparanase-selected aptamers showed an increase of absorbance upon 
increasing heparanase concentration above the negative controls, confirming binding. 
Error bars represent standard deviation of the mean from triplicate results. 
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The streptavidin ELISA method was applied to investigate binding and recognit ion of 
heparanase-selected aptamers to heat denatured and active heparanase. 200nM each 5' 
biotinylated aptamer were incubated in streptavidin-coated PCR tubes overnight, then 
blocked in 5mg/ml BSA in PBS. After the wash step, heparanase (some of which had been 
previously denatured by heating to 95°C for one hour), serially diluted from 0-400nM was 
incubated in its respective well for one hour and the ELISA was run to completion . 
Figures 4.9 to 4.11 show the results of each aptamer. 
1.2 
1 T ...I 
- 1 
~ 
E ~ c 0 0.8 Ln r ~ - l.5M short cu 0.6 v I c 11) .c 0.4 ... 0 
- l.5M short 11\ 
.c 
< 0.2 (denatured 
heparanase) 
0 
0 100 200 300 400 
[heparanase] (nM) 
Figure 4.9 - A streptavidin ELISA carried out by immobilising 200nM 5' biotlnylated 1.5M 
short aptamer to the wells of streptavidin-coated PCR tubes overnight at 4°C. After a 
wash step, denatured or active heparanase were added and the ELISA run to 
completion. Results showed that 1.5M short aptamer bound active heparanase 
similarly to the previous assays. However, the aptamer did not bind heat denatured 
heparanase as the absorbance did not increase upon increasing the concentration of 
heat denatured heparanase. Error bars represent standard deviation of the mean from 
triplicate experiments. 
The results clearly indicate that all aptamers recognised and bound active heparanase as 
the absorbance showed a clear increase from that of the denatured heparanase, which 
did not increase at all upon adding increasing concentrations of the enzyme. Therefore, 
not only did the enzyme denature at 95°C but the selected aptamers did not recognise it, 
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suggesting that the aptamer recognises residues of the protein in its structured 
conformation. 
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Figure 4.10 - A streptavidin ELISA carried out as above, using 200nM 5' biotinylated 
1.5M long aptamer. Results showed that the aptamer bound active heparanase 
similarly to the previous assays. However, the aptamer did not bind heat denatured 
heparanase as the absorbance did not increase upon increasing the concentration of 
heat denatured heparanase. 
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Figure 4.11 - A streptavidin ELISA carried out as above, using 200nM 5' biotinylated 
3.0M aptamer. Results showed that the aptamer bound active heparanase similarly to 
the previous assays. However, the aptamer did not bind heat denatured heparanase as 
the absorbance did not increase upon increasing the concentration of heat denatured 
heparanase. 
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4.3 Fluorescence Quenching ntratlons 
To enable a fluorophore to fluoresce, it undergoes three main processes. Firstly, it must 
be excited by subjecting it to a photon of light at a particular wavelength, usually the 
same as that where it has its maximum absorbance. This causes it to maintain an excited 
state of high energy for a short amount of time when it is able to interact with other 
molecules and undergo structural changes. This causes some energy to dissipate and a 
consequent emission at a certain wavelength. Quenching, or decrease in fluorescence 
emission of a fluorophore in a peptide or protein may also occur with an excited 
fluorophore, and can be due to complex formation (static quenching) or collisional 
(dynamic quenching) between fluorophores and a quencher [3, 4]. Fluorophores then 
emit a photon of energy at a longer wavelength than the excitation wavelength, due to 
some of the energy already having been dissipated, returning them to their ground state. 
This process can be used to measure binding interactions, using an appropriate equation 
to plot the changes in fluorescence emission against concentration of the reactant added 
to the emitting molecule [3]. 
Both human polymorphic recombinant heparanase and GST fusion linker peptide contain 
tryptophan, tyrosine and phenylalanine residues, which have natural intrinsic 
fluorescence contained by dense populations of delocalised electrons in their aromatic 
rings [3]. Tryptophan is the major emitter of the three residues and if excited at 280nm 
forms an emission peak between 300 and 350nm depending on whether the tryptophan 
residues are exposed or 'hidden' within the folding of the protein [3]. Human 
recombinant mutant heparanase contains 6 tryptophan residues, all within the SOkDa 
subunit at sites 199, 220, 295, 340, 365 and 405. Linker peptide contains 2 tryptophan 
residues at sites 118 and 144. 
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In these experiments, aptamers generated for both the linker peptide and human 
recombinant heparanase were titrated with their respective targets based on [3]. Due 
to limited volumes of heparanase being available, it was decided to titrate volumes of 
aptamer to a heparanase solution, to continuously increase the concentration of aptamer 
until it was in excess over heparanase. This however, would add volume to the cuvette 
and dilute the total sample concentration. Thus, to assess the effects of this, salt solution 
was titrated in place of aptamer and the effect of the dilution was observed. 
To analyse the data, fluorescence counts obtained from each addition were inserted into 
Microcal Origin, plotted and non-linear curve analyses drawn using equation 1. 
fl[(El- E2)[(1 + K· 0 + K· PO) - ~(l + K· D + K· PO)2 - 4 · K· K· D· PO ]1+ E2. 0 1. ~ 
Acalc(PO)=L . 2·K J D 
Equation 4.1 - Quadratic equation for flttlnl non-linear blndlnl curves [3]. Acalc(PO) 
represents the maximum fluorescence of free heparanase divided by the fluorescent 
sllnals In presence of aptamer (F). PO Is the total aptamer concentration. K represents 
the equilibrium association constant. 0 Is concentration of enzyme. Ells the maximum 
value of Acalc(PO) and E2 Is F when F Is equal to Fo. To achieve 'best fit', fllures for K 
and E1 can be modified to a delree. 
Analysing the data in this way yields important information about the interactions of 
protein and aptamer, as it allows the calculation of association constants KA for each 
aptamer to their cognate target. 
Preliminary experiments were conducted using linker peptide, heparanase and aptamer 
alone to ensure that heparanase and its linker peptide showed a distinguishable peak if 
excited at 280nm (their absorption wavelengths) and that the aptamer did not show the 
same fluorescence emission profile (figures 4.12 and 4.13). Results showed evidence for 
the tryptophan peak at 335-340nm in both heparanase and the linker peptide, with no 
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peak from aptamer on ly, indicating this experiment's suitability for the study of aptamer-
target protein interactions. Concentrations of 2S0nM heparanase and SOOnM linker 
peptide were also derived f rom this experiment as they showed intense fluorescence 
signals, and 100mM salt solution was deemed as a suitable diluent, as no interference 
was observed. To minimise the dilution effect the aptamers would have on the 
concentration of heparanase, 20~M aptamer stock solution was used. This allowed two 
additions of 1.25~1 to achieve the first two ratios of 10:1 (heparanase:aptamer) and 5:1, 
then th e volume was doubled fo r each subsequent addition so t hat a total volume of 20~1 
was added to reach a final ratio of 0.625:1. 
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Figure 4.12 - Emission acquisition of 250nM heparanase only (red line) and SOOnM 3.0M 
aptamer only (blue line), diluted In l00nM salt solution, to determine the presence of 
natural fluorescence in heparanase and that the spectrum of aptamer does not 
Interfere. 
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Figure 4.13 - Emission acquisition of SOOnM linker peptide, diluted in salt solution, to 
determine its natural fluorescence spectrum. 
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Figure 4.14 - Dilution effects upon 250nM heparanase. A total of 20~1 100mM salt 
solution was titrated In place of aptamer to observe any decrease In fluorescence. A 
total decrease of 20.2% was observed between the first and last tltratlons and 
maximum fluorescence signal was observed at 33Snm. 
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Figure 4.15 - Dilution effects upon 500nM linker peptide. A total of 20I,,d 100mM salt 
solution was titrated in place of aptamer to observe any decrease in fluorescence. A 
total decrease of 17.1% was observed between the first and last titrations and 
maximum fluorescence signal was observed at 345nm. 
Figures 4,14 and 4,15 show experiments conducted when titrating 100mM salt solution in 
place of aptamer to observe the effect of time and dilution upon the change in 
fluorescence of heparanase and linker peptide. Unfortunately, even though the volumes 
added were the minimum the pipette could accurately dispense, it still decreased the 
fluorescence by 20,2% and 17,1% respectively, 
Figure 4,16 shows the results of titrating 250nM heparanase with short aptamer. In the 
experiment, the fluorescence counts at 335nm decreased by 38% after addition of the 
last aliquot of aptamer, clearly indicating that the reduction in fluorescence was due to 
the interaction between the protein and the aptamer and not just a dilution effect. 
Analysis of the decrease in fluorescence using the quadratic equation indicated above, 
suggested an association constant of 7.3xl07M -1 between the short aptamer and 
heparanase. 
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Figure 4.16 - Analysis of titration between 250nM heparanase and 1.5M short aptamer. 
After fitting the curve using the quadratic equation, a KA of 7.3x107M-1 was determined. 
Upon titrating l.5M long aptamer with heparanase, a Significant decrease in fluorescence 
was also observed, indicating the binding of this aptamer to heparanase. Figure 4.17 
shows the analysis for the data, which determines an affinity constant of 8.3x107M-1 for 
the long aptamer and the heparanase enzyme, similar to that obtained with the short 
aptamer, which is the variable region of the long aptamer, without the primer sequences. 
It appears that the primer sequences have an effect on binding, which is not, however, 
significant. 
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Figure 4.17 - Analysis of titration between 2S0nM heparanase and 1.5M long aptamer. 
After fitting the curve using the quadratic equation, the calculated KA was 8.3x107 M- l • 
The 3.0M aptamer, when titrated into heparanase, also decreased the fluorescence 
counts, by 31%, showing a clear interaction of the aptamer with the enzyme. The 
calculated value for KA after plotting the decrease in fluorescence versus aptamer 
concentration was found to be 7.7x107M-\ as seen in figure 4.18. 
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Figure 4.18 - Analysis of titration between 250nM heparanase and 3.0M aptamer. After 
fitting the curve using the quadratic equation, the calculated KA was found to be 
7.7xl07M-1 for this aptamer against the heparanase enzyme. 
When titrating the linker peptide with aptamers pink and yellow, both showed a 95% 
decrease in fluorescence between linker peptide alone and the last addition of aptamer, 
indicating an almost total loss of fluorescence emission upon aptamer binding. The two 
aptamers identified were also similar in their binding affinities for the peptide, as they 
displayed a KA of 2.2 and 2.1x106M-1 respectively, shown in figures 4.19 and 4.20 
respectively. 
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Figure 4.19 - Analysis of titration between SOOnM linker peptide and pink aptamer. 
After plotting changes in fluorescence intensity versus aptamer concentration, the 
calculated KA was found to be 2.2x106M-1• 
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Figure 4.20 - Analysis of titration between SOOnM linker peptide and yellow aptamer. 
After plotting changes in fluorescence intensity versus aptamer concentration, the 
calculated KA was found to be 2.1x106M-1• 
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4.5 Discussion 
These studies have shown that the aptamers selected against heparanase using the heat 
elution method did not bind heparanase, as indicated by ELISA and EMSA data. 
Therefore, it is possible that these aptamers were generated nonspecifically through 
binding to the wells of the 'Top Yield' tubes, which are designed specifically to bind to 
such biological molecules as proteins and nucleic acids. It was postulated that a reason 
why the ten round heat method did not generate aptamers was because the data in 
figure 4.3 suggested the aptamers may not have been released by the enzyme, which 
could have been stabilised by the binding of the aptamer. It has, however, been 
determined (see figures 4.9 to 4.11) that the aptamers generated by the salt round of 
selection did not recognise previously heat denatured heparanase, further supporting the 
evidence that the enzyme and aptamers form a stable complex that protects the enzyme 
from denaturation at these temperatures. 
The streptavidin ELiSAs all showed an increase of absorbance upon increasing heparanase 
concentration, suggesting binding between aptamer and heparanase (figures 4.8-4.11). 
Another piece of information obtained from the streptavidin ELISA in figure 4.8 was that 
the absorbance of the curves for 1.5M long and 3.0M aptamers reached a higher 
maximum than that of 1.5M short. This is likely due to more heparanase being retained 
in these two samples as 1.5M long and 3.0M aptamers are larger in size and less 
susceptible to steric hindrance than the smaller 1.5M short aptamer. 
The fluorescence titrations tested all aptamers and yielded important information 
regarding the binding of the aptamers with the heparanase and heparanase linker 
peptide. The results of the fluorescence quenching titrations confirmed the results 
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obtained in the ELISA assays, demonstrating binding of the aptamers to the heparanase 
and heparanase linker peptide, and allowed the quantification of this interaction. 
The decrease, or quenching, of the fluorescence counts (38% for 1.5M short, 23% for 
1.5M long, 31% for 3.0M and 95% for both pink and yellow) indicate that both pink and 
yellow aptamers are binding in very close proximity to the two tryptophan residues at 118 
and 144 and this is why the counts decreased so dramatically; nearly completely 
abolishing emission of fluorescence. As the linker peptide is only 6kDa compared to the 
aptamers' 22kDa, this could be expected if complexation between the two molecules 
were to occur, in agreement with the observations in our experiments. The lower 
quenching percentage from the heparanase-selected aptamers suggest they are binding 
further from a region containing one or more of the six tryptophan residues. As all 
tryptophans are spread within the SOkDa subunit at sites 199, 220, 295, 340, 365 and 405, 
it is likely that the binding of the aptamer would be closer to one or two tryptophans at a 
time, clearly accounting for the percentage of change observed in the fluorescence 
emission. It is even possible that the aptamer binds to the 8kDa subunit (which contains 
no tryptophan residues) or N-terminus, which carries a positive charge at physiological pH 
so would attract the negatively charged aptamer, but the aptamer binding to this part of 
the heterodimer causes such changes in the structure that they would affect the overall 
fluorescence emission of the tryptophans in the 50kDa subunit. 
Binding of proteins and DNA occurs via intermolecular forces such as Van der Waals, 
electrostatic, and ionic and hydrogen bonding and is usually reversible; yielding a rate of 
association and dissociation. High affinity binding implies higher strength intermolecular 
forces, longer time of association between molecules and a low concentration of ligand 
needed to saturate the binding sites. Usually, the association constant (KA) is used as a 
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measurement of binding affinity between aptamer and target, and is the inverse of the 
dissociation constant (Ko). This is shown by equation 4.2 below. 
on - rate [aptamer .heparanase ] 1 
KA= = =-
off - rate [aptamer ] [heparanase ] KD 
Equation 4.2 - Relationship between affinity constant (~) and dissociation constant 
(KD) In binding studies [5]. 
Using this equation to obtain dissociation constants for the aptamers generated to 
heparanase yields 13.7nM, 12nM and 13nM for 1.5M short, long and 3.0M respectively, 
which compares with high affinity aptamers generated by other groups for their targets. 
For the linker peptide, 450 and 480nM for pink and yellow respectively unfortunately 
does not represent such a strong affinity, though this may be expected due to the fact 
that the target is a peptide and not a whole protein. 
As these results were promising, the aptamers were subjected to further testing in in vitro 
studies using cell lines and invasion models to determine their selectivity among other 
proteins and enzymes, their functionality and their ability to inhibit the function of 
heparanase and linker peptide and also determine the presence of the heparanase and 
linker peptide in immunohistochemistry assays, which is the subject of the subsequent 
chapters of this. 
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CHAPTER FIVE 
CELL AND TISSUE-BASED RECOGNITION BY 
APTAMERS 
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5.1 Background 
Previous assays testing anti-heparanase aptamers' '1.5M short', '1.5M long' and '3.0M' 
recognition and binding of heparanase, showed promising results, with reasonable 
affinity constants, supported by results from streptavidin ELiSAs. However, these were 
bench top assays containing a limited number of other proteins and enzymes, so it was 
unknown whether aptamers bound heparanase selectively under duress of an abundance 
of other different compounds in vitro. 
It is well documented that the extracellular matrix (EeM) of the placenta and decidual 
tissue of the uterine wall are rich in heparan sulphate proteoglycans (HSPG), which are 
degraded by heparanase [1]. Heparanase is upregulated in the placenta [2, 3], and 
especially in cytotrophoblasts (as well as lymphocytes, monocytes, neutrophils and 
platelets) [4-10], making placenta an ideal tissue to use in experiments related to 
heparanase activity and/or inhibition. 
The aim of these experiments was to stain cell lines and sections of different areas and 
time points of placenta with polyclonal heparanase antibody [11] to observe volume, 
patterns and distribution of staining. This was to provide a positive control with which to 
compare staining of the same tissue with three different aptamers: 'l.5M short', 'l.5M 
long' and '3.0M'; and give an indication of affinity and selectivity of the three aptamers 
for heparanase. Negative control antibodies, and aptamers raised against the 6kDa linker 
were also used, as well as an antibody that labels trophoblast cells. These experiments 
were carried out using immunohistochemical techniques; wax embedded sections and 
avidin peroxidase with 3,3'-Diaminobenzidine tetrahydrochloride (DAB) staining and 
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f ixed, permeabilised endometrial cell lines labelled with streptavidin-fluorescein 
isothiocyanate (FITe) and propidium iodide (PI) . 
5.2 Immunohistochemistry (IHe) of paraffin-embedded placental tissue 
The placenta is formed during the first stage of pregnancy when cells differentiate from 
the fertilised egg to form the blastocyst. This forms a barrier between the mother and 
foetus and allows exchange of oxygen, waste, hormones and antibodies, without which, 
the foetus would not survive. 
The blastocyst contains an outer layer of cells called trophoblasts, which are invasive, 
eroding and metastasising cells; and the inner cell mass, which is located inside the 
trophoblast layer and later forms the foetus (figure 5.1) . The blastocyst is formed in the 
first few days of pregnancy, when the trophoblasts immediately start secreting human 
chorionic gonadotropin (hCG, the hormone used in the pregnancy test), which make the 
endometrium receptive to implanting the embryo [12]. 
Figure 5.1 - Blastocyst at five days (left) formed by cytotrophoblasts (red) surrounding 
inner cell mass (blue), which later becomes the foetus. Placentation occurs (right) upon 
release of mucins and hormones from the cytotrophoblasts and endometrial wall, 
allowing the cytotrophoblasts to differentiate into invasive, anchoring and hormone-
secreting trophoblasts (syncytiotrophoblasts), which all facilitate implantation. 
Modified from [13]. 
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Mucins, which extend from the endometrium, slow the moving blastocyst and a complex 
release of hormones and protease inhibitors from both parties allow the trophoblasts to 
anchor to and invade the endometrium and myometrium (the inner and middle layers of 
the uterine wall) [12]. Cytotrophoblasts; the mononuclear precursor to all other 
trophoblasts, begin to differentiate upon the presence of these molecules, each type 
serving a different function, from secreting hormones (syncytiotrophoblasts), to 
anchoring the blastocyst, to becoming invasive and leading implantation at the front line 
[12]. Here, at two weeks of pregnancy, they begin remodelling the uterine spiral arteries 
- this is critical for a successful pregnancy [14]. The endometrium; now named decidua, 
forms the maternal part of the placenta [15]. 
At three weeks, the foetus has developed its blood system. Chorionic villi contain 
capillaries, which are the end-point of the foetal blood supply [12]. These are separated 
from the maternal blood by a layer of cyto- and syncytiotrophoblasts, which prevents 
immunological response and attack from the mother [12]. In between chorionic villi, 
inside the intervillous spaces, maternal blood is pooled, which forms the exchange site 
between the maternal and foetal blood supply. 
First trimester and term chorionic villi show different morphology. First trimester 
chorionic villi show a mesenchymal core containing foetal capillaries, surrounded by a 
layer of cytotrophoblasts and syncytiotrophoblasts. Term chorionic villi show increased 
numbers of foetal capillaries, which lie close to the outer edge of the mesenchymal core 
to facilitate exchange of molecules between maternal and foetal blood. There are also 
fewer cytotrophoblasts, and increased syncytiotrophoblast clusters at the periphery of 
the villi [12]. 
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511m sections from different areas and time-points of the placenta were used to ascertain 
whether anti-heparanase aptamers '1.5M short', '1.5M long' and '3.0M' were competent 
at recognition and binding of heparanase in tissue previously shown to upregulate the 
enzyme. Characterisation of binding between the aptamers and target would clarify the 
most promising functional application for the aptamers; diagnostic or therapeutic. 
Experiments were repeated using tissue from different donors to ensure that all images 
displayed were representative and the results reproducible. 
Sections were subjected to IHC by labelling with heparanase polyclonal antibody or 
anticytokeratin-7 antibody at 1:100 dilution in accordance with concentrations used in a 
previous study with these antibodies and tissue [1], biotinylated aptamers raised against 
the heparanase enzyme or linker peptide at a dilution of 1:200 to generate a similar molar 
concentration to that of the antibody, or a mouse negative control antibody added neat; 
followed by the respective secondary antibodies on the primary antibody treated samples 
only at a 1:200 dilution as used in a previous study [1]. Avidin peroxidase was used as the 
enzyme to develop the reaction of the DAB substrate, showing presence of heparanase as 
brown staining, whilst counterstaining with haematoxylin to show the nuclei in blue. 
5.2.1 Term placenta 
Term placenta experiments were repeated four times using tissue from different donors 
to ensure that all observations were accurate and representative. Overall, and as shown 
by figure 5.2, the sections stained with heparanase antibody have the highest level of 
staining, mainly around the periphery of the tissue and some within the foetal capillaries, 
showing the presence of heparanase. There is a high contrast between the levels of 
staining in this section with that seen in the negative control section. 1.5M long aptamer 
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showed the greatest result of all the aptamers; an identical staining pattern and intensity 
compared to the heparanase antibody. l.sM short, pink and yellow aptamers only 
stained within the foetal capillaries and 3.0M showed a low level of stromal staining, 
which suggests that it is non-specific. 
The morphology of the tissue and its staining by cytokeratin-7 antibody, suggests that this 
tissue is transverse section chorionic villi, and therefore, the cell types around the 
periphery that have shown presence of heparanase are cytotrophoblasts and 
syncytiotrophoblasts. 
Figure 5.2 - Term 60 placental sections cut at silm then subjected to IHC using 
heparanase polyclonal antibody (Ab), biotinylated heparanase aptamers (l.sM short, 
1.sM long, 3.0M), linker peptide aptamers (pink, yellow), positive control anti 
cytokeratin-7 antibody (CK-7) or a mouse monoclonal antibody as negative control 
(negative) and imaged at x20 magnification. Images are representative from four 
repetitions of reproducible results. Aptamer 1.sM long matched the staining pattern 
and intensity of the heparanase antibody, showing its specific recognition for 
heparanase, and the cytokeratin-7 antibody confirmed the heparanase-expressing cell 
types to be cyto- and syncytiotrophoblasts. 
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5.2.2 First trimester placenta 
First trimester placenta experiments were conducted in triplicate. Figure 5.3 shows the 
different morphology this placental tissue has from that of term placenta. The immature 
chorionic villi are smaller in numbers and have larger diameters, together with a thicker 
trophoblast cell layer; shown by CK-7 antibody staining, compared to that of term 
placenta, correlating with the increased number of undifferentiated cytotrophoblasts. 
Heparanase-positive staining, shown by the heparanase antibody, was seen in the 
cytotrophoblasts lining the intervillous space of the chorionic villi, and in endothelial cells 
of the developing blood vessels. There was also some staining inside the villi in these 
sections in certain areas. No staining was observed when a mouse antibody was used as 
a negative control. Of the aptamers, l.5M long and 1.5M short exhibited a staining 
pattern almost identical, although less intense than that of the antibody. 3.0M did show 
staining, although more uniformly throughout the stroma and not in the same pattern as 
the antibody, which suggests non-specific staining. Pink and yellow aptamers have 
exhibited little or no staining above the level of the negative control, suggesting there is 
no linker peptide in this sample. 
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Figure 5.3 - 5503 first trimester placental sections cut at 511m then subjected to IHe 
using heparanase polyclonal antibody (Ab), biotinylated heparanase aptamers (1.5M 
short, 1.5M long, 3.0M), linker peptide aptamers (pink, yellow), positive control anti 
cytokeratin-7 antibody (CK-7) or a mouse monoclonal antibody as negative control 
(negative) and imaged at x20 magnification. Images were representative of triplicate 
experiments, from which the results were reproducible. Of the aptamers, 1.5M long 
and short, respectively, showed a staining pattern and intensity close to that of the 
heparanase antibody. 
5.2.3 Term decidua 
In these sections there was only a very low level of staining so it is very difficult to form 
reliable conclusions. The cytokeratin-7 antibody has shown some trophoblasts around 
the periphery of the tissue in figure 5.4, but the aptamers and heparanase antibody have 
shown relatively low levels of heparanase compared with other tissue types in this study. 
This could be expected if heparanase is used for remodelling, as the tissue is term and 
therefore would be completely matured. The heparanase antibody has shown the 
highest level of staining, located within the tissue and around the periphery at the 
Page I 157 
location of trophoblasts shown by the cytokeratin-7 antibody. The negative control has 
shown staining inside the tissue; with its level higher than l.5M short, 3.0M, pink and 
yellow aptamers, unfortunately reinforcing the observation that the conclusions from this 
tissue are not reliable . 1.5M long aptamer however, has once again shown a similar level 
of staining, although not so much at the location of the trophoblasts, as that by the 
heparanase antibody, continuing the pattern of the previous tissue samples. 
l· .. 
negative. . 
Figure 5.4 - 5503 term decidua sections cut at 5~m then subjected to IHC using 
heparanase polyclonal antibody (Ab), biotinylated heparanase aptamers (1.5M short, 
1.5M long, 3.0M), linker peptide aptamers (pink, yellow), positive control anti 
cytokeratin-7 antibody (CK-7) or a mouse monoclonal antibody as negative control 
(negative) and imaged at x20 magnification. Images are representative from triplicate 
experiments. Aptamer 1.5M long showed a staining pattern most consistent with the 
heparanase antibody. 
5.2.4 First trimester decidua 
The overall results shown by experiments using first trimester decidual tissue are 
summarised by figure 5.5. Heparanase antibody has highlighted areas of heparanase in 
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the cyto- and syncytiotrophoblasts; confirmed by the presence of staining in the section 
labelled with CK-7 antibody, and in high volumes within the tissue itself. This high 
expression of heparanase is expected due to the rapid development of first trimester 
tissue. Of the heparanase aptamers, l.5M short and 3.0M have shown a low level of 
staining throughout the tissue but not in the trophoblasts, and 1.5M long aptamer once 
again has shown the highest staining of heparanase, consistent with previous tissues, 
where it mirrored the staining patterns of the antibody. Pink and yellow aptamers have 
also shown high staining, suggesting presence of linker peptide within the tissue and 
trophoblasts, which would fit with the high levels of heparanase shown by the 
heparanase antibody, as one would expect to see linker within and around the 
trophoblasts due to their production and secretion of heparanase. 
negative 
Figure 5.5 - 5526 first trimester decidua sections cut at 5J..lm then subjected to IHe using 
heparanase polyclona.1 antibody .(Ab), biotinylated heparanase aptamers (1.5M short, 
1.5M long, 3.0M), linker peptide aptamers (pink, yellow), positive control anti 
cytokeratin-7 antibody (CK-7) or a mouse monoclonal antibody as negative control 
(negative) and imaged at x20 magnification. Images are representative of triplicate 
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experiments. Heparanase aptamer 1.5M long and linker aptamers pink and yellow 
suggested presence of heparanase and linker peptide respectively, within the 
trophoblasts and tissue. 
5.3 Immunofluorescence (IF) of placental-derived cell lines 
Four different placental-derived cell lines were chosen for these experiments, BeWo; a 
trophoblast carcinoma cell line, Ishikawa; an endometrial carcinoma cell line, PL4; a first 
trimester immortalised trophoblast cell line, and first trimester placental stromal cells. 
Cells were grown on coverslips and were subsequently fixed and permeabilised in 
paraformaldehyde and triton-X lOa, respectively, before being incubated with 
heparanase/cytokeratin-7/control mouse antibodies or heparanase/linker peptide 
biotinylated aptamers. Secondary antibodies were added to antibody-labelled coverslips, 
and then streptavidin-FITC conjugate was added to all coverslips, before being mounted 
with medium containing propidium iodide for labelling nuclei. Experiments were 
conducted in triplicate to gain consistency and ensure each cell line be treated with each 
label. The figures show the most representative images from each cell line and the 
overall conclusions are drawn from the reproducible results. In these fluorescent images, 
FITC molecules are responsible for the green staining showing heparanase presence, and 
propidium iodide for the red or blue staining, showing presence of the nuclei. 
5.3.1 Be Wo cells 
From the results for heparanase antibody, it is clear that heparanase is present In the 
cytoplasm, plus inside the nucleus also in this cell line, as seen in figure 5.6. The 
appearance of heparanase is very granular. None of the aptamers have recognised 
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heparanase inside the nucleus in the same manner as the antibody; however, the 
aptamers selected for heparanase have all shown staining of granular appearance in the 
cytoplasm in accordance with that shown by the heparanase antibody, with 1.5M long 
aptamer looking the most promising. Pink aptamer showed a very low level of staining 
inside the cytoplasm and at the cell membrane and yellow aptamer showed staining at 
the cell membrane and exterior to the cells, not all in a granular form. Either could 
indicate presence of linker peptide, however, as they appeared no more pronounced than 
the negative control, it is likely to be background staining. 
.SM short aptame r 
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Figure 5.6 - BeWo trophoblast carcinoma cells subjected to IF using heparanase 
antibody, 1.5M short, long and 3.0M biotinylated heparanase-selected aptamers, pink 
and yellow biotinylated linker peptide-selected aptamers or a negative control mouse 
antibody, and imaged at x40 magnification showing heparanase expression (green) and 
nuclei (blue). Pink and yellow aptamers did not show increased volumes of staining 
from the negative control, whereas all of the heparanase-selected aptamers showed an 
increased level of staining, however, not as great as the heparanase antibody. 
5.3.2 Ishikawa cells 
In the Ishikawa cell line, the heparanase antibody has shown granular areas of staining in 
the cytoplasm and nucleus, as seen by figure 5.7. 15M short, 3.0M and pink aptamers 
show a low level of non-granular heparanase staining in the nucleus, which is different 
from the negative control as it has only showed staining in the cytoplasm. There are 
some small areas of granular staining with a more vibrant colour in the nucleus, but 
overall, these aptamers exhibit much less staining than exhibited by the antibody. l.5M 
long aptamer shows the same granular vibrant staining patterns of the heparanase 
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antibody but not in as large a volume. Yellow aptamer has shown a very interesting 
result; it has completely stained the whole nucleus vibrant green, which does not appear 
to be background staining as the other samples do not show this. This could suggest a 
strong presence of linker peptide in the nucleus of these cells, which could be very 
exciting, as currently, little is known about the fate of the linker peptide after processing 
of the proenzyme. 
SM short aptamer 
.SM long aptamer 
.OM aptamer 
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Figure 5.7 - Ishikawa endometrial carcinoma cells subjected to IF using heparanase 
antibody, 1.5M short, long and 3.0M biotinylated heparanase-selected aptamers, pink 
and yellow biotinylated linker peptide-selected aptamers or a negative control mouse 
antibody, and imaged at x40 magnification showing heparanase expression (green) and 
nuclei (red or blue). Heparanase antibody and 1.5M long aptamer showed recognition 
of heparanase in the cytoplasm and nucleus and yellow aptamer stained the nucleus in 
large amounts, suggesting presence of linker peptide. 
5.3.3 PL4 cells 
The pattern of staining in the PL4 cell line shows high and granular heparanase levels 
mainly in the cytoplasm as shown by the heparanase antibody in figure 5.8, which was 
expected as the PL4 cell line is trophoblast. The signal was very strong using the 
antibody; however, it was just as strong with the aptamers selected for heparanase; l.5M 
long aptamer even more so. Yellow aptamer showed a level of staining above the level of 
the negative control, which could indicate binding of the aptamer to linker peptide and its 
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presence in the cytoplasm. Pink aptamer did not show an elevated level of staining from 
the negative control, suggesting it did not recognise the presence of linker in this cell line. 
paranase antibody 
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Figure 5.8 - PL4 immortalised trophoblast cells subjected to IF using heparanase 
antibody, 1.5M short, long and 3.0M biotinylated heparanase-selected aptamers, pink 
and yellow biotinylated linker peptide-selected aptamers or a negative control mouse 
antibody, and imaged at x40 magnification showing heparanase expression (green) and 
nuclei (blue). Heparanase antibody, aptamers 1.5M short, long and 3.0M all showed 
recognition of heparanase; mostly so by 1.5M long. Yellow aptamer also suggested 
presence of linker peptide in the cytoplasm. 
5.3.4 Stromal cells 
There was a very low level of heparanase staining in this cell type in general as seen in 
figure 5.9. As stromal cells are packing cells found inside the placenta, they may contain a 
low level of heparanase as they would undergo remodelling in pregnancy (as seen in the 
placental sections). However, they are not invasive cells by nature and so may not show 
the level of heparanase upregulation as trophoblast or carcinoma cell lines do. The 
heparanase antibody showed a low level of staining of a granular appearance in the 
cytoplasm and nucleus of the cells. All aptamers except for l.sM short did not show a 
level of staining elevated from the negative control and l.sM short was able to recognise 
heparanase to a higher extent in this tissue than the heparanase antibody. 
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Figure 5.9 - Placental stromal cells subjected to IF using heparanase antibody, 1.5M 
short, long and 3.0M biotinylated heparanase-selected aptamers, pink and yellow 
biotinylated linker peptide-selected aptamers or a negative control mouse antibody, 
and imaged at x40 magnification showing heparanase expression (green) and nuclei 
(blue). 1.5M short aptamer, and to a lesser extent, heparanase antibody bound and 
recognised heparanase above the level of the negative control. 
5.4 Discussion 
Overall, these results compared the aptamers selected for heparanase favourably with 
the polyclonal antibody in terms of recognition and specificity for heparanase in cell and 
tissue sections. 
The morphology and cytokeratin-7 staining in the placenta and decidual tissues suggests 
that the staining confined to the periphery displayed by the heparanase antibody and 
1.5M long aptamer is from trophoblasts; confirming its identity as heparanase, as 
trophoblasts are heparanase-secreting invasive cells [2, 4]. 
15M long aptamer showed the most consistent staining in comparison with the 
heparanase antibody, with l.SM short aptamer the next most promising. This may have 
been due to these both originating from the same aptamer and therefore they are 
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expected to share some structural features and/or binding nucleotides. In some sections 
3.0M aptamer exhibited higher areas of staining than the negative control, however, as it 
was not in the same areas of the tissue that the heparanase antibody stained in, this 
suggests that it may have been non-specific. 
Table 5.1 - A summary of representative data from immunofluorescence studies 
showing staining patterns of heparanase antibody, heparanase aptamers 1.5M short, 
1.5M long and 3.0M; linker peptide aptamers pink and yellow, plus a negative control 
mouse antibody upon the cell lines tested. Location of staining is nuclear (N) and/or 
smic (C) for each of the four cell lines. 
""" 
Antibody + + + + + + + + 
1.5M short + + + + + + 
1.5M long + + + + 
3.0M + + + + 
Pink + + 
Yellow + + + 
Negative + 
Table 5.1 summarises the data presented in the immunofluorescence studies. These 
showed volumes of heparanase located in the cytoplasm and nucleus of all cell lines, with 
bias toward nucleus or cytoplasm different in each cell line. Stromal cells did not show a 
large volume of heparanase and this was expected due to these cells not being invasive in 
nature, whereas Ishikawa, Pl4 and BeWo cells were carcinoma, trophoblast and 
trophoblast carcinoma-derived cells respectively and are all invasive and would therefore 
be expected to express and secrete heparanase. In these studies the aptamers 105M long 
and short were shown to recognise heparanase to different extents in the different cell 
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lines; sometimes with better recognition than shown by the antibody. This further 
reinforces my previous results. 
The aptamers selected for the linker peptide unfortunately cannot be confirmed as 
selective binders in the cell and tissue studies, as there is no antibody to compare them 
to, despite the high affinity shown for the linker peptide in previous studies (see chapter 
4). However, the result for immunofluorescence using yellow aptamer definitely deserves 
further study as this suggested the presence of linker in the cytoplasm of trophoblast Pl4 
cells and its strong presence in the nucleus of carcinomal Ishikawa cells. Finding a way of 
proving that linker aptamers bind to the linker peptide, either by making an antibody or 
finding another inhibitor to compare them to in these assays, may provide useful 
information about the fate of the linker region after excision. Equally, the difference 
between the yellow and the pink aptamer, both of which were selected against the linker 
peptide, may be due to the ability of one to recognise the peptide both excised and as 
part of the proenzyme (yellow) whereas the other not (pink), explaining the reduced 
staining with the pink aptamer. Studying the potential inhibition of formation of active 
enzyme from the proenzyme by cathepsin l in the presence of yellow, but possibly not 
pink, aptamer could further confirm this hypothesis. 
Investigations thus far had shown binding of the aptamers with reasonable affinity and 
recognition with specificity for the enzyme, especially exhibited by 1.5M long, shown by 
ELISA data and fluorescence quenching studies in which this aptamer also exhibited the 
highest KA• Aptamer 1.5M short may not have shown the most promise in the previous 
studies with respect to binding affinity or retention of heparanase, but due to its smaller 
size than both antibody and the other aptamers, it may have been favoured in cell and 
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tissue-based studies, due to its increased tissue penetration in such assays. In addition to 
the binding and ability to label heparanase in cell and tissue studies, it was important to 
investigate the inhibitory effect, if any, of the aptamers on the enzymes function in vitro, 
as it is possible that the aptamers were able to bind to the enzyme without, however, 
inhibiting its function. This has been the subject of study in the following chapter, chapter 
6, of this thesis. 
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CHAPTER SIX 
INHIBITION OF INVASIVE CELLS BY APTAMERS 
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6.1 Background 
It has been demonstrated that aptamers 1.5M short, 1.5M long and 3.0M bind with high 
affinity and selectively recognise heparanase in ELiSAs, fluorescence titrations and cell 
and tissue labelling at a different binding site than the polyclonal antibody. However, it 
was unknown what effect, if any, this binding had on the enzyme's function of 
hydrolysing heparan sulphate proteoglycans and invading the ECM. To investigate this 
further, two types of invasion assay were conducted; one using an artificial 
representation of ECM, and the other, a recently developed myoma model using human 
uterine leiomyoma tissue. 
6.2 Matrigellnvasion Assay 
Matrigel, a representation of ECM, is an extract of Engelbreth-Holm-Swarm (EHS) mouse 
sarcoma. It is a liquid that is rich in ECM proteins such as collagen IV, laminin and 
heparan sulphate proteoglycans and contains growth factors such as TGF-~, epidermal 
growth factor, insulin-like growth factor, fibroblast growth factor and tissue plasminogen 
activator and has been developed in response to the first documented invasion assays, 
which contained only type IV collagen and laminin on a base of type I collagen [1, 2). 
Matrigel is now used widely in invasion assays (figure 6.1) in combination with an insert 
assembly; a small plastic transwell insert 'cup' with a filter or membrane as its underSide, 
that usually fit into the wells of a 12 or 24-well plate. 
Page 1175 
\, e I of a 24-\Ne I pia e 
/ 
;.ledia contair.ing cells 
t r'1a rige 
Figure 6.1- Diagram of Matrigel assay setup. 
Typically, the matrigel is left to polymerise before cells in their respective media (with or 
without inhibitors) are added on the upper surface. This is then left for a period of 24-48 
hours in an incubator to allow the cells to permeate and invade the matrigel, before the 
experiment is completed by removing the contents of the upper surface of membrane, 
then fixing and staining the cells on its underside. The results are determined by the 
number of cells on the underside of the membrane, as those cells are the ones which 
have completely traversed the 'EeM'. This experiment has been widely used to assess the 
invasiveness of different cell lines and also to test different inhibitors of invasive cells. 
The matrigel invasion assay is simple to perform and analyse, not time-consuming or 
particularly labour-intensive; however as the matrigel itself is an extract of mouse 
sarcoma, there are thoughts that it may not show an accurate representation of the 
nature of invading cells in human tissue, as tumour invasion is not just dependent on the 
tumour cell, but on the numbers and types of cells in the tissue which it is invading. 
This experiment was conducted using 2 different cell lines; first trimester immortalised 
trophoblast cell line; PL4, and ovarian carcinoma cell line; DC MZ-6. Both cell lines had 
been previously tested in this experiment [3] and a high level of heparanase had also 
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been observed by immunofluorescence. A polyclonal anti-heparanase antibody that had 
also previously been used in this assay [4] was used as a positive control. This antibody 
was shown to inhibit the invasion of OC MZ-6 cells, although it was determined that it did 
not significantly inhibit the invasion of PL4 cells, whose activity was attributed to different 
mechanisms than the sole function of heparanase [3]. 
Anti-heparanase aptamers 1.5M short, 1.5M long and 3M were used as potential 
inhibitors, together with linker peptide aptamers pink and yellow (all at l~M) and the 
aforementioned polyclonal anti-heparanase antibody (O.7~M). The concentration of 
antibodies was based on their previous optimisation in this assay [3], whilst the aptamers' 
concentration was chosen to fall within the range of ICso of another small molecule 
heparanase inhibitor [5]. The controls used were cells only, with no inhibitor, showing 
the maximum invasion from both cell types, and a negative control mouse antibody to 
show that any inhibitory effect of the anti-heparanase antibody is due to its heparanase 
specificity. Cells were also grown on a coverslip with no matrigel or inhibitor, purely to 
demonstrate that they were at a suitable confluency for the experiment. After ending the 
experiment, cells on the top of the membrane were removed and those on the underside 
were haematoxylin-stained. Each membrane was removed and mounted, 8-10 images 
from representative areas on each membrane were taken and the cells were manually 
counted. Data were analysed using Microsoft Office Excel and, to assess the statistical 
significance, an unpaired two-tailed t-test was conducted. 
Experiments using PL4 cells {figure 6.2} were conducted in duplicate. The coverslips 
showed adequate cell confluency for each experiment. The treatments of no inhibitor 
and control mouse antibody show similar values, as expected due to no relevant inhibitor 
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added to either. There is a significant decrease in number of cells traversing the ECM and 
membrane between no inhibitor at 42.13 ± 5.25 and the heparanase antibody 21.86 ± 
7.43 (p=0.00009), thus showing significant inhibition of invasion . Between no inhibitor 
and 1.5M long aptamer 32.75 ± 7.09 there was a weak significance of inhibition (p=O.Ol), 
as was with the pink aptamer 32.6 ± 10.3 (p=0.04) . None of the other aptamers exhibited 
sign ificant inhibitory effects in these experiments as all were similar to no inhibitor and 
control mouse antibody. 
III 
QJ 
u 
"'C 
80 
70 
60 
~ 50 
~ ~ c: IV 40 
~ 
-.c 30 
o E 
~ QJ 20 ~ E E ~ 
::J QJ 
c: Q. 
10 
o 
Figure 6.2 - PL4 cells cultured in medium supplemented with heparanase antibody, 
1.5M short, 1.5M long, 3.0M, pink and yellow aptamers. The negative controls were 
represented as no inhibitor and a control mouse antibody. Figures represent the 
average of triplicate experiments and error bars show standard deviation of the mean. 
There was a significant inhibition of invasion between no inhibitor and heparanase 
antibody treatments (p=00009), and a weak significance between no inhibitor and the 
1.5M long and pink aptamers (p=O.01, p=O.04). 
Experiments with OC MZ-6 cells (figure 6.3) were conducted in triplicate . Once again, the 
cells were cultured to suitable confluency for the experiment and no inhibitor and control 
mouse antibody showed similar values. Heparanase antibody showed significantly 
decreased numbers of cells through the matrigel, with 40.6 ± 7.13 cells compared to no 
inhibitor at 74.4 ± 34.28 (p=0.0164) and compared with a negative control antibody at 
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66.6 ± 15.77 (p=0.0008) . This corresponds to previous experiments with heparanase in 
this model [3, 4]. l.sM long aptamer, however, inhibited the migration of cells with 26.9 
± 5.49 cells compared with no inhibitor (p= 0.0032) and with the negative control 
antibody (p< 0.0001) . Aptamers 1.sM short showed little inhibition, whereas 3.0M did 
not significantly inhibit migration of cells in these studies, and neither did pink and yellow 
aptamers. These results suggest that l.sM long is a significant inhibitor of cell invasion in 
this model. 
Figure 6.3 - OC MZ-6 cells cultured in medium supplemented with heparanase antibody, 
1.5M short, 1.5M long, 3.0M, pink and yellow aptamers. The negative controls were 
represented as no inhibitor and a control mouse antibody. Figures are representative 
of the average of triplicate experiments and error bars show standard deviation of the 
mean. 
6.3 Myoma Organotypic Model of Invasion 
The organotypic myoma model of invasion overcomes the problem of using mouse or 
artificial tissue in these assay types [6]. It is a developing technique which uses human 
uterine leiomyoma tissue (commonly known as fibroid tissue) in place of matrigel. It is 
more laborious and time-consuming, as the cells are cultured for two-weeks of invasion. 
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However, more analytical techniques can be employed upon termination of the 
experiment and a better understanding of invasion gained. 
M edi (± Inhi bi tor cont ining HSC-3 ce ll s 
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Figure 6.4 - Diagram of Myoma organotypic model setup. 
After excision from the donor, myomas were cut into 8mm discs and transferred to 
6.5mm transwell inserts inside 24 well plates. 7x105 human tongue squamous carcinoma 
cells (HSC-3), shown to express and secrete heparanase [7], in 50111 medium with or 
without inhibitor (at identical concentrations as used in the Matrigel invasion assay) were 
added to the upper surface of the tissue and the cells were allowed to adhere (figure 6.4) . 
After incubation for 24 hours, the myomas were placed atop a disc of nylon membrane 
upon a steel grid, where the cells were cultured for 14 days. 
Termination of the experiment yielded four changes of media (which were retained at -
20°e) and the myoma tissue itself, which were bisected longitudinally, dehydrated and 
embedded in paraffin for immunohistochemical analysis. ELISA and RIA were carried out 
on the collected media to check for collagen degradation products using antibodies raised 
in rabbits by immunisation with synthetic peptide sequences from type III collagen, since 
in previous studies HSC-3 cells were shown to degrade type III collagen [8]. ELISA 
detected the N-terminal telopeptide from type III collagen, whilst RIA detected the C-
terminal telopeptide. 
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The experiment was conducted in triplicate, to make the results more reliable, with no 
cells in two of the samples. This showed the natural 'background' of the tissue without 
influence of cells or inhibitors. As another control, cells were added to the myoma tissue 
but no inhibitor added. This showed the maximum invasion potential of the cells through 
the tissue, assuming that none of the inhibitors acted as agonists! An unrelated aptamer 
(selected against a target involved in Alzheimer's disease) was also used in one sample, to 
show that any inhibitory effect of heparanase aptamers were not due to aptamers in 
general. Also used were 1.5M short, 1.5M long and 3M anti-heparanase aptamers, pink 
and yellow linker peptide aptamers and (2-{4-[(E)-3-(4-bromophenyl) acryloylamino]-3-
fluorophenyl} benzooxazol-5-yl) acetic acid, abbreviated to BAFB, which was shown to 
have inhibitory effects upon heparanase in previous studies [5]. After day 14, when the 
experiment was terminated by dehydrating, fixing, wax-embedding then subjecting the 
sections to IHe, nine representative images (at x100 magnification) were taken from each 
repeat of every treatment. Each image was analysed using ImageJ software to determine 
the maximum invasion depth (distance from the surface of the tissue to the deepest 
invaded cell), maximum invaded area and invasion index [1- (non invading area/total 
area)]. Figures were analysed using Microsoft Office Excel and unpaired, two-tailed t-
tests to assess the statistical Significance. 
6.3.1 Invasion Data 
Figure 6.5 shows two images gained from this study. One shows the migration of cells 
through myoma tissue when exposed to fresh medium only with no inhibitor added. This 
section clearly shows that a dense population of HSC-3 cells have invaded the upper layer 
of tissue, and interspersed through the rest of the tissue there are a number of large cell 
populations. The opposite is shown from the second image, which is derived from cells 
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exposed to l.5M short aptamer. This section shows no cells at all have invaded the 
middle and lower areas of the tissue, and much less have invaded the upper surface. 
These findings suggest that the cells exposed to 1.5M short aptamer were not able to 
invade the tissue. 
Between the two sections there is a clear difference in total HSC-3 cell numbers, with 
many more cells present in the section not exposed to inhibitor over that exposed to 
1.5M short aptamer. However, care was taken to administer the same numbers of cells 
to all samples at the beginning of each experiment by aliquoting them from a universal 
mixture. This suggests that cells exposed to no inhibitor were able to proliferate over the 
14 day period, whereas those exposed to 1.5M short aptamer did not proliferate at such 
a high rate. An explanation for this would be that because the non-inhibited cells were 
able to invade, they could gain confluency due to the increased surface area available to 
them, whilst because the inhibited cells did not invade, they had less available surface 
area in which to proliferate. It is also possible that l.5M short aptamer has cytotoxic 
properties and for this reason the cells have not shown proliferation. However, in this 
particular image, a small number of cells have invaded a short distance into the tissue, 
and figures 6.6 to 6.8 show that invasion was not completely halted; rather reduced, 
suggesting the cells were still viable. 
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Figure 6.5 - Representative images derived from immunohistochemistry of myoma 
sections after termination of the experiment at day 14. Magnification is x100. The 
image on the left shows dense invasion from HSC-3 cells and has not been exposed to 
inhibitor, whereas the image on the right was exposed to l.sM short aptamer and 
shows little invasion localised to the upper surface of the tissue. 
Figure 6.6 shows the maximal invasion depths from all treatments represented as upper 
and lower quartiles, median, maximum and minimum valu es. The ti ssues exposed to 
heparanase antibody were the only t reatments that showed a significant decrease in 
maximal invasion depth 228.9~m ± 241.2 from those without inhibitor added 1712.3~m ± 
145.5 (p<O.OOOl) . Treatments of unrelated aptamer, BAFB and those wh ere no inh ibitor 
were added show a much lower dispersal of the data th an those from th e heparanase 
and linker-generated aptamers, which , as shown by the boxes, have a larger spread of 
data towards the lower invasion depths. This suggests th at alt hough th e result of th e 
means for heparanase and linker-selected aptamers are not st ati st ically lower t han t hat 
for no inhibitor added, the datasets showed a proportion of images showing lower 
invasion depths. 
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Figure 6.6 - A box and whisker diagram showing maximum invasion depth (n=27 
samples) represented as upper (Q3) and lower (Ql) quartiles, median, minimum (min) 
and maximum (max) values. Heparanase antibody-treated tissue was the only 
treatment showing a significantly lower maximum invasion depth from tissues not 
exposed to inhibitor (p<O.OOOl). 
Figures 6.7 and 6.8 show the total invasion area and invasion index from each treatment. 
Heparanase antibody (13809.9 ± 136081lm2) and l.5M short aptamer (67492.8 ± 74483.8 
11m2), both showed significantly less invasion (p<O.OOOl) compared to no inhibitor added 
(354354.6 ± 173621.9 11m2). No significant differences were observed by the other 
treatments, which were all similar to the negative control (no inhibitor). These results 
suggest that both heparanase antibody and l.SM short aptamers are effective inhibitors 
of invasion of HSC-3 cells, but that l.5M long, 3.0M, pink and yellow aptamers together 
with BAFB do not function as inhibitors in this study. In studies using BAFB [SL solubility 
in aqueous solutions were an issue, and addition of small amounts of solvent such as 
DMSO were necessary before the compounds would dissolve. However, for this assay, 
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the tissues were stored frozen in a low percentage DMSO solution in medium and upon 
defrosting, were washed numerous times to remove the DMSO for the experiment. 
Therefore, it was not possible for the introduction of DMSO into the experiment via this 
inhibitor so a decision was made to attempt to dissolve the inhibitor in PBS only and mix 
well. Unfortunately this may not have been successful, and could explain why this 
compound did not show any inhibitory effects in this study. 
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Figure 6.7 - A box and whisker diagram showing area of Invasion (n=27 samples) from 
myoma tissues subjected to different treatments represented as upper (Q3) and lower 
(Ql) quartiles, median, minimum (min) and maximum (max) values. Heparanase 
antibody and 1.5M short both showed siglficantly less inavsion than the other 
treatments (p<O.OOOl). 
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Figure 6.8 - A box and whisker diagram showing invasion index [1- (noninvadlng 
area/total area)] (n=27 samples) from myoma tissues subjected to different treatments 
represented as upper (Q3) and lower (Q1) quartiles, median, minimum (min) and 
maximum (max) values. Heparanase antibody and 1.5M short both showed slglflcantly 
less inavsion than the other treatments (p<O.OOOl). 
6.3.2 RIA 
Radioimmunoassays were conducted to detect the (-terminal telopeptide from type III 
collagen by incubating the media samples in a reaction with a tracer (iodine-conjugated 
synthetic (-terminal telopeptide) and primary antibody (raised against synthetic C-
terminal telopeptide) for two hours at 3rc. The primary antibody favourably binds 
collagen degradation product from the media sample in competition with tracer, hence 
the existence of large concentrations of collagen degradation product will create loss of 
the unbound tracer in a subsequent wash step and lower the counts in that sample . 
Figures 6.9 to 6.12 show radioimmunoassay data obtained for days 4, 7, 10 and 14. The 
media change from day 4 showed no significant differences from the control, to which no 
inhibitor was added. This was expected as the cells would not have had enough time at 
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four days to equilibrate, divide and invade the tissue . The media change upon 
termination of the experiment at day 14 only showed statistical significance from the 
treatment with no cells added (p=O.OOl). At day 14, it is possible that the cells had 
ceased invasion and were subject to senescence due to the volume of waste products 
that had accumulated on the tissues' surface. 
Days 7 and 10 showed the most promising results. From day 7, the treatments of 
heparanase antibody (p=O.OOl), no cells (p=0.0002), and aptamers l.5M short (p=0.0006), 
long (p=0.0004), 3.0M (p=O.OOl) and pink (p=0.003) all showed significantly lower 
collagen degradation products than that for the tissue with no inhibitor added. 
Treatments with yellow and unrelated aptamers and BAFB had no significant effect on 
collagen degradation product. 
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Figure 6.9 - Day 4 media change subjected to RIA to test for collagen degradation 
products. There were no significant differences between any of the treatments. Data 
shown are the means from triplicates of each of three samples of media and error bars 
represent standard deviation of the mean. 
Page I 187 
~ 
u 
::::l 
0 
0 
ex: 
~ 
z 
0 
~-<C-
o"'" 
:2 ~ 
C) 
w 
0 
z 
w 
C) 
<C 
..... 
..... 
o 
~ 
300 
250 
200 
150 
100 
50 
a 
Figure 6.10 - Day 7 media change subjected to RIA for collagen degradation products. 
Treatments with heparanase antibody (p=O.OOl), 1.5M short (p=0.0006), long 
(p=0.0004), 3.0M (p=O.OOl), Pink (p=0.003) aptamers and no cells (p=0.0002) were all 
significantly lower than the control with no inhibitor added. Data shown are the means 
from triplicates of each of three samples of media and error bars represent standard 
deviation of the mean. 
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Figure 6.11 - Day 10 media change subjected to RIA for collagen degradation products. 
Treatments with no cells (p=0.009) were significantly lower, and heparanase antibody 
(p=O.07), 1.5M short (p=O.04), long (p=O.02) and 3M aptamers (p=O.06) were lower with 
slight significance than the control with no inhibitor added. Data shown are the means 
from triplicates of each of three samples of media and error bars represent standard 
deviation of the mean. 
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Figure 6.12 - Day 14 media change subjected to RIA for collagen degradation products. 
Treatments with no cells (p=O.001) were significantly lower and heparanase antibody 
(p=O.09) and 1.5M long aptamer (p=O.04) were lower with weak significance than the 
control with no inhibitor added. Data shown are the means from triplicates of each of 
three samples of media and error bars represent standard deviation of the mean. 
Day 10 results show that the values for collagen degradation product in experim ents to 
which no HSC-3 cells were added still remained significantly lower than the control with 
no inhibitor (p=O.009), which was expected as invasion should not occur in the absence of 
invasive cells. Heparanase antibody (p=0.07) and 1.5M short (p=O.04), long (p=O.02) and 
3.0M aptamers (p=0.06) showed less collagen degradation product by a weak 
significance. However, aptamers pink, yellow and unrelated, with BAFB once again 
showed no significant decrease in collagen degradation product than the negative 
control, indicating that they were not acting as succesful inhibitors of invasion . 
6.3.3 ELISA 
This assay shows a negative correlation between collagen degradation product and 
absorbance as the primary antibody was firstly incubated with the medium sample before 
being exposed to the synthetic peptide coating the wells of the ELISA plate . This meant 
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that if there were collagen degradation products in the medium the antibody would bind 
them and not the synthetic peptide, giving less colour. 
Figures 6.13 to 6.16 show ELISA data obtained from media changes on days 4, 7, 10 and 
14 respectively. The pattern of data was similar throughout all media changes and the 
only significant increase in absorbance was seen from the heparanase antibody (p=O.Ol 
on day 4, 0.03 on day 7,0.03 on day 10 and 0.02 on day 14), l.5M short aptamer (p=O.Ol, 
0.02, 0.007 and 0.02 respectively) and 1.5M long aptamer (no significance on day 4, 
p=0.07 on day 7, and 0.03 on both days 10 and 14). Unfortunately the data for aptamer 
3.0M was very variable, shown by the error bars, so a statistical significance in relation to 
the treatments with no inhibitor could not be obtained in any of the media changes. This 
is likely due to the condition of the cells or tissue in the experiment as all of the media 
changes show the same variability. None of the other treatments, including the 
treatment without cells, showed any significant difference in absorbance and therefore 
collagen degradation product from samples without inhibitor, suggesting that only 
heparanase antibody and l.5M short and long aptamers, and possibly the 3M, were able 
to successfully inhibit the invasion of HSC-3 cells. 
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Figure 6.13 - ELISA d~tecting N-terminal telopeptide from collagen degradation 
products at day 4 media change. Heparanase antibody (p=O.Ol) and 1.5M short 
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aptamer (p=O.Ol) showed increased absorbance (therefore less collagen degradation 
product present). Data shown are the means from triplicates of each of three samples 
of media and error bars represent standard deviation of the mean. 
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Figure 6.14 - ELISA detecting N-terminal telopeptide from collagen degradation 
products at day 7 media change. Heparanase antibody (p=0.03), 1.5M short aptamer 
(p=0.02) and 1.5M long aptamer (p=O.07) showed increased absorbance (therefore less 
collagen degradation product present). Data shown are the means from triplicates of 
each of three samples of media and error bars represent standard deviation of the 
mean. 
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Figure 6.15 - ELISA detecting N-terminal telopeptide from collagen degradation 
products at day 10 media change. Heparanase antibody (p=0.03), 1.5M short aptamer 
(p=0.007) and 1.5M long aptamer (p=0.03) showed increased absorbance (therefore less 
collagen degradation product present). Data shown are the means from triplicates of 
each of three samples of media and error bars represent standard deviation of the 
mean. 
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Figure 6.16 - ELISA detecting N-terminal telopeptide from collagen degradation 
products at day 14 media change. Heparanase antibody (p=O.02), 1.5M short aptamer 
(p=O.02) and 1.5M long aptamer (p=O.03) showed increased absorbance (therefore less 
collagen degradation product present). Data shown are the means from triplicates of 
each of three samples of media and error bars represent standard deviation of the 
mean. 
6.4 Discussion 
These studies were conducted in order to examine the effect that heparanase and linker 
peptide-selected aptamers have on the formation, secretion and function of active 
heparanase in invasion assays, using cells that had been previously shown to express 
heparanase [3,4, 7]. 
The results of the matrigel invasion assay showed that both the PL4 and OC MZ-6 cell 
lines were successfully inhibited by the polyclonal heparanase antibody, which for the OC 
MZ-6 line, correlates with previous results using this antibody [3, 4]. Similarly, in this 
assay, the 15M long aptamer showed significant inhibition of OC MZ-6 cells at a 
concentration of 111 M, to a greater degree than the heparanase antibody, although to a 
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lesser extent for the PL4 cells. Both the 1.5M long and pink aptamers only showed a weak 
statistical decrease in number of PL4 cells traversing the membrane. This would correlate 
with the results of the previous study by Harris et 01. [3] that the primary function of 
heparanase in these cells is one of either a transcriptional regulator of COX-2 expression 
(and subsequent migration as seen in a different trophoblast cell line) and/or as the 
inactive proenzyme stimulating migration via PI3K or p38, rather than strictly direct 
invasion and remodelling. 
In the organotypic model of invasion, measurements taken from the images show 
significantly lower invasion depth, area of invasion and invasion index for the tissues 
treated with heparanase antibody and significantly lower invasion area and invasion index 
from tissues treated with 1.5M short aptamer. The former was expected, as in previous 
studies and chapters of this thesis the polyclonal heparanase antibody has been shown to 
be a functional inhibitor and superior for labelling and staining of heparanase [3,4]. 1.5M 
short aptamer, however, has not shown the greater promise in other experiments 
detailed in this thesis, although it has similar affinity for heparanase as indicated by 
binding assays. Furthermore, this is the first experiment in which human tissue has been 
used and perhaps the truncated nature of this aptamer has favoured it with this celiline. 
In experiments conducted to ascertain the localisation of heparanase within oral cancer 
cell cultures [7], heparanase activity was found in cell extracts and intact cells, but not in 
the conditioned medium, suggesting that heparanase acts at the plasma membrane or 
within the cytoplasm of the cell itself, which would correlate with the processing of 
proheparanase to its active form inside the late endosomes/lysosomes before secretion 
to the cell surface. As the full-length version of this aptamer (Le. 1.5M long) was not 
shown to significantly inhibit invasion in this assay, and other than the antibody, the only 
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aptamer that had any significant inhibitory effect was l.SM short (the only severely 
truncated aptamer), this suggests a possible perfusion of 1.5M short aptamer across the 
plasma membrane to inhibit heparanase before its secretion to the cell surface or at the 
cell surface itself, where it would be subject to less steric hindrance by other molecules, 
due to its small size. 
It is possible that inhibition of invasion of cells in both assays by aptamers 1.5M long and 
short aptamers respectively, could be due to a direct cytotoxic effect they exhibit on the 
cells. However, as the cells treated with these aptamers have shown reduced and not 
complete invasion, it would suggest that the cells were still viable. An assay to determine 
the aptamers' natural cytotoxicity over these cells would further complement the results 
shown in this chapter. 
The RIA, and to some extent, ELISA data reinforce these results as both the heparanase 
antibody and 1.5M short aptamer are suggested to inhibit invasion. However, 1.5M long, 
3.0M and even pink aptamer (in RIA) are also suggested to exhibit inhibitory activity. This 
would correlate with previous results in this thesis, where these aptamers have shown to 
bind heparanase or linker peptide. Binding to the linker peptide may cause inhibition of 
heparanase due to the prevention of the formation of the active enzyme, through 
blocking the digestion of the linker peptide in the proenzyme. Failure of the yellow 
aptamer to have the same effect may be due to the fact that, although this aptamer also 
binds the linker peptide, may bind in such a way as not to prevent proteolytic cleavage. 
The invasion depths for these aptamers, although statistically non Significant, showed 
lower minimum values, and lower median values in invasion area and index than yellow 
and unrelated aptamers, BAFB and no inhibitor, suggesting that a proportion of them may 
have been subject to inhibition. The RIA and ELISA data may not have been replicated on 
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the same scale in the image data because the RIA and ELISA are more sensitive to small 
changes in collagen degradation. 
Overall, aptamers in these studies were found to have the ability to inhibit heparanase 
activity and tissue penetration, often at a level similar or superior to the polyclonal 
antibody. The most promising aptamer sequence was shown to be the one identified 
after elution from the 1.5M salt, although, depending on the assay, and perhaps the 
accessibility of the protein, it was either the 'long' or the 'short' form of this aptamer that 
exhibited the highest activity. Lack of significant activity by the 3.0M aptamer may be 
due to the position of the binding of this aptamer to the enzyme. All aptamers were 
originally selected for affinity for the enzyme, but not for inhibitory action. Thus, it is 
possible that a higher binding species may bind to such site as to not have any or little 
functional effect, whereas another species of lower affinity may be a better functional 
inhibitor. Similarly, although the aptamer species against the linker peptide have 
contributed significant information as to the fate of the peptide, or presence of 
proenzyme in the cell (see chapter 5), it appears that one of the peptide-derived 
aptamers has an inhibitory affinity, whereas the other does not. Again, this may be that 
the one of the aptamers prevents proteolytic cleavage of the linker peptide, whereas the 
other aptamer does not. It may also be due to the fact that both aptamers were selected 
against the synthetic peptide, and thus, one may be able to bind to the peptide in the 
holoenzyme (proenzyme), whereas the other does not and binds only to the already 
cleaved peptide (as shown by the fluorescence quenching experiments, see chapter 4). 
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CHAPTER SEVEN 
DEVELOPING APTAMERS AS USEFUL DIAGNOSTIC OR 
THERAPEUTIC TOOLS 
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7.1 Background 
Previously, aptamers were selected against human polymorphic recombinant heparanase 
and the 6kDa linker peptide using a salt selection method. Three aptamers selected for 
heparanase and two for the linker peptide were suggested to bind with high affinity, 
shown by ELISA and fluorescence quenching studies. These aptamers were also tested 
for specificity and inhibition of formation or activity of active heparanase in in vitro cell 
and invasion assays. l.5M short and long aptamers were the most promising in these 
studies; showing Kos of 13.7 and 12nM respectively, were seen to label heparanase in cell 
lines and tissue sections and suggested significant inhibition of tumour cell lines through 
tissue in cell invasion assays; 1.5M long aptamer significantly inhibiting ovarian carcinoma 
cell line DC MZ-6 in a Matrigel invasion assay and 1.5M short aptamer significantly 
inhibiting human tongue squamous carcinoma cells (HSC-3) in a myoma organotypic 
model. As these aptamers showed the greatest promise, assessing their functionality as 
therapeutics or in a diagnostic assay was essential. 
7.2 Serum Stability Assays 
To assess the aptamers' suitability as therapeutic agents, it was necessary to have an 
understanding of how stable the unmodified aptamers would be in the body, as, in the 
bloodstream alone, there are many nucleases capable of degrading the aptamers, 
rendering them inactive [1]. A simple experiment to achieve this was conducted by 
incubating 5~M of each aptamer in 17~1 human or mouse serum for different time 
periods, then stopping the reaction using 1M EDTA and running the product on a 12% 
Page \199 
native polyacrylamide gel, stained with ethidium bromide. Figures 7.1 to 7.5 show the 
results for each aptamer with human and mouse serum. 
Figure 7.1 - Products of '1.SM short' aptamer incubated with human (left) or mouse 
(right) serum for different lengths of time, then the reactions stopped and products run 
on a 12% native PAGE, stained with ethidium bromide. lanes are marked with duration 
of incubation time. Each band of the DNA ladder represents 2Sbp, beginning with 2Sbp. 
Comparison of bands on the gels for l.5M short aptamer (figure 7.1) incubated for 
different time points with human and mouse serum, with that of aptamer only showed 
that l.5M short aptamer was not subject to nuclease degradation from human serum as 
the bands did not show any smearing or decrease in size or intensity from aptamer only, 
and hence, no breakdown of the aptamer into smaller fragments was observed. With 
mouse serum, there was a decrease in primary band intensity at five hours' incubation 
time, suggesting that nucleases may have degraded the aptamer into smaller fragments 
not visible on the gel. 
Figure 7.2 shows the results obtained from incubation of l.5M long aptamer with human 
and mouse serum for different time periods. Upon increasing the time of exposure to 
both human and mouse serum, an increase of smearing below the aptamer's main band 
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is observed. However, with human serum, the samples have not run in a straight line and 
therefore the increase in smearing may be due to the lack of lane width for the sample 
incubated for four hours. The band nevertheless disappeared altogether at 5 hours for 
human serum and 3 hours in mouse serum. This suggests that at these times, the 
aptamers have been completely digested by nucleases present in the serum and are 
present in such small fragments that ethidium bromide either cannot intercalate with 
them at all or they have run off the bottom of the gel. 
Figure 7.2 - Products of 'l.5M long' aptamer incubated with human (left) or mouse 
(right) serum for different lengths of time, then the reactions stopped and products run 
on a 12% native PAGE, stained with ethidium bromide. lanes are marked with duration 
of incubation time. Each band of the DNA ladder represents 25bp, beginning with 25bp. 
Figure 7.3 shows the results obtained for 3.0M aptamer when exposed to human and 
mouse serum. There is an increase in smearing from three hours onwards in human 
serum; however, as the aptamer has not run in a straight line, the smear may appear 
more intense due to the aptamer having less gel width . With mouse serum, there is a 
decrease in band intensity and an increase of smearing from only 30 minutes, suggesting 
that 3.0M aptamer is very susceptible to degradation by mouse serum. 
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Figure 7.3 - Products of '3.0M' aptamer incubated with human (left) or mouse (right) 
serum for different lengths of time, then the reactions stopped and products run on a 
12% native PAGE, stained with ethidium bromide. lanes are marked with duration of 
incubation time. Each band of the DNA ladder represents 2Sbp, beginning with 2Sbp. 
Figure 7.4 - Products of 'pink' aptamer incubated with human (left) and mouse (right) 
serum for different lengths of time, then the reactions stopped and products run on a 
12% native PAGE, stained with ethidium bromide. lanes are marked with duration of 
incubation time. Each band of the DNA ladder represents 25bp, beginning with 25bp. 
Upon incubating pink aptamer (figure 7.4) with human serum, there is no reduction of 
band intensity or increase in smearing in comparison to the band shown by the aptamer 
alone. This suggests that pink aptamer is not susceptible to degradation by human 
serum. Mouse serum however, has caused a decrease in band intensity and increase in 
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smearing from three hours in comparison to the band of aptamer alone, suggesting that it 
has been degraded by nucleases present in the serum in this time frame. 
Yellow aptamer (figure 7.5) has shown an unexpected result in the case of human serum. 
There is a very weak band for human and yellow aptamer incubated for 30 minutes, 
which does not correspond with the rest of the results for this serum which are all intense 
bands. If nuclease degradation had happened with this aptamer, one would expect to see 
a decrease in intensity of bands and increase in intensity of smearing with increase of 
incubation time. Therefore, this suggests that this result is an error perhaps caused by an 
incorrect concentration of aptamer being added to the serum in the first place. Upon 
incubating yellow aptamer with mouse serum, all of the bands show decreased intensity 
and increased smearing, with the primary aptamer band disappearing from three hours 
onwards. This suggests that yellow aptamer is subject to nuclease degradation from 
nucleases present in mouse serum. 
Figure 7.5 - Products of 'yellow' aptamer incubated with human (left) or mouse (right) 
serum for different lengths of time, then the reactions stopped and products run on a 
12% native PAGE, stained with ethidium bromide. lanes are marked with duration of 
incubation time. Each band of the DNA ladder represents 25bp, beginning with 25bp. 
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7.3 Interactions with Serum Albumins 
Serum albumin is a 67kDa protein found in the blood or serum of vertebrates, where it 
constitutes approximately 60% of the total plasma proteins. At pH 7.4 it is negatively 
charged and acts as a transporter as many ligands are able to reversibly bind it non-
covalently via its many binding sites [2, 3]. The binding of drugs to serum albumin in the 
bloodstream has important consequences on the bioavailability of those drugs, as their 
free and active concentrations in the bloodstream affects the intensity of their effects as 
well as the time spent in the body [2], although it has been found in the interactions of 
albumin with pesticides, that their affinity for albumin is lower than that for their primary 
targets [4]. 
To investigate the possible interactions between l.sM short and long aptamers to human 
serum albumin (HSA), fluorescence quenching techniques were used, similar to chapter 
four, where aptamers were titrated into heparanase or its linker peptide. Experiments 
were performed at 37°( in a 3ml cuvette containing 1ml HSA diluted to concentration 
using PBS, pH 7.4. Excitation was performed at 290nm and emission was displayed from 
300-400nm, with the slits narrowed to ± 3nm and a time interval of 90 seconds between 
each addition. 
Aptamers 1.5M short and long were firstly titrated stepwise into water and PBS, pH 7.4 at 
37°(, generating concentrations between 0-8~M to investigate their intrinsic 
fluorescence, as the presence of any aromatic ring in the molecular chain can invoke 
natural fluorescence [5]. It is seen from figure 7.6 and 7.7 that both aptamers have 
intrinsic fluorescence as there are peaks at 380nm, which increases in fluorescence 
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intensity upon increasing the aptamer concentration; l.5M short showing less 
fluorescence than 1.5M long. Water was used as a diluent to show that the aptamer and 
not PBS was the cause of the fluorescence, although the fluorescence for l.sM short 
increased upon using PBS as the diluent, however this was likely due to a difference in pH 
as in fluorescence spectroscopy, pH changes have a significant influence on results. 
Fluorescence of the aptamers caused a problem since the aptamers at these 
concentrations would obscure any quenching of HSA; therefore the concentration of HSA 
had to be high enough and the aptamer concentrations low enough to eliminate the 
interference. The optimum concentrations were therefore found to be 60~M HSA; which 
is 1/10th of the maximum level in plasma, and additions of aptamer from 0-7 .4~M, 
corresponding to a maximum of 200~g/L; within the same range found in patients' 
plasma in clinical trials of aptamer ARC1779 to vWF [6]. 
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Figure 7.6 - Fluorescence spectra of 1.5M short aptamer in water (left) and PBS buffer 
(right) at 37°C. Fluorescence increases upon increasing the concentration of aptamer in 
both PBS and water, showing that although the fluorescence is higher in PBS the 
aptamer is in fact the cause and the pH difference in water and PBS is the most ;ikelv 
reason for the increase of fluorescence of the aptamer in PBS. 
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Figure 7.7 - Fluorescence spectrum of increasing concentrations of 1.5M long aptamer 
in water showing the intrinsic fluorescence of this aptamer. 
When carrying out fluorescence studies, a decrease in fluorescence intensity not due to 
the quenching i.e. interaction between species can occur, and is termed the inner filter 
effect (IFE) [7]. The cause of this effect is the absorption of (in this case) the aptamer at 
the excitation or emission wavelength of the fluorophore, known as primary and 
secondary IFE respectively [7]. The IFE can masquerade as true quenching from the 
interactions of aptamer and HSA and therefore must be corrected using the appropriate 
equation. Therefore, the titrations were carried out in parallel using a 
spectrophotometer to determine the absorption at excitation and emission wavelengths. 
The slFE was found to be negligible as neither aptamer was found to absorb at 380nm 
(data not shown), whereas the plFE i.e. absorption of the aptamer at the excitation 
wavelength of 290nm was a contributing factor. Therefore, Parker's equation was used 
to correct this effect [7]. 
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Figure 7.8 and 7.9 show the means of three fluorescence spectra obtained from stepwise 
titrations of 1.5M short and long aptamers with HSA at 3rc. Figure 7.10 is a normalised 
plot of the fluorescence quenching for both aptamers, plotted as HSA FIFo ratio against 
aptamer concentration, using an average of six values with standard deviations not higher 
than 11%, measured at the maximum emission of 345nm . As shown in the graph, l.5M 
short aptamer is able to quench the fluorescence of HSA at 3rc by 1.5% (± 0.03%) and 
9% (± 1.2%) at 1:100 and 1:10 molar ratios respectively, with quenching of 10% achieved 
by a molar concentration 9.1 times lower than HSA. l.5M long aptamer is able to quench 
the fluorescence of HSA by 10% at a concentration 18.2 times lower than HSA, and by 
2.4% (± 0.1%) and 16% (± 0.6%) at 1:100 and 1:10 molar ratios. The results show that 
both aptamers are able to quench the fluorescence of HSA, although l.5M long is more 
effective. 
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Figure 7.8 - Means of three experiments showing gradual HSA fluorescence quenching 
by increasing concentrations of 1.5M short aptamer at 37°C in PBS. 
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Figure 7.9 - Means of three experiments showing gradual HSA fluorescence quenching 
by increasing concentrations of 1.5M long aptamer at 37°C in PBS. The decrease in 
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mean of six values showing no greater standard deviation than 11%. The quenching 
effect is more considerable for 1.5M long than short. 
To gain more information about the type of interaction occurring between the aptamers 
and HSA, UV spectrometry titrations were carried out by titrating increasing 
concentrations of aptamers 1.5M short and long into PBS and 6JlM HSA diluted in PBS 
(figures 7.11 and 7.12). The addition of both aptamers to PBS and HSA increased the 
overall absorbance, showing that the aptamer was responsible for this increase and not 
HSA. The increase was more pronounced for 1.5M long than short, and both produced a 
shift of the maximum absorbance to the left upon addition of increasing concentrations 
of aptamer The shift seen from 1.5M short aptamer moved 6nm to the left, suggesting 
that only a slight conformational change in the protein was occurring [5] and therefore, 
HSA quenching by this aptamer is most likely due to dynamic quenching. However, in the 
case of 1.5M long, not only was there a substantial shift in the maximal absorption by 
20nm to the left, but a complete change in the shape of the peak was observed, 
incorporating the peak at 260nm of the aptamer, suggesting that one complex was 
formed and that the quenching was due to the static quenching phenomenon with 1.5M 
long aptamer [5]. 
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7.4 Development of a Piezoelectric Aptasensor 
A biosensor is a device used for detection of a specific analyte and is composed of a 
sensitive biological agent (e.g. aptamer or antibody), which interacts selectively with the 
analyte of interest; a transducer, which transforms the signal generated from this 
interaction to the electronic equipment, which analyses and displays the signal in a user-
friendly way. 
The field of biosensors, and in particularly, electronic aptamer-based biosensors 
(aptasensors) has recently progressed due to the technique's many advantages [8]. These 
include being able to detect the presence of the compound of interest quickly when 
compared to techniques such as ELISA, which uses a chemical reaction after several 
incubations of successive detection labels. There are no radioactive compounds involved; 
making aptasensors a safer alternative to assays such as RIA. Also, real-time 
measurements are possible in many of the different detection systems, as is the 
opportunity of automation, which makes for high throughput assays [8]. 
Several approaches to development of analytical aptasensors have been used. Most of 
these use aptamers conjugated with functional groups or moieties at their 5' or 3' end so 
that they may be coupled to the solid support and used as a receptor. The disadvantages 
of using these types of assay then become apparent, i.e. the need to couple functional 
moieties to the aptamer can be time consuming and expensive, but also may change the 
binding properties the aptamer has for its target, leading to reduced sensitivity and/or 
selectivity, although research is ongoing to overcome this, and the mUltiple advantages of 
using aptasensors far outweigh these problems [8]. 
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The quartz crystal microbalance (QCM) is a technique that has been employed by groups 
to study the interactions between immobilised aptamers and their respective target 
proteins [9-11]. A gold-coated quartz crystal forms the solid support, which when 
coupled with the microbalance equipment, oscillates at a certain frequency. Frequency 
of its oscillation is directly related to the thickness of deposit on the surface of the crystal, 
which when immobilised aptamers recognise and bind their protein target, the mass at 
the surface increases causing the frequency of oscillation to decrease. This is 
demonstrated by the Sauerbrey equation (equation 7.1), where afr is the change of 
resonance frequency in Hertz, l1m is the change in nanogram mass on the quartz surface, 
A is the size of the aptamer-coated surface in square centimetres and Cf is the sensitivity 
constant. The sensitivity constant is calculated as shown in equation 7.1, by use of the 
original frequency (fr) e.g. 5MHz, the density (pq) and velocity of sound (Vq) of the quartz 
crystal [10]. 
Am M,=-Cry 
using 
Equation 7.1 - Sauerbrey equation [10] linking change In resonance frequency with a 
change in mass at the crystal surface. 
In order to provide the basis of a useful diagnostic technique using QCM, heparanase-
selected aptamers must: 
1. immobilise to the crystal's surface 
2. retain recognition specifically for heparanase 
3. have the ability to be regenerated and reused 
4. recognise heparanase at low concentrations and in the presence of other 
proteins 
5. the results must be reproducible and accurate 
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1m mobilisation of 5' biotinylated heparanase-selected aptamers to the surface of a 5MHz 
crystal was carried out using a solution of 4mg/ml 3,3' -dithiodipropionic acid-di(N-
succinimidylester) (DSP), diluted in water-free N,N-dimethylacetamide (DMA), in 
accordance with other group's methods [10, 12] and immobilises free amino groups of 
lysine residues of streptavidin by peptide bonds. These act as a 'spacer' between the gold 
surface and the biotinylated aptamer, as it has been found that use of the spacer, rather 
than direct immobilisation of amino-modified aptamers to DSP on the surface, increases 
the sensitivity of the device [8, 10]. Experiments were conducted with use of a flow cell 
and stop-flow system to maintain the crystal's surface in solution at all times and PBS was 
used as the buffer and diluent. 
Firstly, upon addition of the crystal to the flow cell, it was important to allow enough time 
for the crystal to equilibrate, so the frequency was monitored immediately after inserting 
the crystal and immersing it in PBS. It was determined necessary to allow between 100-
140 minutes before beginning any experiments. Therefore, each experiment was allowed 
this time of incubation in PBS inside the flow cell before any readings were taken. 
To investigate whether immobilising 1.5M short and long aptamers to the quartz crystal 
surface would retain their recognition for heparanase and if the crystals could be 
regenerated, experiments were conducted on newly immobilised crystals. Inside the flow 
cell, which was exposed to room temperature and humidity, the capacitance was 
adjusted so the microbalance equipment was 'locked on' to the frequency of the crystal, 
then the crystals were incubated in PBS for 140 minutes to equilibrate and a base reading 
taken for approximately ten minutes to ensure the crystal had equilibrated. After pausing 
the reading of measurements, 800nM heparanase in PBS was introduced to the flow cell 
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by use of the peristaltic pump . Immediately after stopping the pump, when the 
heparanase had been introduced to the flow cell, the readings were resumed . After the 
readings had stabilised, the program was paused, PBS was added to the flow cell via the 
pump and the readings resumed once again. This served as a 'wash step' by removing 
any heparanase which was unbound, and any plateau of frequency was used to 
determine the maximum decrease from addition of heparanase. The crystal was then 
regenerated by introducing 100mM EDTA and 3.0M NaSCN wash steps, followed by 
returning the crystal to PBS, pausing the readings and using the pump to make each 
addition. The experiments were also repeated using 800, 400, 200 and 100nM 
heparanase, corresponding to 50, 25, 12.5 and 6.25~g/ml respectively; 104 times over the 
upregulated heparanase levels in cancer patients [13] . These results are shown in figure 
7.13 and show that higher heparanase concentrations decrease the frequency of the 
crystal by a bigger margin, due to more heparanase becoming bound by the aptamers. 
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Figure 7.13 - Binding sensogram showing decrease in frequency of crystals immobilised 
with 1.5M short aptamer exposed to different concentrations of heparanase. Higher 
concentrations of heparanase exhibited a greater decrease in frequency. 
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Figures 7.14 and 7.15 show the results when 800nM heparanase diluted in PBS were 
added to crystals immobilised with l.5M short and long aptamers. The results both show 
a considerable decrease upon exposure to heparanase, by 42.97Hz and 50.35Hz 
respectively. Washing with PBS liberated only 5.51Hz and 4.39Hz, giving total Mr of 
37.46Hz and 45.96Hz for 1.5M short and long aptamers respectively. This suggests that 
heparanase was recognised and bound by both aptamers. 
Returning the crystals to PBS after performing regeneration washes using 100mM EDTA 
and 3.0M NaSCN increased the frequencies to 0.61Hz below the level of original 
equilibration for the crystal immobilised with l.5M short aptamer and 3.09Hz lower than 
that of 1.5M long aptamer. This suggests that the crystals were almost totally 
regenerated, liberating almost all of the bound heparanase and leaving behind the 
immobilised aptamers. 
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Figure 7.14 - Binding and regeneration sensograms for addition of 800nM heparanase 
to quartz crystal immobilised with l.SM short aptamer. After a wash with PBS, an 6fr of 
37.46Hz was observed. Washing with 100mM EDTA then with 3.0M NaSCN allows total 
regeneration of the crystal. 
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to quartz crystal immobilised with 1.5M long aptamer_ Washing with PBS determined 
an Mr of 45.96Hz, then with 100mM EOTA and 3.0M NaSCN allowed almost total 
regeneration of the crystal. 
7.5 Discussion 
The results from these experiments suggest that heparanase and linker peptide-selected 
aptamers are stable in human serum for up to five hours, with the exception of l.5M long 
aptamer, which succumbed to nuclease degradation upon incubation with serum in 
between four and five hours_ Mouse serum, on the contrary, caused complete nuclease 
degradation of all of the aptamers within five hours; 3_0M and yellow aptamers exhibited 
degradation from 30 minutes, whilst pink and l.5M long aptamers both showed nuclease 
degradation between two and three hours and l.5M short aptamer between four and 
five hours. These results suggest that without modification, aptamers may be stable in 
the blood of humans for up to five hours, which correlates with the results shown by 
Bates [14] and Xu [15], with the nucleolin aptamer AS-1411, which is an unmodified 26 
nucleotide DNA aptamer also not subject to nuclease degradation through its formation 
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of a G-quadruplex structure alone. Therefore, these aptamers may form promising 
therapeutics, which may be a consequence of their secondary structures as also reported 
by Di Giusto [16] with circularised aptamers. Conversely, the data also suggests that 
without modification, aptamers would not be stable in the blood of a mouse for longer 
than 30 minutes, so either the aptamers would require modification, or the mouse may 
not form a suitable model for animal testing. 
Fluorescence quenching experiments with human serum albumin showed that 1.5M short 
aptamer was able to quench the fluorescence by 10% at a concentration 9.1 times lower 
than HSA, and 1.5M long aptamer at 18.2 times lower. In a similar study by Silva et 01. 
[17] a pesticide, Methyl Parathion, was required in excess of HSA to generate a quenching 
of 10%, suggesting that these aptamers may bind in closer proximity to the one 
tryptophan residue found in HSA than this pesticide [2]. This tryptophan residue is 
located at site 214 in subdomain IIA, within which there is a large hydrophobic cavity with 
many arginine residues near the surface [2, 4], which have been shown in different 
studies to serve as anchor points for aptamers [18]. The UV titrations suggested that 
1.5M short aptamer did not form a complex with HSA and that the interactions were due 
to dynamic quenching, whereas 1.5M long was suggested to form a ground state complex 
with HSA. These results could be further reinforced by carrying out further titrations at a 
different temperature and applying the Stern-Volmer theory used in previous studies of 
drugs and serum albumins [3, 17, 19]. 
Preliminary results from the QeM experiments with 1.5M short and long aptamers 
suggested that the aptamers had bound successfully to the quartz crystals and that they 
retained the capacity to recognise and bind heparanase; shown when heparanase was 
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introduced to the flow cell and the frequency decreased and remained 37.46 and 45.96Hz 
lower respectively after a wash with PBS, confirming binding. Different concentrations of 
heparanase were also distinguished from 800 to 100nM, in which an increase in 
concentration correlated with a greater decrease in frequency. 
The regeneration steps were successful as the crystals returned to within 4Hz of their 
original frequency before the addition of heparanase. This was in accordance with other 
groups [10] and was expected due to the absence of mono or bivalent metal ions in EDTA, 
which are required for the formation of the aptamers' complex structures. Removal of 
these ions causes unfolding of the aptamers and release of the bound heparanase. As a 
precaution, 3.0M NaSCN, the final elution of the selection process, was also used due to 
its ability to remove the remainder of bound aptamers from heparanase in selection. It 
was expected that addition of PBS would renew the crystal by causing the refolding of the 
immobilised aptamers due to PBS containing Magnesium ions [10]. These preliminary 
results were very promising for the future use of these aptamers in a diagnostic assay; 
however, further experiments need to be conducted. To provide information regarding 
the longevity of immobilised crystals, their limits of detecting heparanase and binding 
data between aptamers and heparanase, it is necessary to conduct experiments 
consecutively and immediately after immobilisation of 1.5M short, long and an unrelated 
(negative control) aptamer to each crystal. Firstly, experiments repeated using 800nM 
heparanase, followed by regeneration would determine reproducibility at that 
concentration, and could be used to determine binding data such as KA and Ko for each 
aptamer using this methodology. Repeats of each experiment using a series of different 
concentrations down to 10pM would determine if the lowest concentrations of 
heparanase detected by the system would correspond to heparanase levels in the sera of 
cancer patients [13]. The first experiments of addition of 800nM heparanase would then 
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be repeated and compared to the original results. This would show whether the crystal's 
capacity to recognise heparanase was diminished after so many regeneration steps and 
the whole set of experiments would give a clear indication as to how many times the 
crystal could be regenerated and reused, and if it were a reliable and accurate way of 
detecting concentrations of heparanase in solution and therefore be used as a diagnostic 
tool. Many assays have been generated to reliably test the activity of heparanase and its 
inhibitors that could be transferred into a diagnostic setting. However, their 
disadvantages; the use of radiation [10, 11], cost [20, 21], or the time consuming element 
[22-24] could mean that a reliable QeM-based assay with the ability for regeneration of 
crystals as well as specific detection of heparanase at low concentrations in real time 
upon addition of sample, would be highly desirable. 
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CHAPTER EIGHT 
CONCLUSION AND FURTHER WORK 
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The aim of this project was to select for aptamers against human recombinant 
polymorphic heparanase and its excised linker peptide with the aim of inhibition of the 
active enzyme or its cleavage of the linker peptide from the proenzyme to form the active 
enzyme, or its identification in biological samples to provide the basis for a future 
therapeutic or diagnostic reagent in the field of cancer medicine. 
Using an amplified library with each species containing a 25 nucleotide variable sequence; 
hence allowing complex structures to be formed, a modified SELEX protocol was 
optimised for the targets. Target proteins were incubated with the aptamer library and 
bound aptamers were eluted using a salt elution series. The higher salt elutions 
containing aptamers were chosen for testing based on them containing species with 
higher affinity as those with low affinity would have eluted at lower salt concentrations. 
These were 1.5M NaCI and 3.0M NaSCN for heparanase and 3.0M NaSCN for the linker 
peptide. After cloning and sequencing aptamers from these fractions, it was determined 
that the 1.5M NaCI elution had produced one species with consensus and the 3.0M 
NaSCN showed aptamers that shared consensus in all sequenced samples with one 
exception. In the case of the linker peptide, two sequences were repeated with the 
highest frequency amongst those generated. Based on their predicted structures using 
Mfold, the aptamers were truncated as much as possible to remove any nucleotides not 
implicated in structure formation; generating a 30 and 72 nucleotide sequence from the 
1.5M NaCI elution of heparanase, named '1.5M short' and '1.5M long' respectively and a 
55 nucleotide sequence from the 3.0M elution; named '3.0M'. In terms of the linker, 
both sequences were retained as 72 nucleotides based on their predicted structures, and 
were named 'pink' and 'yellow'. 
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Preliminary assays were carried out to determine that the aptamers did indeed bind their 
respective target before carrying out in vitro testing. A sandwich-based ELISA utilising the 
biotin-streptavidin interaction to immobilise biotinylated l.5M short, 1.5M long and 3.0M 
aptamers to the solid support of the well was manipulated, and adding increasing 
concentrations of heparanase determined that the aptamers did indeed bind heparanase. 
However, binding of the aptamers was not at the antibody binding site, as its interactions 
were not disrupted in a competition ELISA with increasing aptamer concentrations. It was 
also determined that the aptamers selected for heparanase did not recognise the heat-
denatured enzyme, suggesting that they recognise a sequence of residues in a structured 
conformation. This could be further investigated by subjecting the aptamer to circular 
dichroism analysis or structural NMR spectroscopy. 
The almost complete quenching of the intrinsic fluorescence generated by tryptophan 
residues of the linker peptide by aptamers pink and yellow suggested that their binding 
obscured the signal by both tryptophan residues, supported by the fact that the aptamers 
are larger, at 22kDa, compared to the linker peptide at 6kDa. Quenching of one third of 
the intrinsic fluorescence of heparanase by aptamers 1.5M short, long and 3.0M 
suggested that the aptamers either bound and obscured the signal of two out of the six 
tryptophans within the 50kDa subunit, or within a different area, possibly the 8kDa 
subunit, therefore altering the enzyme's structure enough to show this level of 
quenching. Fluorescence titrations also demonstrated the association constants between 
heparanase and its aptamers were in the range of high affinity of 107M-!, with the most 
promising aptamer shown to be the 1.5M long. Affinity constants for linker peptide with 
aptamers pink and yellow were in the range 106M-!, perhaps due to the lower 
conformational structure of a peptide in comparison to a full-length protein. 
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In vitro assays using the selected aptamers to label heparanase and linker peptide in 
immunohistochemistry and immunofluorescence studies showed that overall the 
favoured aptamers for detection of heparanase in tissue and cell samples were the l.5M 
long and short respectively. They both showed similar staining, both in terms of pattern 
and intensity, as the heparanase antibody, which is expected as they originated from the 
same sequence and therefore may share some structural features or binding nucleotides. 
Of the aptamers selected for the linker peptide, yellow was favoured in these studies as it 
most frequently showed a level of staining over the negative control and suggested it may 
be able to recognise linker peptide either cleaved or uncleaved from the proenzyme, and 
pink may not. This could be further confirmed by conducting an assay into the processing 
of proheparanase using cathepsin l in the presence of both aptamers separately, plus the 
relevant controls. Further fluorescence assays using the biotinylated aptamers used for 
IHe and IF labelling could also be conducted to determine the effect of biotin on the 
aptamer affinity for heparanase as compared with the unmodified aptamers. 
Invasion assays using all aptamers selected, plus the heparanase polyclonal antibody and 
a small-molecule inhibitor of heparanase, BAFB [1] as inhibitors, determined that the 
polyclonal antibody was the most successful inhibitor of invasion of tumour-derived cells 
in both assays, which corresponds to previous experiments [2, 3]. 1.5M short aptamer 
showed a decrease in invasion area and index in human uterine leiomyoma tissue, 
suggesting it was favoured because of its size and may have been able to travel through 
the plasma membrane or act at the plasma membrane itself to inhibit heparanase, where 
the longer aptamers may not, due to the steric hindrance or non-specific interaction with 
other molecules. Aptamers 1.5M long, 3.0M and pink were all suggested to show a 
degree of inhibition, which was anticipated due to their performance in the previous 
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binding and labelling studies. Unfortunately, small molecule inhibitor, SAFS, was not able 
to show any inhibition in these assays due to its low solubility in the appropriate buffer 
for the assay. Thus, attempting to dissolve the BAFB in a more suitable solvent and 
repeating the assay would show a suitable comparison of inhibition by a small molecule 
of a different variety to an aptamer. Due to time and financial constraints, it was not 
possible to test different concentrations and/or cell lines in these experiments; however, 
this would be an interesting further line of study, as it would allow us to elucidate the 
effect of increasing concentrations of 1.5M long, 3.0M and pink aptamers would have on 
heparanase inhibition. Furthermore, the extent of inhibition in hypoxic conditions could 
also be determined, as culturing the cells using 1% rather than 20% O2 was previously 
shown to enhance invasion in the ovarian carcinoma cell line [3). To further demonstrate 
that the aptamers in this study did indeed reduce invasion due to their inhibitory effect 
on heparanase and not a cytotoxic effect upon the cells directly, a cytotoxicity assay could 
be conducted to complement these results. 
Aptamers have been shown to be stable in human serum, suggesting their potential for 
therapeutic applications, although their lack of resistance in mouse serum would have an 
adverse effect in their study in this model, requiring them to be appropriately modified to 
increase stability. Previous in vivo testing of small molecule inhibitors for heparanase 
have been carried out using Fischer 344 rats immunised with mammary adenocarcinoma 
13762 MAT cells [4). Therefore, testing the stability of these aptamers in rat serum would 
be appropriate, and if the aptamers showed stability, would allow a comparison 
experiment to be conducted with the other relevant small molecule inhibitors. longer 
time incubations with aptamers and human serum would also give an indication of the 
maximum amount of time the aptamers would be stable for, as in the assays conducted 
in this study, some aptamers still remained stable at the maximum time point of five 
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hours. Aptamers' stability is likely to be linked to increased structural conformations, as 
this has been previously shown to be a crucial factor in nuclease degradation 
experiments. Additionally, aptamers have been studied for their interaction with serum 
proteins to evaluate the effect these may have in the pharmacokinetic properties of the 
aptamers. Both aptamers studied have shown an interaction with HSA, which, however, 
has been significantly lower than their interaction with heparanase although the longer 
aptamer has shown a higher affinity for HSA than the short one. 
Selected aptamers have also been shown to have a diagnostic potential, both from the 
results obtained in the early ELISA studies and in subsequent studies using quartz crystal 
microbalance, which offers a number of advantages for point of care delivery of 
diagnosis. Aptamers were shown to perform well in the QeM system, and were able to be 
immobilised on the crystal and used in a variety of concentration and sufficiently 
regenerated for further measurements. However, additional experiments would be 
necessary to establish limits of upper and lower detection of heparanase, reproducibility, 
regeneration and lifespan of crystal. Further work using spiked human serum would 
demonstrate the limits of detection of heparanase in biological samples using this 
technique. 
This project has achieved its objectives of generating high affinity and specificity aptamers 
for recombinant polymorphic heparanase and its linker peptide. These aptamers have 
shown the ability to recognise their cognate targets both 'In t . and 
spec roscoplc 
biochemical assays as well as in tissue and cell culture analys'ls F rth 
. u ermore, they have 
shown the potential to inhibit heparanase activity and reco . h '" 
gmse eparanase In diagnostic 
platforms. Thus, this research has opened the possibil't f d . 
I Y or eve loping and optimising 
these molecules into future therapeutic and diagno t' d I' . 
S IC mo a Itles. 
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